<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1-5309-24
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ILARIS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CANAKINUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        43890.42
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS Pharma Stein AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS Pharma Stein AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Novartis Europharm Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L04AC08 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Ilaris is<br />Ilaris contains the active substance canakinumab, a monoclonal antibody that belongs to a group of<br />medicines called interleukin inhibitors. It blocks the activity of a substance called interleukin-1 beta<br />(IL-1 beta) in the body, which is present at increased levels in inflammatory diseases.<br />What Ilaris is used for<br />Ilaris is used for treatment of the following inflammatory diseases:<br />- Periodic fever syndromes:<br />&bull; Cryopyrin-associated periodic syndromes (CAPS),<br />&bull; Tumour necrosis factor receptor associated periodic syndrome (TRAPS),<br />&bull; Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD),<br />&bull; Familial Mediterranean fever (FMF).<br />- Still&rsquo;s disease including adult onset Still&rsquo;s disease (AOSD) and systemic juvenile idiopathic<br />arthritis (SJIA)<br />- Gouty arthritis<br />More information on each of these diseases is given below.<br />Periodic fever syndromes<br />Ilaris is used in adults and children aged 2 years and older to treat the following:<br />- Cryopyrin-associated periodic syndromes (CAPS) &ndash; this is a group of auto-inflammatory<br />diseases, which include:<br />&bull; Muckle-Wells syndrome (MWS),<br />&bull; Neonatal-onset multisystem inflammatory disease (NOMID), also called chronic infantile<br />neurological, cutaneous, articular syndrome (CINCA),<br />&bull; Severe forms of familial cold auto-inflammatory syndrome (FCAS) / familial cold<br />urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin<br />rash.<br />- Tumour necrosis factor receptor associated periodic syndrome (TRAPS)<br />- Hyperimmunoglobulin D syndrome (HIDS) also known as mevalonate kinase deficiency<br />2<br />(MKD)<br />- Familial Mediterranean fever (FMF): Ilaris is used to treat FMF. Ilaris can be used together with<br />colchicine, if appropriate.<br />In patients with periodic fever syndromes (CAPS, TRAPS, HIDS/MKD and FMF), the body produces<br />too much IL-1 beta. This may cause fever, headache, fatigue, skin rash, or painful joints and muscles.<br />By blocking the activity of IL-1 beta, Ilaris may improve these symptoms.<br />Still&rsquo;s disease<br />Ilaris is used in adults, adolescents and children to treat active Still&rsquo;s disease including adult-onset<br />Still&rsquo;s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and<br />older if other treatments have not worked well enough. Ilaris can be used alone or in combination with<br />methotrexate.<br />Still&rsquo;s disease including SJIA and AOSD is an inflammatory disease that can cause pain, swelling and<br />inflammation of one or more joints, as well as rash and fever. A pro-inflammatory protein called IL-1<br />beta plays an important role in Still&rsquo;s disease inflammation. Ilaris blocks the activity of IL-1 beta,<br />which may improve the signs and symptoms of Still&rsquo;s disease.<br />Gouty arthritis<br />Ilaris is used in adults to treat the symptoms of frequent gouty arthritis attacks if other treatments have<br />not worked well enough.<br />Gouty arthritis is caused by the formation of urate crystals. These crystals cause excessive production<br />of IL-1 beta, which in turn can lead to sudden, severe pain, redness, warmth and swelling in a joint<br />(known as a gouty arthritis attack). By blocking the activity of IL-1 beta, Ilaris may lead to an<br />improvement in these symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>a. Do not use Ilaris<br />- if you are allergic to canakinumab or any of the other ingredients of this medicine (listed in<br />section 6).<br />- if you have, or suspect you have, an active and severe infection.<br />b. Take special care with Ilaris<br />Talk to your doctor before using Ilaris if any of the following applies to you:<br />&minus; if you currently have an infection or if you have had repeated infections or a condition such as a<br />known low level of white blood cells which makes you more likely to get infections.<br />&minus; if you have or have ever had tuberculosis or direct contact with a person with an active<br />tuberculosis infection. Your doctor may check whether you have tuberculosis using a specific<br />test.<br />&minus; if you have signs of a liver disorder such as yellow skin and eyes, nausea, loss of appetite, darkcoloured<br />urine and light-coloured stools.<br />&minus; if you need to have any vaccinations. You are advised to avoid being vaccinated with a type of<br />vaccine called a live vaccine while being treated with Ilaris (see also &ldquo;Other medicines and<br />Ilaris&rdquo;).<br />Contact your doctor immediately<br />- If you have ever developed an atypical, widespread rash or skin peeling after taking Ilaris.<br />The serious skin reaction, DRESS (drug reaction with eosinophilia and systemic symptoms), has<br />rarely been reported in association with Ilaris treatment, predominantly in patients with systemic<br />juvenile idiopathic arthritis (sJIA). Seek medical attention immediately if you notice an atypical,<br />widespread rash, which may occur in conjuction with high body temperature and enlarged<br />lymph nodes.<br />3<br />Still&rsquo;s disease<br />&minus; Patients with Still&rsquo;s disease may develop a condition called macrophage activation syndrome<br />(MAS), which can be life-threatening. Your doctor will monitor you for potential triggering<br />factors of MAS that include infections and re-activation of the underlying Still&rsquo;s disease (flare).<br />Children and adolescents<br />&minus; CAPS, TRAPS, HIDS/MKD, FMF and SJIA: Ilaris can be used in children aged 2 years and<br />older.<br />&minus; Gouty arthritis: Ilaris is not recommended for children or adolescents under 18 years of age.<br />c. Taking other medicines, herbal or dietary supplements<br />Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other<br />medicines.<br />&minus; Live vaccines: You are advised to avoid being vaccinated with a type of vaccine called a live<br />vaccine while you are being treated with Ilaris. Your doctor may want to check your vaccination<br />history and give you any vaccinations that you have missed before you start treatment with<br />Ilaris. If you need to be given a live vaccine after starting treatment with Ilaris, discuss this with<br />your doctor. A live vaccine should normally be given 3 months after your last injection of Ilaris<br />and 3 months before the next one.<br />&minus; Medicines called tumour necrosis factor (TNF) inhibitors, such as etanercept, adalimumab or<br />infliximab. These are used mainly in rheumatic and autoimmune diseases. They should not be<br />used with Ilaris because this may increase the risk of infections.<br />d. Pregnancy and breast-feeding<br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask<br />your doctor or pharmacist for advice before taking this medicine.<br />&minus; You are advised to avoid becoming pregnant and must use adequate contraception while using<br />Ilaris and for at least 3 months after the last Ilaris treatment. It is important to tell your doctor if<br />you are pregnant, if you think you may be pregnant or are planning to have a baby. Your doctor<br />will discuss with you the potential risks of taking Ilaris during pregnancy.<br />&minus; If you received canakinumab while you were pregnant, it is important that you inform the<br />baby&rsquo;s doctor or nurse before any vaccinations are given to your baby. Your baby should not<br />receive live vaccines until at least 16 weeks after you received your last dose of canakinumab<br />before giving birth.<br />&minus; It is not known whether Ilaris passes into human milk. Your doctor will discuss with you the<br />potential risks of taking Ilaris before breast-feeding.<br />e. Driving and using machines<br />Ilaris treatment may give you a spinning sensation (dizziness or vertigo) or intense tiredness<br />(asthenia). This may affect your ability to drive or use tools or machines. If you feel a spinning<br />sensation or feel tired, do not drive or use any tools or machines until you are feeling normal again.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor has told you. Check with your doctor, pharmacist or nurse if you are not sure.</p><p>&nbsp;</p><p>Keep your doctor informed of your condition and any symptoms before you use or are given Ilaris (see section&nbsp;2). Your doctor may decide to delay or interrupt your treatment, but only if necessary.</p><p>&nbsp;</p><p>Ilaris is intended for subcutaneous use. This means that it is injected through a short needle into the fatty tissue just under the skin.</p><p>&nbsp;</p><p>If you have gouty arthritis, your treatment will be overseen by a doctor with specialist training. Ilaris should be injected by a healthcare professional only.</p><p>&nbsp;</p><p>If you have CAPS, TRAPS, HIDS/MKD, FMF or Still&rsquo;s disease (AOSD or SJIA), you may inject yourself with Ilaris after proper training, or a caregiver may inject it for you.</p><p>&nbsp;</p><p><strong>How much Ilaris to use</strong></p><p><u>Cryopyrin- associated periodic syndromes (CAPS)</u></p><p>The recommended starting dose of Ilaris is:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Adults and children</em><em> aged 4&nbsp;years or more</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 150&nbsp;mg for patients who weigh more than&nbsp;40&nbsp;kg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2&nbsp;mg/kg for patients who weigh between 15&nbsp;kg and 40&nbsp;kg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4&nbsp;mg/kg for patients who weigh between 7.5&nbsp;kg and less than 15&nbsp;kg</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>C</em><em>hildren aged 2 or 3&nbsp;years</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4&nbsp;mg/kg for patients with body weight of&nbsp;7.5&nbsp;kg or more</p><p>&nbsp;</p><p>Ilaris is injected every 8&nbsp;weeks as a single dose.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have not responded well enough to the treatment after 7&nbsp;days, your doctor may give you another dose of 150&nbsp;mg or 2&nbsp;mg/kg.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you respond well enough to the second dose, your treatment will be continued with 300&nbsp;mg or 4&nbsp;mg/kg every 8&nbsp;weeks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you do not respond well enough to the second dose, a third dose of Ilaris at 300&nbsp;mg or 4&nbsp;mg/kg may be given.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you respond well enough to the third dose, your treatment will be continued at 600&nbsp;mg or 8&nbsp;mg/kg every 8&nbsp;weeks.</p><p>&nbsp;</p><p>For children given a starting dose of 4&nbsp;mg/kg who have not responded well enough after 7&nbsp;days, the doctor may give a second dose of 4&nbsp;mg/kg. If the child responds well enough to this, treatment may be continued with a dose of 8&nbsp;mg/kg every 8&nbsp;weeks.</p><p>&nbsp;</p><p><u>Tumour necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD) and familial Mediterranean fever (FMF)</u></p><p>The recommended starting dose of Ilaris is:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Adults and children</em><em> aged 2&nbsp;years or more</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 150&nbsp;mg for patients who weigh more than 40&nbsp;kg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2&nbsp;mg/kg for patients who weigh between 7.5&nbsp;kg and less than 40&nbsp;kg</p><p>&nbsp;</p><p>Ilaris is injected every 4&nbsp;weeks as a single dose.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have not responded well enough to the treatment after 7&nbsp;days, your doctor may give you another dose of 150&nbsp;mg or 2&nbsp;mg/kg.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you respond well enough to this, your treatment will be continued with 300&nbsp;mg or 4&nbsp;mg/kg every 4&nbsp;weeks.</p><p>&nbsp;</p><p><u>Still&rsquo;s disease (SJIA and AOSD)</u></p><p>The recommended dose of Ilaris for patients with Still&rsquo;s disease with body weight of 7.5&nbsp;kg and above is 4&nbsp;mg/kg (up to a maximum of 300&nbsp;mg). Ilaris is injected every 4&nbsp;weeks as a single dose.</p><p>&nbsp;</p><p><u>Gouty arthritis</u></p><p>Your doctor will discuss with you the need to start or adjust a urate lowering therapy to lower the uric acid level in your blood.</p><p>&nbsp;</p><p>The recommended dose of Ilaris for adult gouty arthritis patients is 150&nbsp;mg given as a single dose at the time of a gouty arthritis attack.</p><p>&nbsp;</p><p>If you need another treatment with Ilaris, and got relief from the last dose, you must wait at least 12&nbsp;weeks before the next dose.</p><p>&nbsp;</p><p><strong>Injecting Ilaris yourself or injecting a patient with Ilaris</strong></p><p>If you are a patient with CAPS, TRAPS, HIDS/MKD, FMF or Still&rsquo;s disease (AOSD or SJIA), or a caregiver of a patient with one of these conditions, you may administer Ilaris injections yourself after proper training in the correct injection technique.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The patient or caregiver and the doctor should decide together who will administer the Ilaris injections.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The doctor or nurse will demonstrate how to administer Ilaris injections.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not try to administer an injection yourself if you have not been properly trained or if you are not sure how to do it.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ilaris 150&nbsp;mg/ml solution for injection is supplied in a single-use vial for individual use.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Never re-use the leftover solution.</p><p>&nbsp;</p><p>For instructions on how to administer Ilaris injections, please read the section &ldquo;Instructions for use&rdquo; at the end of this leaflet. If you have any questions, talk to your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p><strong>How long to use Ilaris</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>CAPS,</strong><strong> TRAPS, HIDS/MKD, FMF or Still&rsquo;s disease (AOSD or SJIA)</strong>: You should continue using Ilaris for as long as the doctor tells you.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Gouty arthritis</strong>: If you have a gouty arthritis attack, you will be given a single dose of Ilaris. If you experience a new attack, your doctor may consider giving you a new dose of Ilaris but not earlier than 12&nbsp;weeks from the previous dose.</p><p>&nbsp;</p><p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>If you use more Ilaris than you should</strong></p><p>If you accidentally inject more Ilaris than the recommended dose, it is unlikely to be serious, but you should inform your doctor, pharmacist or nurse as soon as possible.</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>If you forget to use Ilaris</strong></p><p>If you have CAPS, TRAPS, HIDS/MKD, FMF or Still&rsquo;s disease (AOSD or SJIA) and have forgotten to inject a dose of Ilaris, inject the next dose as soon as you remember. Then talk to the doctor to discuss when you should inject the next dose. You should then continue with injections at the recommended intervals as before.</p><p>&nbsp;</p><p><strong>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>If you stop using Ilaris</strong></p><p>Stopping your treatment with Ilaris may cause your condition to get worse. Do not stop taking Ilaris unless your doctor tells you to.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Some side effects could be serious. </strong><strong>Tell your doctor immediately, if you notice any of the side effects below:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever lasting longer than 3&nbsp;days or any other symptoms that might suggest a serious infection. These include shivering, chills, malaise, loss of appetite, body aches, typically in connection with a sudden onset of illness, sore throat or mouth ulcers, cough, phlegm, chest pain, difficulty breathing, ear pain, prolonged headache or localised redness, warmth or swelling of your skin or inflammation of connective tissue (cellulitis). These symptoms could be due to a serious infection, an unusual infection (opportunistic infection) or be related to low levels of white blood cells (called leukopenia or neutropenia). Your doctor may check your blood regularly if considered necessary.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions with rash and itching and possibly also hives, difficulty breathing or swallowing, dizziness, unusual awareness of your heart beat (palpitations) or low blood pressure.</p><p>&nbsp;</p><p><strong>Other side effects of Ilaris include:</strong></p><p><strong>Very common</strong> (may affect more than 1 in 10&nbsp;people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections of any kind. These can include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Respiratory infections such as chest infection, flu, sore throat, runny nose, blocked nose, sneezing, feeling of pressure or pain in the cheeks or forehead with or without fever (pneumonia, bronchitis, influenza, sinusitis, rhinitis, pharyngitis, tonsilitis, nasopharyngitis, upper respiratory tract infection).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other infections such as ear infection, skin infection (cellulitis), stomach pain and feeling sick (gastroenteritis) and painful and frequent urination with or without fever (urinary tract infection).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Upper abdominal pain.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in joints (arthralgia).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drop in level of white blood cells (leukopenia).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal kidney function test results (creatinine renal clearance decreased, proteinuria).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site reaction (such as redness, swelling, warmth and itching).</p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1 in 10&nbsp;people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Candida - vaginal yeast infection (vulvovaginal candidiasis).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling dizzy, spinning sensation (dizziness or vertigo).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in the back or muscles.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling weak or very tired (fatigue, asthenia).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drop in level of white blood cells which help prevent infection (neutropenia).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal levels of triglycerides in your blood (lipid metabolism disorder).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal liver function test results (transaminases increased) or high level of bilirubin in the blood, with or without yellow skin and eyes (hyperbilirubinaemia).</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100&nbsp;people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heartburn (gastro-oesophageal reflux disease).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drop in level of blood cells which help prevent bleeding (platelets).</p><p>&nbsp;</p><p>Tell your doctor or your child&rsquo;s doctor immediately if you notice any of these symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the label and carton. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in a refrigerator (2&deg;C&nbsp;‑&nbsp;8&deg;C). Do not freeze.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep the vial in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The solution should be used immediately after first piercing the vial stopper to prepare the injection.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine if you notice that the solution is not clear to opalescent or contains particles.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Any unused medicine must be discarded after withdrawal of the dose.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>What Ilaris contains</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is canakinumab. One vial contains 150&nbsp;mg canakinumab in 1&nbsp;ml of solution.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are mannitol, histidine, histidine hydrochloride monohydrate, polysorbate 80, water for injections.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                b.      What Ilaris looks like and contents of the pack

-               Ilaris is supplied as a solution for injection in a 2 ml glass vial.

-               The solution is a clear to opalescent liquid. It is colourless to slightly brownish-yellow. Do not use if the liquid contains easily visible particles, is cloudy or is distinctly brown.

-               Ilaris is available in packs containing one vial.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The Marketing Authorization Holder for this Product is Novartis Pharma AG.</p><p>www.Novartis.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                d. This leaflet was last approved by EMA in May/2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو عقار إيلارس؟</strong></p><p dir="RTL">يحتوي عقار إيلارس على المادة الفعَّالة كاناكينوماب، وهو أحد الأجسام المضادة أُحادِية النَّسِيْلَة التي تنتمي إلى مجموعة من الأدوية تُسمى مثبطات الإنترلوكين، ويقوم بحصر نشاط مادة تُسمى إنترلوكين-1 بيتا في الجسم، وهي مادة تتواجد بمستويات مرتفعة في حالة الإصابة بالأمراض الالتهابية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما هي دواعي استعمال عقار إيلارس؟</strong></p><p dir="RTL">يُستَخدَم عقار إيلارس لعلاج الأمراض الالتهابية التَّالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمات الحُمّى الدَّورية:</p><ul><li dir="RTL">المتلازمات الدَّورية المرتبطة بكرايوبايرين،</li><li dir="RTL">المتلازمة الدورية المرتبطة بمستقبل عامل نخر الورم،</li><li dir="RTL">متلازمة فرط الجلوبولين المناعي &quot;د&quot;/ نقص أنزيم ميفالونات كيناز،</li><li dir="RTL">حمى البحر المتوسط العائلية.</li></ul><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء ستيل بما في ذلك داء ستيل البادئ في البالغين والتهاب المفاصل الجهازي اليفعي مجهول السبب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المفاصل النقرَسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مُوَضَّح أدناه معلومات إضافية حول كل مرض من هذه الأمراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>متلازمات الحُمّى الدَّورية</u></p><p dir="RTL">يُستخدم عقار إيلارس في البالغين والأطفال بعمر عامين فأكثر لعلاج الآتي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المتلازمات الدَّورية المرتبطة بكرايوبايرين - وهي مجموعة من الأمراض الالتهابية الذاتية، التي تشمل الآتي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة ماكل- ويلز،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض التهابي متعدد الأجهزة وليدي البدء ويعرف أيضًا بالمتلازمة الجلدية والمفصلية العصبية الطفولية المزمنة،</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأشكال الشَّديدة من متلازمة البرد العائلي الالتهابية الذاتية/ شرى البرد العائلي مع ظهور علامات وأعراض تتجاوز الطفح الجلدي الشَّرَوِيّ النَّاجم عن البرد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المتلازمة الدورية المرتبطة بمستقبل عامل نخر الورم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة فرط الجلوبولين المناعي &quot;د&quot; وتُعرف أيضًا بنقص أنزيم ميفالونات كيناز.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى البحر المتوسط العائلية: يُستَخدَم عقار إيلارس لعلاج حُمّى البحر المتوسط العائلية. يُمكِن استخدام عقار إيلارس بمصاحبة كُولْشيسين، إذا كان ذلك مناسبًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في المرضى المُصابين بمتلازمات الحُمّى الدَّورية (المتلازمات الدَّورية المرتبطة بكرايوبايرين، والمتلازمة الدَّورية المرتبطة بمستقبل عامل نخر الورم، ومتلازمة فرط الجلوبولين المناعي &quot;د&quot;/ نقص أنزيم ميفالونات كيناز وحمى البحر المتوسط العائلية)، ينتج الجسم كمية كبيرة جدًّا من إنترلوكين-1 بيتا. قد يُسبب هذا حُمّى أو صداعًا أو إرهاقًا أو طفحًا جلديًّا أو ألمًا بالمفاصل والعضلات. عند حصر نشاط إنترلوكين-1 بيتا، قد يُحسِّن عقار إيلارس هذه الأعراض.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>داء ستيل</u></p><p dir="RTL">يُستَخدَم عقار إيلارس في البالغين والمراهقين والأطفال لعلاج داء ستيل النَّشط بما في ذلك داء ستيل البادئ في البالغين والتهاب المفاصل الجهازي اليفعي مجهول السبب في المرضى بعُمْر عامين فأكثر إذا لم تعمل العلاجات الأخرى جيدًا بما يكفي. يُمكِن استخدام عقار إيلارس بمفرده، أو بمصاحبة الميثوتريكسات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">داء ستيل بما في ذلك داء ستيل البادئ في البالغين والتهاب المفاصل اليفعي الجهازي مجهول السبب وهو مرض التهابي يُمكِن أن يُسبب ألمًا وتورُّمًا والتهابًا في مفصل واحد أو أكثر، فضلًا عن الطفح الجلدي والحُمّى. يقوم أحد البروتينات المحرضة للالتهاب ويُسمى إنترلوكين-1 بيتا بدور مُهِم في حالات الالتهاب المُصاحبة لداء ستيل. يقوم عقار إيلارس بحصر نشاط إنترلوكين-1 بيتا، والذي قد يُحسِّن علامات وأعراض داء ستيل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التهاب المفاصل النقرَسي</u></p><p dir="RTL">يُستَخدَم عقار إيلارس في البالغين لعلاج أعراض نوبات التهاب المفاصل النقرَسي المتكررة إذا لم تعمل العلاجات الأخرى جيدًا بما يكفي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">التهاب المفاصل النقرَسي سببه تكوُّن بلورات اليورات. تسبب هذه البلورات زيادة في إنتاج إنترلوكين-1 بيتا، والذي بدوره قد يُؤدي إلى ألم مفاجئ شديد واحمرار ودفء وتورُّم في المفصل (تُعرَف هذه الحالة باسم نوبة التهاب المفاصل النقرَسي). عن طريق حصر نشاط إنترلوكين-1 بيتا، قد يُؤدي عقار إيلارس إلى تحسُّن في هذه الأعراض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>موانع استعمال عقار إيلارس</strong><strong>:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية تجاه كاناكينوماب أو أي مكونات أخرى بهذا الدَّواء (المدرجة في القسم: 6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا أو يُشتَبَه في إصابتك بعدوى نشطة وشديدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ب.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الاحتياطات عند استعمال عقار إيلارس</strong></p><p dir="RTL"><strong>تحدَّث إلى طبيبك قبل استخدام عقار إيلارس </strong>إذا انطبق عليك أيٌّ مما يلي:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت مصابًا حاليًّا بعدوى أو إذا كنت قد أُصبت بعدوى متكررة أو حالة مثل انخفاض معروف بمستوى خلايا الدَّم البيضاء وهو ما يجعلك أكثر عُرضة للإصابة بالعدوى.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت تُعاني أو قد عانيت من قبل من مرض السُّل أو كنت على اتصال مباشر بشخص مُصاب بعدوى السُّل النشطة. قد يتحقق طبيبك مما إذا كنت مُصابًا بمرض السُّل أم لا بالاستعانة بإجراء اختبار معين.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت تعاني من علامات أحد اضطرابات الكبد مثل: اصفرار بالجلد والعينين، غثيان، فقدان الشهية، بول ذي لون داكن وبراز ذي لون فاتح.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا كنت بحاجة إلى تلقي أيَّة لقاحات. يُنصَح بتجنُّب تلقي التَّطعيم بنوع من اللقاحات يُسمى اللقاح الحي أثناء العلاج بعقار إيلارس (انظر أيضًا: &quot;استعمال أدوية أخرى مع عقار إيلارس&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اتصل بطبيبك على الفور</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت سابقًا من طفح جلدي غير نمطي واسع الانتشار أو تقشُّر الجلد بعد استعمال عقار إيلارس.</p><p dir="RTL">نادرًا ما أبلغ مرضى، معظمهم يعانون من التهاب المفاصل الجهازي اليفعي مجهول السبب، عن إصابتهم بتفاعل جلدي خطير ألا وهو الطفح الجلدي الدوائي المصحوب بكثرة خلايا اليُوزينِيَّات والأعراض الجهازية عند خضوعهم للعلاج بعقار إيلارس. اطلب العناية الطبية فورًا إذا لاحظت طفحًا جلديًّا غير نمطي واسع الانتشار، قد يكون مصحوبًا بارتفاع في درجة الحرارة وتضخُّم العقد الليمفاوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>داء ستيل</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يُصاب المرضى المُصابون بداء ستيل بحالة تُسمى متلازمة تَنْشيط البَلاعِم، وهي حالة قد تُشكل تهديدًا للحياة. سيراقبك طبيبك تحسبًا لوجود عوامل تحفيزية مُحتَمَلة لمتلازمة تَنْشيط البَلاعِم والتي تشمل: العدوى وإعادة تنشيط داء ستيل الكامن (الاحتدام).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المتلازمة الدورية المرتبطة بكرايوبايرين، المتلازمة الدورية المرتبطة بمستقبل عامل نخر الورم، متلازمة فرط الجلوبولين المناعي </strong><strong>(</strong><strong>د</strong><strong>) </strong><strong>في الدَّم</strong><strong>/ </strong><strong>نقص أنزيم ميفالونات الكيناز، حُمّى البحر المتوسط العائلية والتهاب المفاصل اليفعي الجهازي مجهول السبب</strong><strong>:</strong> يمكن استخدام عقار إيلارس في الأطفال بعمر عامين فأكثر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التهاب المفاصل النقرَسي</strong><strong>:</strong> لا يوصى بعلاج الأطفال أو المراهقين الذين تقل أعمارهم عن 18 عامًا بعقار إيلارس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ج.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك أو الممرض إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اللقاحات الحية: يُنصَح بتجنُّب تلقي تطعيمات بنوع من اللقاحات يُسمى اللقاح الحي أثناء العلاج بعقار إيلارس. قد يرغب طبيبك في فحص تاريخ تطعيماتك وإعطائك أيَّة لقاحات كنت قد أغفلتها قبل بدء العلاج بعقار إيلارس.إذا كنت بحاجة إلى تلقي لقاح حي بعد بدء العلاج بعقار إيلارس، فناقش ذلك مع طبيبك. يجب أن يُعطى اللقاح الحي عادةً بعد 3 أشهر من آخر عملية حَقْن بعقار إيلارس وقبل 3 أشهر من الحَقْن التَّالي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية تُسمى بمثبطات عامل نخر الورم، مثل: إيتانيرسيبت أو أداليموماب أو إنفليكسيماب. تُستَخدَم بشكل أساسي في الأمراض الروماتيزمية وأمراض المناعة الذاتية. يجب ألا تُستَخدَم مع عقار إيلارس؛ لأنَّ هذا الاستخدام قد يُؤدي إلى زيادة خطر الإصابة بعدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;د.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الحمل والرضاعة</strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعًا، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين لذلك، فاستشيري طبيبكِ أو الصيدلي الخاص بكِ قبل تناوُل هذا الدَّواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُنصَح بتجنُّب الحَمْل كما يجب استخدام وسيلة منع حَمْل مناسبة أثناء استخدام عقار إيلارس ولمدة 3 أشهر على الأقل بعد آخر علاج بعقار إيلارس. من المهم إخبار طبيبكِ إذا كنتِ حاملًا، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للحمل. سيناقش معكِ طبيبكِ المخاطر المُحتملة التي قد تنتج عن استعمال عقار إيلارس أثناء الحمل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تلقيتِ كاناكينوماب أثناء الحمل، فمن المُهِم أن تبلغي طبيب الطفل أو الممرضة قبل إعطاء أي تطعيمات له. يجب أَلَّا يتلقى طفلكِ أية لقاحات حية حتى مرور 16 أسبوعًا على الأقل بعد تلقيكِ آخر جرعة خاصَّة بكِ من كاناكينوماب قبل الولادة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; من غير المعروف ما إذا كان عقار إيلارس يمر في لبن الأم، أم لا. سيناقش معكِ طبيبكِ المخاطر المُحتملة التي قد تنتج عن استعمال عقار إيلارس قبل الرضاعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ه.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>تأثير عقار إيلارس على القيادة واستخدام الآلات</strong></p><p dir="RTL">قد يعطيك العلاج بعقار إيلارس إحساسًا بالدوران (دوخة أو دوار) أو شعورًا بتعب شديد (وهن). قد يُؤثر هذا في قدرتك على قيادة المركبات أو استخدام الأدوات أو الآلات. إذا شعرت بدوران أو تعب، فتجنب القيادة أو استخدام أية أدوات أو آلات حتى تشعر بأنك على ما يُرام مرة أخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">استخدم دائمًا هذا الدَّواء كما أخبرك طبيبك بالضبط. يُرجى مراجعة طبيبك، الصيدلي الخاص بك أو الممرضة إذا لم تكن متأكدًا من كيفية الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أبقِ طبيبك على علم بحالتك وأية أعراض تعاني منها قبل استخدامك أو تلقيك عقار إيلارس (انظر قسم: 2). قد يقرر طبيبك تأخير علاجك أو إيقافه مؤقتًا، ولكن يحدث ذلك فقط إذا اقتضت الضرورة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عقار إيلارس معد للاستخدام أسفل الجلد. وهذا يعني أنه يتم حقنه داخل النَّسيج الدُّهني تحت الجلد مباشرة بواسطة إبرة قصيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت مُصابًا بالتهاب المفاصل النِّقرَسي، فسيشرف على علاجك طبيب متدرب تدريبًا متخصصًا. يجب أن يُحقَن عقار إيلارس من قِبَل أخصائي الرعاية الصحية فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت مُصابًا بالمتلازمات الدَّورية المرتبطة بكرايوبايرين، أو المتلازمة الدَّورية المرتبطة بمستقبل عامل نخر الورم، أو متلازمة فرط الجلوبولين المناعي (د)/ نقص أنزيم ميفالونات كيناز، أو حُمّى البحر المتوسط العائلية أو داء ستيل (داء ستيل البادئ في البالغين أو التهاب المفاصل الجهازي مجهول السبب في المراهقين)، فيُمكِنك حَقْن نفسك بعقار إيلارس بعد تلقي تدريب مناسب، أو قد يتولى مقدم الرعاية حَقْنك بالعقار.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ما كمية عقار إيلارس التي يجب استعمالها؟</strong></p><p dir="RTL"><u>المتلازمات الدَّورية المرتبطة بكرايوبايرين</u></p><p dir="RTL">جرعة البدء المُوصى بها من عقار إيلارس هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>البالغون والأطفال ممن تبلغ أعمارهم </em><em>4 </em><em>سنوات فأكثر</em><em>.</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 150 مجم للمرضى الذين يزنون أكثر من 40 كجم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 مجم/ كجم للمرضى الذين تتراوح أوزانهم بين 15 كجم و40 كجم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4 مجم/ كجم للمرضى الذين تتراوح أوزانهم بين 7.5 كجم وأقل من 15 كجم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>الأطفال بعُمْر </em><em>2 </em><em>أو </em><em>3 </em><em>سنوات</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4 مجم/ كجم للمرضى الذين يزنون 7.5 كجم فأكثر</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحقَن عقار إيلارس كل 8 أسابيع في هيئة جرعة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تستجب حالتك جيدًا بما يكفي للعلاج بعد مرور 7 أيام، فقد يعطيك طبيبك جرعة أخرى قدرها 150 مجم أو 2 مجم/ كجم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا استجابت حالتك جيدًا بما يكفي للجرعة الثَّانية، فستتم مواصلة علاجك بجرعة قدرها 300 مجم أو 4 مجم/ كجم كل 8 أسابيع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تستجب جيدًا بما يكفي للجرعة الثَّانية، فقد يتم إعطاؤك جرعة ثالثة من عقار إيلارس قدرها 300 مجم أو 4 مجم/ كجم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا استجابت حالتك جيدًا بما يكفي للجرعة الثَّالثة، فستتم مواصلة علاجك بجرعة قدرها 600 مجم أو 8 مجم/ كجم كل 8 أسابيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة للأطفال ممن تلقوا جرعة بدء قدرها 4 مجم/ كجم ولم يستجيبوا جيدًا بما يكفي للعلاج بعد مرور 7 أيام، فقد يعطي الطبيب جرعة ثانية قدرها 4 مجم/ كجم. إذا استجاب الطفل جيدًا بما يكفي لذلك، فقد تتم مواصلة العلاج بجرعة قدرها 8 مجم/ كجم كل 8 أسابيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>المتلازمة الدَّورية المرتبطة بمستقبل عامل نخر الورم، ومتلازمة فرط الجلوبولين المناعي </u><u>&quot;</u><u>د</u><u>&quot;/ </u><u>نقص أنزيم ميفالونات كيناز وحُمّى البحر المتوسط العائلية</u></p><p dir="RTL">جرعة البدء المُوصى بها من عقار إيلارس هي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>البالغون والأطفال بعمر عامين فأكثر</em><em>.</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 150 مجم للمرضى الذين يزنون أكثر من 40 كجم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2 مجم/ كجم للمرضى الذين تتراوح أوزانهم بين 7.5 كجم وأقل من 40 كجم</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحقَن إيلارس كل 4 أسابيع في هيئة جرعة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم تستجب حالتك جيدًا بما يكفي للعلاج بعد مرور 7 أيام، فقد يعطيك طبيبك جرعة أخرى قدرها 150 مجم أو 2 مجم/ كجم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا استجابت حالتك جيدًا بما يكفي لذلك، فستتم مواصلة علاجك بجرعة قدرها 300 مجم أو 4 مجم/ كجم كل 4 أسابيع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>داء ستيل </u><u>(</u><u>التهاب المفاصل اليفعي الجهازي مجهول السبب وداء ستيل البادئ في البالغين</u><u>)</u></p><p dir="RTL">الجرعة الموصى بها من عقار إيلارس لعلاج المرضى المصابين بداء ستيل الذين يبلغ وزن الجسم لديهم 7.5 كجم فأكثر هي 4 مجم/ كجم (تصل إلى 300 مجم كحد أقصى). يُحقَن إيلارس كل 4 أسابيع في هيئة جرعة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>التهاب المفاصل النقرَسي</u></p><p dir="RTL">سيناقش معك طبيبك الحاجة إلى بدء أو تعديل العلاج الخافض لليورات لخفض مستوى حمض اليوريك في الدَّم لديك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة المُوصى بها من عقار إيلارس بالنسبة للمرضى من البالغين المُصابين بالتهاب المفاصل النِّقرَسي هي 150 مجم تُعطى في هيئة جرعة واحدة في وقت حدوث نوبة التهاب المفاصل النِّقرَسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت بحاجة إلى علاج آخر بعقار إيلارس، وكان قد تم تخفيف الألم الذي تعاني منه بعد تلقي الجرعة الأخيرة، يجب عليك الانتظار 12 أسبوعًا على الأقل قبل تلقي الجرعة التَّالية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حَقن نفسك بعقار إيلارس</strong> <strong>أو حَقْن مريض بعقار إيلارس</strong></p><p dir="RTL">إذا كنت مريضًا مُصابًا بالمتلازمات الدَّورية المرتبطة بكرايوبايرين، أو المتلازمة الدَّورية المرتبطة بمستقبل عامل نخر الورم، أو متلازمة فرط الجلوبولين المناعي &quot;د&quot;/ نقص أنزيم ميفالونات كيناز، أو حُمّى البحر المتوسط العائلية أو داء ستيل (داء ستيل البادئ في البالغين أو التهاب المفاصل اليفعي الجهازي مجهول السبب)، أو كنت قائمًا برعاية مريض مُصاب بواحدة من هذه الحالات، يُمكِنك إعطاء حقن عقار إيلارس بنفسك بعد تلقي تدريب مناسب على تقنية الحَقْن الصحيح.</p><ul><li dir="RTL">يجب أن يقرر المريض أو القائم بالرعاية والطبيب معًامن سيعطي حقن عقار إيلارس.</li><li dir="RTL">سيوضح الطبيب أو الممرض كيفية إعطاء حقن عقار إيلارس.</li><li dir="RTL">لا تحاول إعطاء إحدى الحُقَن بنفسك إذا لم تتلق تدريبًا على الحَقْن بشكل سليم أو إذا لم تكن متأكدًا من كيفية القيام بذلك.</li><li dir="RTL">يتوفر عقار إيلارس 150 مجم/ مللي لتر محلول للحقن في زجاجة معدة للاستخدام مرة واحدة للاستخدام الفردي.</li><li dir="RTL">لا تعد استخدام المحلول المتبقي أبدًا.</li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">للحصول على تعليمات حول كيفية&nbsp; إعطاء حقن عقار إيلارس، يُرجى قراءة قسم &quot;تعليمات الاستخدام&quot; في نهاية هذه النَّشرة. إذا كان لديك أي أسئلة، يُرجى التَّحدث إلى طبيبك أو الصيدلي الخاص بك أو الممرضة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المدة اللازمة لاستخدام عقار إيلارس</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المتلازمة الدورية المرتبطة بكرايوبايرين، أو المتلازمة الدورية المرتبطة بمستقبل عامل نخر الورم، أو متلازمة فرط الجلوبولين المناعي </strong><strong>(</strong><strong>د</strong><strong>) </strong><strong>في الدَّم</strong><strong>/ </strong><strong>نقص أنزيم ميفالونات كيناز، أو حُمّى البحر المتوسط العائلية </strong><strong>أو داء ستيل </strong><strong>(</strong><strong>داء ستيل البادئ في البالغين أو التهاب المفاصل اليفعي الجهازي مجهول السبب</strong><strong>):</strong> يجب أن تستمر في استخدام عقار إيلارس طالما أخبرك الطبيب بذلك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>التهاب المفاصل النقرَسي</strong><strong>:</strong> إذا كنت مُصابًا بنوبة التهاب المفاصل النِقرَسي، فسيتم إعطاؤك جرعة واحدة من عقار إيلارس. إذا تعرَّضت لنوبة جديدة، فقد يفكر طبيبك في إعطائك جرعة جديدة من عقار إيلارس ولكن ليس قبل 12 أسبوعًا من تلقي الجرعة السابقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الجرعة الزائدة من عقار إيلارس</strong></p><p dir="RTL">إذا حَقَنت كمية من عقار إيلارس أكثر من المُوصى بها بطريق الخطأ، فمن غير المُرجَّح أن يكون ذلك خطيرًا، ولكن عليك إبلاغ طبيبك أو الصيدلي الخاص بك أو الممرضة بأسرع ما يُمكِن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ب.&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>نسيان تناول جرعة من عقار إيلارس</strong></p><p dir="RTL">إذا كنت مُصابًا بالمتلازمات الدَّورية المرتبطة بكرايوبايرين، أو المتلازمة الدورية المرتبطة بمستقبل عامل نخر الورم، أو متلازمة فرط الجلوبولين المناعي &quot;د&quot;/ نقص أنزيم ميفالونات كيناز، أو حُمّى البحر المتوسط العائلية أو داء ستيل (داء ستيل البادئ في البالغين أو التهاب المفاصل الجهازي مجهول السبب في المراهقين) وأغفلت حَقْن جرعة من عقار إيلارس، فاحقن الجرعة التَّالية بمجرد تذكرك لها. ثم تحدَّث إلى الطبيب لمناقشته متى يجب عليك حَقْن الجرعة التَّالية. يجب عليك بعد ذلك مواصلة تلقي الحَقْن بالمعدلات المُوصى بها من قبل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ج.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>التوقف عن تناوُل عقار إيلارس</strong></p><p dir="RTL">قد يتسبب إيقافك العلاج بعقار إيلارس في تفاقم حالتك. لا تتوقف عن تناوُل عقار إيلارس ما لم يخبرك طبيبك بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، فاستشر طبيبك أو الصيدلي أو الممرض الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء أعراض جانبية، على الرَّغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بعض الأعراض الجانبية قد تكون خطيرة</strong><strong>. </strong><strong>أخبر طبيبك فورًا، إذا لاحظت أيًّا من الأعراض الجانبية التَّالية</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حُمّى تستمر لأكثر من 3 أيام أو أي أعراض أخرى قد تُشير إلى الإصابة بعدوى خطيرة. يتضمن ذلك: الارتعاش، القشعريرة، الشعور بالضيق، فقدان الشهية، آلامًا بالجسم، عادةً ما يرتبط ذلك بظهور مفاجئ للمرض، التهاب الحَلْق أو قُرَحًا بالفم، سُعالًا، بلغمًا، ألمًا بالصدر، صعوبة في التنفس، ألمًا بالأذن، صداعًا يمتد لفترة طويلة أو احمرارًا موضعيًّا، دفئًا أو تورُّم الجلد أو التهاب الأنسجة الضامة (الْتِهاب النّسِيجِ الخلوي). قد تكون هذه الأعراض نتيجة الإصابة بعدوى خطيرة، عدوى غير مُعتادة (عدوى انتهازية) أو ذات صلة بانخفاض مستويات خلايا الدَّم البيضاء (ما يُسمى بقلَّة كرَيَّاتِ الدَّم البيْضاء أو قلة خلايا العَدِلات). قد يفحص طبيبك الدَّم لديك بصفة منتظمة إذا رأى أن ذلك ضروريًّا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية مع طفح جلدي وحكة وربما أيضًا شرى (أرتكاريا)، صعوبة في التَّنفس أو البلع، دوخة، شعور غير مُعتاد بضربات القلب (الخَفَقان) أو انخفاض ضغط الدَّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية أخرى لعقار إيلارس تشمل ما يلي</strong><strong>:</strong></p><p dir="RTL"><strong>شائعة جدًّا </strong>(قد تُؤثر على أكثر من 1 من بين كل 10&nbsp;أشخاص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى من أي نوع. قد يشمل ذلك ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التَّنفسي مثل عدوى الصدر، الإنفلونزا، التهاب الحَلْق، سيلان الأنف، انسداد الأنف، عطس، شعور بالضغط أو الألم في الخدين أو الجبهة مع أو بدون حُمّى (التهاب رئوي، التهاب الشُّعب الهوائية، إنفلونزا، الْتِهاب الجُيوب الأنفية، التهاب الأنف، التهاب البلعوم، التهاب اللوزتين، التهاب البلعوم الأنفي، عدوى الجهاز التَّنفسي العلوي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى أخرى مثل: عدوى الأذن، عدوى الجلد (الْتِهاب النّسِيجِ الخلوي)، ألم بالمعدة وشعور بالإعياء (التهاب المعدة والأمعاء) وتبوُّل مؤلم ومتكرر مع أو بدون حُمّى (عدوى المسالك البولية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألمًا في أعلى البطن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألمًا بالمفاصل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاضًا في مستوى خلايا الدَّم البيضاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية باختبار وظائف الكُلى (انخفاض تصفية الكرياتينين الكُلوية، بيلة بروتينية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات في موضع الحَقْن (مثل: الاحمرار والتورُّم والدفء والحكة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تُؤثر على ما يصل إلى 1 من بين كل 10&nbsp;أشخاص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى خميرة المبيضات المهبلية (داء المبيضات الفرجي المهبلي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالدوخة، شعور بالدوران (دوخة أو دوار).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالظهر أو العضلات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور بالضعف أو التَّعب الشديد (إرهاق، وهن).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في مستوى خلايا الدَّم البيضاء التي تُساعد على الوقاية من العدوى (قلة خلايا العَدِلات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستويات غير طبيعية للدهون الثلاثية لديك في الدَّم (اضطراب استقلاب الدهون).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية في اختبار وظائف الكبد (زيادة الناقلات الأمينية) أو ارتفاع مستوى البيليروبين بالدَّم، مع أو بدون اصفرار الجلد والعينين (فَرْط البِيِلِيروبينِ بالدَّم).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تُؤثر على ما يصل إلى 1 من بين كل 100 شخص):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحموضة (مرض الجَزْر (الارتجاع) المَعِدِيّ المَريئِيّ).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في مستوى خلايا الدَّم التي تُساعِد في الوقاية من النزيف (الصفائح الدَّموية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو طبيب طفلك على الفور إذا لاحظت حدوث أيٍّ من هذه الأعراض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستعمل هذا الدَّواء بعد انتهاء تاريخ الصلاحية المدون على الملصق والعبوة الكرتونية. يُشير تاريخ انتهاء الصَّلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ في الثلاجة (عند 2&mdash;8 درجات مئوية). لا تعرضه للتَّجميد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتفظ بالزجاجة داخل العبوة الكرتونية الخارجية لحمايتها من الضَّوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب أن يُستَخدَم المحلول فور ثَقْب سدادة الزجاجة لأول مرة للإعداد للحَقْن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء إذا لاحظت أنَّ المحلول غير صافٍ إلى غائم أو يحتوي على جسيمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب التَّخلص من أي دواء غير مستعمل بعد سحب الجرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المادة الفعالة هي كاناكينوماب. تحتوي الزجاجة الواحدة على 150 مجم من كاناكينوماب في 1 مللي لتر من المحلول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي مانيتول، هيستيدين، هيدروكلوريد الهيستيدين أحادي الهيدرات، بوليسوربات 80، ماء للحقن.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتوفر عقار إيلارس في هيئة محلول للحقن في زجاجة بحجم 2 مللي لتر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المحلول عبارة عن سائل صافٍ إلى غائم، وهو عديم اللون يميل إلى الأصفر المائل إلى البني قليلًا. لا تستخدم المنتج إذا كان السائل يحتوي على جسيمات تسهل رؤيتها أو كان ضبابيًّا أو بنيًّا بشكل واضح.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتوفر عقار إيلارس في عبوات تحتوي على زجاجة واحدة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك حق التسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</p><p dir="RTL">www.Novartis.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم اعتماد هذه النَّشرة من قِبَل منظمة الأدوية الأوروبية في: مايو 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ilaris 150 mg/ml solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One vial contains 150 mg of canakinumab*.
Each ml of solution contains 150 mg canakinumab.
* human monoclonal antibody produced in mouse myeloma Sp2/0 cells by recombinant DNA
technology
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.
The solution is clear to opalescent and colourless to slightly brownish yellow.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Periodic fever syndromes</u></p><p><u>&nbsp;</u></p><p>Ilaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2&nbsp;years and older:</p><p>&nbsp;</p><p><em><u>Cryopyrin-associated periodic syndromes</u></em></p><p>Ilaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muckle-Wells syndrome (MWS),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.</p><p>&nbsp;</p><p><em><u>Tumour necrosis factor receptor associated periodic syndrome (TRAPS)</u></em></p><p>Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).</p><p>&nbsp;</p><p><em><u>Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)</u></em></p><p>Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).</p><p>&nbsp;</p><p><em><u>Familial Mediterranean fever (FMF)</u></em></p><p>Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate.</p><p>&nbsp;</p><p>Ilaris is also indicated for the treatment of:</p><p>&nbsp;</p><p><u>Still&rsquo;s disease</u></p><p><u>&nbsp;</u></p><p>Ilaris is indicated for the treatment of active Still&rsquo;s disease including adult-onset Still&rsquo;s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2&nbsp;years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.</p><p>&nbsp;</p><p><u>Gouty arthritis</u></p><p><u>&nbsp;</u></p><p>Ilaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3&nbsp;attacks in the previous 12&nbsp;months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate (see section&nbsp;5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For CAPS, TRAPS, HIDS/MKD, FMF and Still&rsquo;s disease, the treatment should be initiated and supervised by a specialist physician experienced in the diagnosis and treatment of the relevant indication.</p><p>&nbsp;</p><p>For gouty arthritis, the physician should be experienced in the use of biologics and Ilaris should be administered by a healthcare professional.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p><em><u>CAPS: Adults, adolescents and children aged 2&nbsp;years and older</u></em></p><p>The recommended starting dose of canakinumab for CAPS patients is:</p><p><em>Adults, </em><em>adolescents</em><em> and children </em><em>&ge;&nbsp;4&nbsp;years of age</em><em>:</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 150&nbsp;mg for patients with body weight &gt;&nbsp;40&nbsp;kg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2&nbsp;mg/kg for patients with body weight &ge;&nbsp;15&nbsp;kg and &le;&nbsp;40&nbsp;kg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4&nbsp;mg/kg for patients with body weight &ge;&nbsp;7.5&nbsp;kg and &lt;&nbsp;15&nbsp;kg</p><p><em>C</em><em>hildren 2 to &lt;&nbsp;4&nbsp;years of age:</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4&nbsp;mg/kg for patients with body weight &ge;&nbsp;7.5&nbsp;kg</p><p>&nbsp;</p><p>This is administered every eight weeks as a single dose via subcutaneous injection.</p><p>&nbsp;</p><p>For patients with a starting dose of 150&nbsp;mg or 2&nbsp;mg/kg, if a satisfactory clinical response (resolution of rash and other generalised inflammatory symptoms) has not been achieved 7&nbsp;days after treatment start, a second dose of canakinumab at 150&nbsp;mg or 2&nbsp;mg/kg can be considered. If a full treatment response is subsequently achieved, the intensified dosing regimen of 300&nbsp;mg or 4&nbsp;mg/kg every 8&nbsp;weeks should be maintained. If a satisfactory clinical response has not been achieved 7&nbsp;days after this increased dose, a third dose of canakinumab at 300&nbsp;mg or 4&nbsp;mg/kg can be considered. If a full treatment response is subsequently achieved, maintaining the intensified dosing regimen of 600&nbsp;mg or 8&nbsp;mg/kg every 8&nbsp;weeks should be considered, based on individual clinical judgement.</p><p>&nbsp;</p><p>For patients with a starting dose of 4&nbsp;mg/kg, if a satisfactory clinical response has not been achieved 7&nbsp;days after treatment start, a second dose of canakinumab 4&nbsp;mg/kg can be considered. If a full treatment response is subsequently achieved, maintaining the intensified dosing regimen of 8&nbsp;mg/kg every 8&nbsp;weeks should be considered, based on individual clinical judgement.</p><p>&nbsp;</p><p>Clinical experience with dosing at intervals of less than 4&nbsp;weeks or at doses above 600&nbsp;mg or 8&nbsp;mg/kg is limited.</p><p><!--[if gte vml 1]><v:rect id="Rectangle_x0020_2092" o:spid="_x0000_s1081"
 style='position:absolute;margin-left:3.1pt;margin-top:6.4pt;width:228.8pt;
 height:33.6pt;z-index:251658240;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:bottom'
 o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f">
 <o:lock v:ext="edit" grouping="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:95%;
    vertical-align:baseline'><b><i><span style='font-size:11.0pt;line-height:
    95%;color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>CAPS in
    adults and children </span></i></b><b><i><span style='font-size:11.0pt;
    line-height:95%;font-family:Symbol;mso-ascii-font-family:"Times New Roman";
    mso-hansi-font-family:"Times New Roman";color:black;mso-font-kerning:12.0pt;
    mso-ansi-language:EN-US;mso-char-type:symbol;mso-symbol-font-family:Symbol'><span
    style='mso-char-type:symbol;mso-symbol-font-family:Symbol'>³</span></span></i></b><b><i><span
    style='font-size:11.0pt;line-height:95%;color:black;mso-font-kerning:12.0pt;
    mso-ansi-language:EN-US'>&nbsp;4&nbsp;years of age </span></i></b><b><i><span
    style='font-size:11.0pt;line-height:95%;font-family:Symbol;mso-ascii-font-family:
    "Times New Roman";mso-hansi-font-family:"Times New Roman";color:black;
    mso-font-kerning:12.0pt;mso-ansi-language:EN-US;mso-char-type:symbol;
    mso-symbol-font-family:Symbol'><span style='mso-char-type:symbol;
    mso-symbol-font-family:Symbol'>³</span></span></i></b><b><i><span
    style='font-size:11.0pt;line-height:95%;color:black;mso-font-kerning:12.0pt;
    mso-ansi-language:EN-US'>&nbsp;15&nbsp;kg</span></i></b><span
    style='font-size:11.0pt;line-height:95%;mso-ansi-language:EN-US'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:rect id="Rectangle_x0020_1044" o:spid="_x0000_s1078" style='position:absolute;
 margin-left:21.25pt;margin-top:44.7pt;width:133.65pt;height:18.55pt;z-index:251661312;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:middle' o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" stroked="f">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;line-height:85%;
    color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>150&nbsp;mg or
    2&nbsp;mg/kg</span></b><span lang=DE-CH style='font-size:11.0pt;line-height:
    85%'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:rect id="Rectangle_x0020_2084" o:spid="_x0000_s1079" style='position:absolute;
 margin-left:289.8pt;margin-top:45.95pt;width:118.85pt;height:25.65pt;
 z-index:251672576;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:middle'
 o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" stroked="f">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;line-height:85%;
    color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>4&nbsp;mg/kg</span></b><span
    lang=DE-CH style='font-size:11.0pt;line-height:85%'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:rect id="Rectangle_x0020_2093" o:spid="_x0000_s1080" style='position:absolute;
 margin-left:232.05pt;margin-top:6.4pt;width:229.55pt;height:37.5pt;z-index:251673600;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:bottom' o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f">
 <o:lock v:ext="edit" grouping="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:95%;
    vertical-align:baseline'><b><i><span style='font-size:11.0pt;line-height:
    95%;color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>CAPS in children
    2‑&lt;&nbsp;4&nbsp;years of age or </span></i></b><span style='font-size:
    11.0pt;line-height:95%;mso-ansi-language:EN-US'><o:p></o:p></span></p>
    <p align=center style='margin:0in;text-align:center;line-height:95%;
    vertical-align:baseline'><b><i><span style='font-size:11.0pt;line-height:
    95%;color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>children </span></i></b><b><i><span
    style='font-size:11.0pt;line-height:95%;font-family:Symbol;mso-ascii-font-family:
    "Times New Roman";mso-hansi-font-family:"Times New Roman";color:black;
    mso-font-kerning:12.0pt;mso-ansi-language:EN-US;mso-char-type:symbol;
    mso-symbol-font-family:Symbol'><span style='mso-char-type:symbol;
    mso-symbol-font-family:Symbol'>³</span></span></i></b><b><i><span
    style='font-size:11.0pt;line-height:95%;color:black;mso-font-kerning:12.0pt;
    mso-ansi-language:EN-US'>&nbsp;4&nbsp;years of age </span></i></b><b><i><span
    style='font-size:11.0pt;line-height:95%;font-family:Symbol;mso-ascii-font-family:
    "Times New Roman";mso-hansi-font-family:"Times New Roman";color:black;
    mso-font-kerning:12.0pt;mso-ansi-language:EN-US;mso-char-type:symbol;
    mso-symbol-font-family:Symbol'><span style='mso-char-type:symbol;
    mso-symbol-font-family:Symbol'>³</span></span></i></b><b><i><span
    style='font-size:11.0pt;line-height:95%;color:black;mso-font-kerning:12.0pt;
    mso-ansi-language:EN-US'>&nbsp;7.5&nbsp;kg and &lt;&nbsp;15&nbsp;kg</span></i></b><span
    style='font-size:11.0pt;line-height:95%;mso-ansi-language:EN-US'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:shapetype id="_x0000_t34" coordsize="21600,21600" o:spt="34"
 o:oned="t" adj="10800" path="m,l@0,0@0,21600,21600,21600e" filled="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="val #0"/>
 </v:formulas>
 <v:path arrowok="t" fillok="f" o:connecttype="none"/>
 <v:handles>
  <v:h position="#0,center"/>
 </v:handles>
 <o:lock v:ext="edit" shapetype="t"/>
</v:shapetype><v:shape id="Straight_x0020_Arrow_x0020_Connector_x0020_66"
 o:spid="_x0000_s1077" type="#_x0000_t34" style='position:absolute;
 margin-left:343.6pt;margin-top:77.15pt;width:26.9pt;height:.05pt;rotation:90;
 z-index:251680768;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:3.17497mm;
 mso-wrap-distance-top:0;mso-wrap-distance-right:3.17497mm;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
" strokeweight="1.5pt">
 <o:lock v:ext="edit" shapetype="f"/>
</v:shape><v:shape id="Elbow_x0020_Connector_x0020_1045" o:spid="_x0000_s1076"
 type="#_x0000_t34" style='position:absolute;margin-left:78.5pt;margin-top:77.15pt;
 width:26.9pt;height:.05pt;rotation:90;z-index:251687936;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" adj="14012" strokeweight="1.5pt"/><v:rect id="Rectangle_x0020_1051" o:spid="_x0000_s1065"
 style='position:absolute;margin-left:-10.15pt;margin-top:189.75pt;width:108.4pt;
 height:45.05pt;z-index:251659264;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:middle'
 o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
" filled="f" fillcolor="#d9f9fb" strokeweight="1pt">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;line-height:85%;
    color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>Maintenance
    dose: 150&nbsp;mg or 2&nbsp;mg/kg every 8&nbsp;weeks</span></b><span
    style='font-size:11.0pt;line-height:85%;mso-ansi-language:EN-US'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:rect id="Rectangle_x0020_1050" o:spid="_x0000_s1064" style='position:absolute;
 margin-left:107.5pt;margin-top:191.25pt;width:103pt;height:43.55pt;z-index:251660288;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:middle' o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
" filled="f" fillcolor="#d9f9fb" strokeweight="1pt">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;line-height:85%;
    color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>Additional
    dose of 150&nbsp;mg or 2&nbsp;mg/kg can be considered</span></b><span
    style='font-size:11.0pt;line-height:85%;mso-ansi-language:EN-US'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:shapetype id="_x0000_t32" coordsize="21600,21600" o:spt="32"
 o:oned="t" path="m,l21600,21600e" filled="f">
 <v:path arrowok="t" fillok="f" o:connecttype="none"/>
 <o:lock v:ext="edit" shapetype="t"/>
</v:shapetype><v:shape id="Straight_x0020_Arrow_x0020_Connector_x0020_1052"
 o:spid="_x0000_s1067" type="#_x0000_t32" style='position:absolute;
 margin-left:40.5pt;margin-top:134.15pt;width:45.45pt;height:54.95pt;flip:x;
 z-index:251662336;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" strokecolor="windowText" strokeweight="1.5pt">
 <v:stroke endarrow="open"/>
 <o:lock v:ext="edit" shapetype="f"/>
</v:shape><v:shape id="Straight_x0020_Arrow_x0020_Connector_x0020_1047" o:spid="_x0000_s1066"
 type="#_x0000_t32" style='position:absolute;margin-left:98.25pt;margin-top:134.15pt;
 width:50.9pt;height:54.35pt;z-index:251663360;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="t" fillcolor="#d9f9fb" strokecolor="windowText" strokeweight="1.5pt">
 <v:stroke endarrow="open"/>
 <o:lock v:ext="edit" shapetype="f"/>
</v:shape><v:rect id="Rectangle_x0020_2081" o:spid="_x0000_s1052" style='position:absolute;
 margin-left:166.15pt;margin-top:366.55pt;width:124.75pt;height:40.75pt;
 z-index:251664384;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:middle'
 o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" strokeweight="1pt">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;line-height:85%;
    color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>Additional
    dose of 300&nbsp;mg or 4&nbsp;mg/kg can be considered</span></b><span
    style='font-size:11.0pt;line-height:85%;mso-ansi-language:EN-US'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:rect id="Rectangle_x0020_2088" o:spid="_x0000_s1062" style='position:absolute;
 margin-left:242.2pt;margin-top:190.5pt;width:88.95pt;height:39pt;z-index:251665408;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:middle' o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
" filled="f" fillcolor="#d9f9fb" strokeweight="1pt">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;line-height:85%;
    color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>Maintenance
    dose 4&nbsp;mg/kg every 8&nbsp;weeks</span></b><span style='font-size:11.0pt;
    line-height:85%;mso-ansi-language:EN-US'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:rect id="Rectangle_x0020_2090" o:spid="_x0000_s1063" style='position:absolute;
 margin-left:364.2pt;margin-top:191.25pt;width:94pt;height:39.65pt;z-index:251666432;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:middle' o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
" filled="f" fillcolor="#d9f9fb" strokeweight="1pt">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;line-height:85%;
    color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>Additional
    dose of 4&nbsp;mg/kg can be considered</span></b><b><span lang=EN-GB
    style='font-size:11.0pt;line-height:85%;color:black;mso-font-kerning:12.0pt;
    mso-ansi-language:EN-GB'><o:p></o:p></span></b></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:rect id="Rectangle_x0020_1055" o:spid="_x0000_s1058" style='position:absolute;
 margin-left:1in;margin-top:277.9pt;width:187.15pt;height:32.25pt;z-index:251667456;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:middle' o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" stroked="f">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;line-height:85%;
    color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>Satisfactory
    clinical response after 7&nbsp;days?</span></b><span style='font-size:11.0pt;
    line-height:85%;mso-ansi-language:EN-US'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:rect id="Rectangle_x0020_1046" o:spid="_x0000_s1074" style='position:absolute;
 margin-left:29.3pt;margin-top:99.35pt;width:129pt;height:33.3pt;z-index:251668480;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:middle' o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" stroked="f">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;line-height:85%;
    color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>Satisfactory
    clinical response after 7&nbsp;days?</span></b><span style='font-size:11.0pt;
    line-height:85%;mso-ansi-language:EN-US'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:rect id="Rectangle_x0020_2080" o:spid="_x0000_s1054" style='position:absolute;
 margin-left:36.8pt;margin-top:366.55pt;width:121.5pt;height:40.75pt;z-index:251669504;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:middle' o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
" filled="f" fillcolor="#d9f9fb" strokeweight="1pt">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;line-height:85%;
    color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>Maintenance
    dose: 300&nbsp;mg or 4&nbsp;mg/kg every 8&nbsp;weeks</span></b><span
    style='font-size:11.0pt;line-height:85%;mso-ansi-language:EN-US'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:rect id="Rectangle_x0020_1043" o:spid="_x0000_s1050" style='position:absolute;
 margin-left:149.15pt;margin-top:440.75pt;width:162.5pt;height:52.4pt;
 z-index:251670528;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:middle'
 o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
" filled="f" fillcolor="#d9f9fb" strokeweight="1pt">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;line-height:85%;
    color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>If full treatment
    response after 7&nbsp;days, maintenance dose:<o:p></o:p></span></b></p>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;line-height:85%;
    color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>600&nbsp;mg or
    8&nbsp;mg/kg every 8&nbsp;weeks</span></b><span style='font-size:9.0pt;
    line-height:85%;mso-ansi-language:EN-US'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:rect id="Rectangle_x0020_2085" o:spid="_x0000_s1075" style='position:absolute;
 margin-left:292.05pt;margin-top:99.35pt;width:126pt;height:26.9pt;z-index:251671552;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:middle' o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" stroked="f">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;line-height:85%;
    color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>Satisfactory
    clinical response after 7&nbsp;days?</span></b><span style='font-size:11.0pt;
    line-height:85%;mso-ansi-language:EN-US'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:shape id="Straight_x0020_Arrow_x0020_Connector_x0020_72" o:spid="_x0000_s1055"
 type="#_x0000_t32" style='position:absolute;margin-left:92.2pt;margin-top:316.35pt;
 width:68.2pt;height:50.35pt;flip:x;z-index:251674624;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" strokecolor="windowText" strokeweight="1.5pt">
 <v:stroke endarrow="open"/>
 <o:lock v:ext="edit" shapetype="f"/>
</v:shape><v:shape id="Straight_x0020_Arrow_x0020_Connector_x0020_75" o:spid="_x0000_s1053"
 type="#_x0000_t32" style='position:absolute;margin-left:166.8pt;margin-top:316.55pt;
 width:65.15pt;height:50pt;z-index:251675648;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="t" fillcolor="#d9f9fb" strokecolor="windowText" strokeweight="1.5pt">
 <v:stroke endarrow="open"/>
 <o:lock v:ext="edit" shapetype="f"/>
</v:shape><v:rect id="Rectangle_x0020_2091" o:spid="_x0000_s1059" style='position:absolute;
 margin-left:348.85pt;margin-top:277.9pt;width:123pt;height:53.15pt;z-index:251676672;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:middle' o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" strokeweight="1pt">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;line-height:85%;
    color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>If full
    treatment response after 7&nbsp;days, maintenance dose:<o:p></o:p></span></b></p>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;line-height:85%;
    color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>8&nbsp;mg/kg
    every 8&nbsp;weeks</span></b><span style='font-size:11.0pt;line-height:
    85%;mso-ansi-language:EN-US'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:shape id="Straight_x0020_Arrow_x0020_Connector_x0020_99" o:spid="_x0000_s1061"
 type="#_x0000_t32" style='position:absolute;margin-left:416.55pt;margin-top:232.4pt;
 width:0;height:42.8pt;z-index:251677696;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:3.17494mm;
 mso-wrap-distance-top:0;mso-wrap-distance-right:3.17494mm;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" strokecolor="windowText" strokeweight="1.5pt">
 <o:lock v:ext="edit" shapetype="f"/>
</v:shape><v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202"
 path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2082" o:spid="_x0000_s1056"
 type="#_x0000_t202" style='position:absolute;margin-left:92.2pt;margin-top:320.6pt;
 width:36.6pt;height:19.45pt;z-index:251678720;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:middle'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
" filled="f" fillcolor="#d9f9fb" strokecolor="white">
 <v:stroke opacity="0"/>
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center'><b><span lang=DE-CH
    style='font-size:11.0pt;color:black'>Yes</span></b><span lang=DE-CH
    style='font-size:11.0pt'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><v:shape id="Text_x0020_Box_x0020_1054" o:spid="_x0000_s1057" type="#_x0000_t202"
 style='position:absolute;margin-left:195.4pt;margin-top:320.6pt;width:36.65pt;
 height:19.45pt;z-index:251679744;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:middle'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" strokecolor="white">
 <v:stroke opacity="0"/>
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:95%'><b><span
    lang=DE-CH style='font-size:11.0pt;line-height:95%;color:black'>No</span></b><span
    lang=DE-CH style='font-size:11.0pt;line-height:95%'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><v:shape id="Straight_x0020_Arrow_x0020_Connector_x0020_2089" o:spid="_x0000_s1068"
 type="#_x0000_t32" style='position:absolute;margin-left:373.2pt;margin-top:133.05pt;
 width:53.55pt;height:55.45pt;z-index:251681792;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="t" fillcolor="#d9f9fb" strokecolor="windowText" strokeweight="1.5pt">
 <v:stroke endarrow="open"/>
 <o:lock v:ext="edit" shapetype="f"/>
</v:shape><v:shape id="Text_x0020_Box_x0020_2087" o:spid="_x0000_s1073" type="#_x0000_t202"
 style='position:absolute;margin-left:390.1pt;margin-top:137.15pt;width:36.65pt;
 height:19.45pt;z-index:251682816;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:middle'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" strokecolor="white">
 <v:stroke opacity="0"/>
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:95%'><b><span
    lang=DE-CH style='font-size:11.0pt;line-height:95%;color:black'>No</span></b><span
    lang=DE-CH style='font-size:11.0pt;line-height:95%'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><v:shape id="Straight_x0020_Arrow_x0020_Connector_x0020_1053" o:spid="_x0000_s1060"
 type="#_x0000_t32" style='position:absolute;margin-left:142.55pt;margin-top:256.85pt;
 width:39.1pt;height:0;rotation:90;z-index:251683840;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:3.17497mm;mso-wrap-distance-top:0;
 mso-wrap-distance-right:3.17497mm;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" strokeweight="1.5pt"/><v:shape id="Straight_x0020_Arrow_x0020_Connector_x0020_97"
 o:spid="_x0000_s1051" type="#_x0000_t32" style='position:absolute;
 margin-left:231.9pt;margin-top:410.85pt;width:0;height:28.9pt;z-index:251684864;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:3.17494mm;mso-wrap-distance-top:0;
 mso-wrap-distance-right:3.17494mm;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAZHWDV+UBAAAVBAAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWykU9tu2zAMfR+wfxD03tptkqYx6hRF
enkptgLpPoCQ5QsmU4KkOc7fj5IdJw3ytPnBEEXykOdQfHjsW8U6aV2jMec31ylnEoUuGqxy/uvz
9eqeM+cBC1AaZc730vHH9fdvD5BVFkzdCEYI6DLIee29yZLEiVq24K61kUi+UtsWPJm2SgoLO0Ju
VXKbpndJCw3y9RHqGTywP7b5ByilxW9ZbAA7cASpRHZ6M/aoxP8jQ4bdmzVb82FD5+JH92FZU+Sc
lENoSSKejI4xjMzkLKs6AvSlbUO8LkvWR5R9+EcM2XsmhktxvBX1zwuxon65EE2FhwJ0OCkqetya
UBW7TTiec1ktD2S23kJT1Z49Wat3bKMRpfDaMgo58DyFCGjvNAs3sCZ5Jm8UYbIgc2PZMwVm9/P5
6nbBGTFeLOfpPL2sxuxumc6iayIJmbHOv0ndsnDIuRu7n9q+ic8NunfnhwYPCVEM/dooFVkpZDta
h1W6oLEKMDkvFXg6toZG7bDiDFRFGyO8jZBOq6YI6QHI7d1GWdaByjm990LvPmmUnClwnhw03/gF
Aan3L6mhn2dw9ZAcXYPOHhr1ggXze0NvDGkZx3SFoaQsS5rLRGvQlsDFMOnkbCFi4XGBw9ad2uu/
AAAA//8DAFBLAwQUAAYACAAAACEAkS1qSVgGAAAPGgAAGgAAAGNsaXBib2FyZC90aGVtZS90aGVt
ZTEueG1s7FlLbxs3EL4X6H9Y7L2x3oqNyIGtR9zEToJISZEjpaV2GXOXC5Kyo1uRnHopUCAtemiA
3nooigZogAa99McYcNCmP6JD7kOkRMUPuEBQxAKM3dlvhsOZ2W9I7o2bT2PqHWEuCEs6fvVaxfdw
MmEBScKO/3A0+Oy67wmJkgBRluCOP8fCv7n96Sc30NaEknTMEA9GEY6xB4YSsYU6fiRlurWxISYg
RuIaS3ECz6aMx0jCLQ83Ao6OYYCYbtQqldZGjEjib4NFqQz1KfxLpFCCCeVDZQZ7CYph9HvTKZlg
jQ0Oqwoh5qJLuXeEaMcHmwE7HuGn0vcoEhIedPyK/vM3tm9soK1cico1uobeQP/lerlCcFjTY/Jw
XA7aaDQbrZ3SvgZQuYrrt/utfqu0pwFoMoGZZr6YNpu7m7u9Zo41QNmlw3av3atXLbxhv77i805T
/Sy8BmX2Gyv4waALUbTwGpThmyv4RqNd6zYsvAZl+NYKvl3Z6TXaFl6DIkqSwxV0pdmqd4vZlpAp
o3tO+GazMWjXcuMLFFRDWV1qiClL5Lpai9ETxgcAUECKJEk8OU/xFE2gJruIkjEn3j4JIyi8FCVM
gLhSqwwqdfivfg19pSOCtjAytJVf4IlYESl/PDHhJJUd/zZY9Q3I6Zs3J89enzz7/eT585Nnv+Zj
a1OW3h5KQlPv3U/f/PPyS+/v33589+LbbOhlvDDxb3/56u0ff77PPMx4EYrT7169ff3q9Puv//r5
hcP6DkdjEz4iMRbeXXzsPWAxTNDhPx7zi2mMIkRMjZ0kFChBahSH/b6MLPTdOaLIgdvFdhwfcaAa
F/DW7Inl8DDiM0kcFu9EsQU8YIzuMu6Mwh01lhHm0SwJ3YPzmYl7gNCRa+wuSqws92cpcCxxmexG
2HLzPkWJRCFOsPTUM3aIsWN2jwmx4npAJpwJNpXeY+LtIuIMyYiMrWpaKO2RGPIydzkI+bZic/DI
22XUNesePrKR8G4g6nB+hKkVxltoJlHsMjlCMTUDvo9k5HJyOOcTE9cXEjIdYsq8foCFcOnc4zBf
I+l3gGbcaT+g89hGckkOXTb3EWMmsscOuxGKUxd2SJLIxH4uDqFEkXefSRf8gNlviLqHPKBkbbof
EWyl+2w2eAgMa7q0KBD1ZMYdubyFmVW/wzmdIqypBhqAxesxSc4k+SV6b/539A4kevrDS8eMrobS
3YatfFyQzHc4cb5Ne0sUvg63TNxdxgPy4fN2D82S+xheldXm9ZG2P9K2/7+n7XXv89WT9YKfgbrV
sjVbruvFe7x27T4llA7lnOJ9oZfvArpSMACh0tN7VFzu5dIILtWbDANYuJAjreNxJr8gMhpGKIU1
ftVXRkKRmw6FlzIBS38tdtpWeDqLD1iQbVmrVbU9zchDILmQV5qlHLYbMkO32ottWGleexvq7XLh
gNK9iBPGYLYTdYcT7UKogqQ35xA0hxN6ZlfixabDi+vKfJGqFS/AtTIrsGzyYLHV8ZsNUAEl2FUh
igOVpyzVRXZ1Mq8y0+uCaVUArCGKClhkelP5unZ6anZZqZ0j05YTRrnZTujI6B4mIhTgvDqV9Dxu
XDTXm4uUWu6pUOjxoLQWbrSvv8+Ly+Ya9Ja5gSYmU9DEO+74rXoTSmaC0o4/ha0/XMYp1I5Qy11E
Qzg0m0ievfCXYZaUC9lDIsoCrkknY4OYSMw9SuKOr6ZfpoEmmkO0b9UaEMIH69wm0MqH5hwk3U4y
nk7xRJppNyQq0tktMHzGFc6nWv3yYKXJZpDuYRQce2M64w8QlFizXVUBDIiAE6BqFs2AwJFmSWSL
+ltqTDntmmeKuoYyOaJphPKOYpJ5BtdUXrqj78oYGHf5nCGgRkjyRjgOVYM1g2p107JrZD6s7bpn
K6nIGaS56JkWq6iu6WYxa4SiDSzF8nJN3vCqCDFwmtnhM+peptzNguuW1glll4CAl/FzdN1zNATD
tcVglmvK41UaVpydS+3eUUzwDNfO0yQM1m8VZpfiVvYI53AgvFTnB73lqgXRtFhX6ki7Pk8coNQb
h9WOD58I4GziKVzBRwYfZDUlqykZXMGXA2gX2XF/x88vCgk8zyQlpl5I6gWmUUgahaRZSJqFpFVI
Wr6nz8XhW4w6Eve94tgbelh+TJ6vLexvONv/AgAA//8DAFBLAwQUAAYACAAAACEAnGZGQbsAAAAk
AQAAKgAAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc4SPzQrCMBCE
74LvEPZu0noQkSa9iNCr1AcIyTYtNj8kUezbG+hFQfCyMLPsN7NN+7IzeWJMk3ccaloBQae8npzh
cOsvuyOQlKXTcvYOOSyYoBXbTXPFWeZylMYpJFIoLnEYcw4nxpIa0cpEfUBXNoOPVuYio2FBqrs0
yPZVdWDxkwHii0k6zSF2ugbSL6Ek/2f7YZgUnr16WHT5RwTLpRcWoIwGMwdKV2edNS1dgYmGff0m
3gAAAP//AwBQSwECLQAUAAYACAAAACEAu+VIlAUBAAAeAgAAEwAAAAAAAAAAAAAAAAAAAAAAW0Nv
bnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQCtMD/xwQAAADIBAAALAAAAAAAAAAAAAAAA
ADYBAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQBkdYNX5QEAABUEAAAfAAAAAAAAAAAAAAAA
ACACAABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2luZzEueG1sUEsBAi0AFAAGAAgAAAAhAJEtaklY
BgAADxoAABoAAAAAAAAAAAAAAAAAQgQAAGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1sUEsBAi0A
FAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAAAAAAAAAAAAAAAA0goAAGNsaXBib2FyZC9kcmF3aW5n
cy9fcmVscy9kcmF3aW5nMS54bWwucmVsc1BLBQYAAAAABQAFAGcBAADVCwAAAAA=
" strokecolor="windowText" strokeweight="1.5pt">
 <o:lock v:ext="edit" shapetype="f"/>
</v:shape><v:shape id="Text_x0020_Box_x0020_1049" o:spid="_x0000_s1070" type="#_x0000_t202"
 style='position:absolute;margin-left:121.65pt;margin-top:141.85pt;width:36.65pt;
 height:20.65pt;z-index:251685888;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:middle'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" strokecolor="white">
 <v:stroke opacity="0"/>
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:95%'><b><span
    lang=DE-CH style='font-size:11.0pt;line-height:95%;color:black'>No</span></b><span
    lang=DE-CH style='font-size:11.0pt;line-height:95%'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><v:shape id="Text_x0020_Box_x0020_1048" o:spid="_x0000_s1071" type="#_x0000_t202"
 style='position:absolute;margin-left:21.25pt;margin-top:141.85pt;width:36.6pt;
 height:20.65pt;z-index:251686912;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:middle'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" strokecolor="white">
 <v:stroke opacity="0"/>
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:95%'><b><span
    lang=DE-CH style='font-size:11.0pt;line-height:95%;color:black'>Yes</span></b><span
    lang=DE-CH style='font-size:11.0pt;line-height:95%'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><v:shape id="Straight_x0020_Arrow_x0020_Connector_x0020_2083" o:spid="_x0000_s1069"
 type="#_x0000_t32" style='position:absolute;margin-left:275.05pt;margin-top:133.05pt;
 width:63.15pt;height:54.7pt;flip:x;z-index:251688960;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" strokecolor="windowText" strokeweight="1.5pt">
 <v:stroke endarrow="open"/>
 <o:lock v:ext="edit" shapetype="f"/>
</v:shape><v:shape id="Text_x0020_Box_x0020_2086" o:spid="_x0000_s1072" type="#_x0000_t202"
 style='position:absolute;margin-left:275.05pt;margin-top:137.15pt;width:36.6pt;
 height:19.45pt;z-index:251689984;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:middle'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" strokecolor="white">
 <v:stroke opacity="0"/>
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center'><b><span lang=DE-CH
    style='font-size:11.0pt;color:black'>Yes</span></b><span lang=DE-CH
    style='font-size:11.0pt'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td style="vertical-align:top"><img width="615" height="116" src="file:///C:/Users/alsheab1/AppData/Local/Temp/8/msohtmlclip1/01/clip_image001.gif" /></td></tr><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td colspan="3" style="vertical-align:top"><img width="649" height="530" src="file:///C:/Users/alsheab1/AppData/Local/Temp/8/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>TRAPS, HIDS/MKD and FMF: Adults, adolescents and children aged 2&nbsp;years and older</u></em></p><p>The recommended starting dose of canakinumab in TRAPS, HIDS/MKD and FMF patients is:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 150&nbsp;mg for patients with body weight &gt;&nbsp;40&nbsp;kg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2&nbsp;mg/kg for patients with body weight &ge;&nbsp;7.5&nbsp;kg and &le;&nbsp;40&nbsp;kg</p><p>&nbsp;</p><p>This is administered every four weeks as a single dose via subcutaneous injection.</p><p>&nbsp;</p><p>If a satisfactory clinical response has not been achieved 7&nbsp;days after treatment start, a second dose of canakinumab at 150&nbsp;mg or 2&nbsp;mg/kg can be considered. If a full treatment response is subsequently achieved, the intensified dosing regimen of 300&nbsp;mg (or 4&nbsp;mg/kg for patients weighing &le;&nbsp;40&nbsp;kg) every 4&nbsp;weeks should be maintained.</p><p>&nbsp;</p><p>Continued treatment with canakinumab in patients without clinical improvement should be reconsidered by the treating physician.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:rect id="_x0000_s1043" style='position:absolute;
 margin-left:25.9pt;margin-top:80.75pt;width:129pt;height:33.3pt;z-index:251699200;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:middle' o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEA6zH+BdoDAAClCQAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzcVlmO4zYQ/Q+QOxD8V2uxvMgYdcOb
BgE6E6M9cwCaoixiKFIh6W2C3CVnyclSpOS2u3uQADPJT2wYLqoei1WvFurdw6kR6MC04UrmOL6L
MGKSqpLLXY4/fSyCCUbGElkSoSTL8ZkZ/HD/4w/vyHSnSVtzisCCNFOS49radhqGhtasIeZOtUyC
rlK6IRaWeheWmhzBciPCJIpGYUO4xPdXU0tiCdpr/g2mhKKfWbkg8kAMmBR0evuk91HQ77dMpvLw
Xrebdq2d5/TDYa0RL3MMzEnSAEU47BU9DJbhq127q4FTpRuHV1WFTpCBJMkGI7B1BnkcjYfxsLPH
ThZRBxgNJoMIABQQKaDjqD+w/uUfTNB69fdGwM3OHRBuXDStc1Ae3sY8iC9BPzEKVbITDMVROnqm
4LLFtI+QIIOkWtQAYzOt1bFmpDQQkUPDiUBlB/dsXXcCv9vjz6oEaqHkzr5g/iXWngMm01Yb+56p
Bjkhxxri8SeRw6OxnYMXiGdDFVwIn2khXzwAm90TyBhsdTqXO1/Wv2VRtpqsJmmQJqNVkEbLZTAr
FmkwKuLxcDlYLhbL+Hd3bpxOa16WTLpjLi0Wp2/qt+FUK6Mqe0dVE0IRccoubQZNFkfXJjNK8NKZ
cy4ZvdsuhEYHInK8zIqsmPdpuIGFL93wWYJYXoUUJ2k0T7KgGE3GQVqkwyAbR5MgirN5NorSLF0W
L0N65JJ9f0jomONsmAx9lm6cfhVb5D9vYyPThlumkeBNjifPIDJ1VbmSpU+tJVx08g0Vzv0rFZDu
S6JBNP1YsKeNbxp7mqvy7Ajbwj9UslZQXNC9MHJBqJX+gtERBmmOza97ohlG4icJTZHFaQow6xfp
cJzAQt9qtrcaIimYyjG1GqNusbCwhk37VvNdDWfFniipZnurKt6XdOeV808Yu7FnwXzc3ncIBTVE
P3ozIDx5gYgdXBT+oEpJO/PLLTHMmxdy01JfXy1dU9uV12QI9PYZuAXMWXWBWtNBLzDT0qt2VvmS
g2frr+C8FqjvmdfOpAbXBcyZHDMZfNrAFfYFCIjd2Nw6JtBnpt11B7fQN5cPqyqYEd1wAPqI5RLZ
c8sqQmFSfeQNM+gDO6In1RCJUUukMqCIEviOokE0jFL4JSCloOWW1gVpuHBzH+5cWhNtmK8VnxFG
/jPjwB3w5Wiz9xsIw0AEVukzooJLTolAmplWScMQqVzLjP/8oyRn8+CGNmTG7Xe7mSzXRJOnr3J/
Yfr/xNo1YE8CNI0j5Lnj94ZtWncvQgK9wo0EENx1Gr56QfGK/oXKvQXdru//AgAA//8DAFBLAwQU
AAYACAAAACEAkS1qSVgGAAAPGgAAGgAAAGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1s7FlLbxs3
EL4X6H9Y7L2x3oqNyIGtR9zEToJISZEjpaV2GXOXC5Kyo1uRnHopUCAtemiA3nooigZogAa99McY
cNCmP6JD7kOkRMUPuEBQxAKM3dlvhsOZ2W9I7o2bT2PqHWEuCEs6fvVaxfdwMmEBScKO/3A0+Oy6
7wmJkgBRluCOP8fCv7n96Sc30NaEknTMEA9GEY6xB4YSsYU6fiRlurWxISYgRuIaS3ECz6aMx0jC
LQ83Ao6OYYCYbtQqldZGjEjib4NFqQz1KfxLpFCCCeVDZQZ7CYph9HvTKZlgjQ0Oqwoh5qJLuXeE
aMcHmwE7HuGn0vcoEhIedPyK/vM3tm9soK1cico1uobeQP/lerlCcFjTY/JwXA7aaDQbrZ3SvgZQ
uYrrt/utfqu0pwFoMoGZZr6YNpu7m7u9Zo41QNmlw3av3atXLbxhv77i805T/Sy8BmX2Gyv4waAL
UbTwGpThmyv4RqNd6zYsvAZl+NYKvl3Z6TXaFl6DIkqSwxV0pdmqd4vZlpApo3tO+GazMWjXcuML
FFRDWV1qiClL5Lpai9ETxgcAUECKJEk8OU/xFE2gJruIkjEn3j4JIyi8FCVMgLhSqwwqdfivfg19
pSOCtjAytJVf4IlYESl/PDHhJJUd/zZY9Q3I6Zs3J89enzz7/eT585Nnv+Zja1OW3h5KQlPv3U/f
/PPyS+/v33589+LbbOhlvDDxb3/56u0ff77PPMx4EYrT7169ff3q9Puv//r5hcP6DkdjEz4iMRbe
XXzsPWAxTNDhPx7zi2mMIkRMjZ0kFChBahSH/b6MLPTdOaLIgdvFdhwfcaAaF/DW7Inl8DDiM0kc
Fu9EsQU8YIzuMu6Mwh01lhHm0SwJ3YPzmYl7gNCRa+wuSqws92cpcCxxmexG2HLzPkWJRCFOsPTU
M3aIsWN2jwmx4npAJpwJNpXeY+LtIuIMyYiMrWpaKO2RGPIydzkI+bZic/DI22XUNesePrKR8G4g
6nB+hKkVxltoJlHsMjlCMTUDvo9k5HJyOOcTE9cXEjIdYsq8foCFcOnc4zBfI+l3gGbcaT+g89hG
ckkOXTb3EWMmsscOuxGKUxd2SJLIxH4uDqFEkXefSRf8gNlviLqHPKBkbbofEWyl+2w2eAgMa7q0
KBD1ZMYdubyFmVW/wzmdIqypBhqAxesxSc4k+SV6b/539A4kevrDS8eMrobS3YatfFyQzHc4cb5N
e0sUvg63TNxdxgPy4fN2D82S+xheldXm9ZG2P9K2/7+n7XXv89WT9YKfgbrVsjVbruvFe7x27T4l
lA7lnOJ9oZfvArpSMACh0tN7VFzu5dIILtWbDANYuJAjreNxJr8gMhpGKIU1ftVXRkKRmw6FlzIB
S38tdtpWeDqLD1iQbVmrVbU9zchDILmQV5qlHLYbMkO32ottWGleexvq7XLhgNK9iBPGYLYTdYcT
7UKogqQ35xA0hxN6ZlfixabDi+vKfJGqFS/AtTIrsGzyYLHV8ZsNUAEl2FUhigOVpyzVRXZ1Mq8y
0+uCaVUArCGKClhkelP5unZ6anZZqZ0j05YTRrnZTujI6B4mIhTgvDqV9DxuXDTXm4uUWu6pUOjx
oLQWbrSvv8+Ly+Ya9Ja5gSYmU9DEO+74rXoTSmaC0o4/ha0/XMYp1I5Qy11EQzg0m0ievfCXYZaU
C9lDIsoCrkknY4OYSMw9SuKOr6ZfpoEmmkO0b9UaEMIH69wm0MqH5hwk3U4ynk7xRJppNyQq0tkt
MHzGFc6nWv3yYKXJZpDuYRQce2M64w8QlFizXVUBDIiAE6BqFs2AwJFmSWSL+ltqTDntmmeKuoYy
OaJphPKOYpJ5BtdUXrqj78oYGHf5nCGgRkjyRjgOVYM1g2p107JrZD6s7bpnK6nIGaS56JkWq6iu
6WYxa4SiDSzF8nJN3vCqCDFwmtnhM+peptzNguuW1glll4CAl/FzdN1zNATDtcVglmvK41UaVpyd
S+3eUUzwDNfO0yQM1m8VZpfiVvYI53AgvFTnB73lqgXRtFhX6ki7Pk8coNQbh9WOD58I4GziKVzB
RwYfZDUlqykZXMGXA2gX2XF/x88vCgk8zyQlpl5I6gWmUUgahaRZSJqFpFVIWr6nz8XhW4w6Eve9
4tgbelh+TJ6vLexvONv/AgAA//8DAFBLAwQUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAGNsaXBi
b2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc4SPzQrCMBCE74LvEPZu0noQkSa9
iNCr1AcIyTYtNj8kUezbG+hFQfCyMLPsN7NN+7IzeWJMk3ccaloBQae8npzhcOsvuyOQlKXTcvYO
OSyYoBXbTXPFWeZylMYpJFIoLnEYcw4nxpIa0cpEfUBXNoOPVuYio2FBqrs0yPZVdWDxkwHii0k6
zSF2ugbSL6Ek/2f7YZgUnr16WHT5RwTLpRcWoIwGMwdKV2edNS1dgYmGff0m3gAAAP//AwBQSwEC
LQAUAAYACAAAACEAu+VIlAUBAAAeAgAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNd
LnhtbFBLAQItABQABgAIAAAAIQCtMD/xwQAAADIBAAALAAAAAAAAAAAAAAAAADYBAABfcmVscy8u
cmVsc1BLAQItABQABgAIAAAAIQDrMf4F2gMAAKUJAAAfAAAAAAAAAAAAAAAAACACAABjbGlwYm9h
cmQvZHJhd2luZ3MvZHJhd2luZzEueG1sUEsBAi0AFAAGAAgAAAAhAJEtaklYBgAADxoAABoAAAAA
AAAAAAAAAAAANwYAAGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1sUEsBAi0AFAAGAAgAAAAhAJxm
RkG7AAAAJAEAACoAAAAAAAAAAAAAAAAAxwwAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3
aW5nMS54bWwucmVsc1BLBQYAAAAABQAFAGcBAADKDQAAAAA=
" filled="f" fillcolor="#d9f9fb" stroked="f"/><v:rect id="_x0000_s1042"
 style='position:absolute;margin-left:297.8pt;margin-top:81.1pt;width:126pt;
 height:26.9pt;z-index:251700224;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:middle'
 o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" stroked="f">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;line-height:85%;
    color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>Satisfactory
    clinical response after 7&nbsp;days?</span></b><span style='font-size:11.0pt;
    line-height:85%;mso-ansi-language:EN-US'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:rect id="_x0000_s1047" style='position:absolute;margin-left:292.35pt;
 margin-top:25.05pt;width:118.85pt;height:20.25pt;z-index:251701248;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:middle' o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" stroked="f">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;line-height:85%;
    color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>2&nbsp;mg/kg</span></b><span
    lang=DE-CH style='font-size:11.0pt;line-height:85%'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:rect id="_x0000_s1049" style='position:absolute;margin-left:235.95pt;
 margin-top:-5.6pt;width:229.55pt;height:31.9pt;z-index:251702272;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:bottom'
 o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
" filled="f" stroked="f">
 <o:lock v:ext="edit" grouping="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:95%;
    vertical-align:baseline'><b><i><span style='font-size:11.0pt;line-height:
    95%;color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>TRAPS,
    HIDS/MKD and FMF patients <br>
    with body weight </span></i></b><b><i><span style='font-size:11.0pt;
    line-height:95%;font-family:Symbol;mso-ascii-font-family:"Times New Roman";
    mso-hansi-font-family:"Times New Roman";color:black;mso-font-kerning:12.0pt;
    mso-ansi-language:EN-US;mso-char-type:symbol;mso-symbol-font-family:Symbol'><span
    style='mso-char-type:symbol;mso-symbol-font-family:Symbol'>³</span></span></i></b><b><i><span
    style='font-size:11.0pt;line-height:95%;color:black;mso-font-kerning:12.0pt;
    mso-ansi-language:EN-US'>&nbsp;7.5&nbsp;kg and ≤&nbsp;40&nbsp;kg</span></i></b><span
    style='font-size:11.0pt;line-height:95%;mso-ansi-language:EN-US'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:shape id="_x0000_s1045" type="#_x0000_t32" style='position:absolute;
 margin-left:357pt;margin-top:43.25pt;width:0;height:36pt;z-index:251705344;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:3.17494mm;mso-wrap-distance-top:0;
 mso-wrap-distance-right:3.17494mm;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
" strokecolor="windowText" strokeweight="1.5pt">
 <o:lock v:ext="edit" shapetype="f"/>
</v:shape><v:rect id="_x0000_s1048" style='position:absolute;margin-left:3.1pt;
 margin-top:-6.25pt;width:228.8pt;height:31.15pt;z-index:251691008;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:bottom' o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f">
 <o:lock v:ext="edit" grouping="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:95%;
    vertical-align:baseline'><b><i><span style='font-size:11.0pt;line-height:
    95%;color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>TRAPS,
    HIDS/MKD and FMF patients <br>
    with body weight &gt;&nbsp;40&nbsp;kg</span></i></b><span style='font-size:
    11.0pt;line-height:95%;mso-ansi-language:EN-US'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:rect id="_x0000_s1046" style='position:absolute;margin-left:24.1pt;
 margin-top:26.6pt;width:133.65pt;height:18.55pt;z-index:251694080;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:middle' o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" stroked="f">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;line-height:85%;
    color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-US'>150&nbsp;mg</span></b><span
    lang=DE-CH style='font-size:11.0pt;line-height:85%'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:shape id="_x0000_s1044" type="#_x0000_t34" style='position:absolute;
 margin-left:77.7pt;margin-top:59.85pt;width:26.9pt;height:.05pt;rotation:90;
 z-index:251711488;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" adj="14012" strokeweight="1.5pt"/><v:rect id="_x0000_s1031" style='position:absolute;
 margin-left:-4.05pt;margin-top:178.1pt;width:96pt;height:40pt;z-index:251692032;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:middle' o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" strokeweight="1pt">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;mso-bidi-font-size:
    9.0pt;line-height:85%;color:black;mso-font-kerning:12.0pt;mso-ansi-language:
    EN-US'>Maintenance dose: 150&nbsp;mg every 4&nbsp;weeks</span></b><span
    style='font-size:11.0pt;mso-bidi-font-size:9.0pt;line-height:85%;
    mso-ansi-language:EN-US'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:rect id="_x0000_s1030" style='position:absolute;margin-left:107.5pt;
 margin-top:178.1pt;width:103pt;height:40pt;z-index:251693056;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:middle'
 o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAzZeL87UDAAD7CAAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzcVtuO2zYQfS/QfyD47tVlZa9tRBt4
fQkKbDeLdfIBY4qyiFCkStK3BP2Xfku/LENKWnuzaQv08lIbhmc8o+HMmTNDv3l7rCXZc2OFVjlN
rmJKuGK6EGqb048fVoMxJdaBKkBqxXN64pa+vf3xhzcw3RpoKsEIRlB2CjmtnGumUWRZxWuwV7rh
Cm2lNjU4VM02KgwcMHItozSOR1ENQtHbc6gFOCA7I/5GKKnZJ17MQe3BYkjJppe/dDlK9s8jw1Tt
35lm3Twanzl72D8aIoqcInIKaoSIRp2hc0M1+uap7TnAsTS199dlSY45TdPRcDTGWCeUx5NJlsRt
PH50hKFDch2PkxgdGHoM43GMcntg9f4vQrBq+edBMM02HRQuUrSNT1DtX9ecpn3RT5whS7aSkyQe
9hk9PD9im3tskCVKzyt04zNj9KHiUFisyOePJyKU7QkBrf4wi0CTzeFnXSC0SLlTIMy/hNpzwTBt
jHXvuK6JF3JqsJ5wEuzvrWsT7F0CGnolpAzAS0UOWEV6g53wJqulKLw1KGa7mUtD9iCRIuHVlfvC
rRaOGyJFnVPf0b6nHqGlKsIxDoRsZcxaKh8cOYHJdVI7OF8m8WQ5Xo6zQZaOloMsXiwGs9U8G4xW
yc1wcb2YzxfJrz7PJJtWoii48qn2Q5xkryakFsxoq0t3xXQdIU0F4/0g4xgn8XmMX5RkLytfTFaT
1d3ryqOXaQQeYFX9d6gOy/Uk8GW64zpw0R3vdHHyv2zwGwliNPYMhwI3GQqVNp8pOeB+yqn9ZQeG
UyJ/Usi1SZJl6OaCkg1vUlTMpWVzaQHFMFROmTOUtMrcoY4P7RojthWelYSeKz3bOV2KjiltVj4/
ad3anSQPLQy5ez7XYO5DGBSeggByi/s3HFRq5WZB3YDlIbxU64b5cLZhj8y1bBoPO54EPpwd7njZ
uzrbEa9HvmFn66wM1PEhv+MXrBi5Qz7AbzB1ieObU64GH9d4M3xGAMI22ngkyCdu/C2Cyz2k/cd8
CBwPa8J393JgeFni6LUzh/CBE4q4U8NLYLgAPoiaW/LAD+RJ16AoaUBpi4Y4xfcovsblk+EnRSlD
q3CsWkEtJC7LBK8yVoGxPHAldITDfxYcC0O8fCfc7awohMMbFiQpMF2iS5IM499/q7eEgSIbTphW
VhTc8MKvwnYAwsNcFY9g4Om70PdA/59AOxcctgDOjAfkeeB3lq8bf9tg/4LBbwQU/CUVfXPtB0P3
N8X/t7jUb78CAAD//wMAUEsDBBQABgAIAAAAIQCRLWpJWAYAAA8aAAAaAAAAY2xpcGJvYXJkL3Ro
ZW1lL3RoZW1lMS54bWzsWUtvGzcQvhfof1jsvbHeio3Iga1H3MROgkhJkSOlpXYZc5cLkrKjW5Gc
eilQIC16aIDeeiiKBmiABr30xxhw0KY/okPuQ6RExQ+4QFDEAozd2W+Gw5nZb0jujZtPY+odYS4I
Szp+9VrF93AyYQFJwo7/cDT47LrvCYmSAFGW4I4/x8K/uf3pJzfQ1oSSdMwQD0YRjrEHhhKxhTp+
JGW6tbEhJiBG4hpLcQLPpozHSMItDzcCjo5hgJhu1CqV1kaMSOJvg0WpDPUp/EukUIIJ5UNlBnsJ
imH0e9MpmWCNDQ6rCiHmoku5d4RoxwebATse4afS9ygSEh50/Ir+8ze2b2ygrVyJyjW6ht5A/+V6
uUJwWNNj8nBcDtpoNButndK+BlC5iuu3+61+q7SnAWgygZlmvpg2m7ubu71mjjVA2aXDdq/dq1ct
vGG/vuLzTlP9LLwGZfYbK/jBoAtRtPAalOGbK/hGo13rNiy8BmX41gq+XdnpNdoWXoMiSpLDFXSl
2ap3i9mWkCmje074ZrMxaNdy4wsUVENZXWqIKUvkulqL0RPGBwBQQIokSTw5T/EUTaAmu4iSMSfe
PgkjKLwUJUyAuFKrDCp1+K9+DX2lI4K2MDK0lV/giVgRKX88MeEklR3/Nlj1Dcjpmzcnz16fPPv9
5Pnzk2e/5mNrU5beHkpCU+/dT9/88/JL7+/ffnz34tts6GW8MPFvf/nq7R9/vs88zHgRitPvXr19
/er0+6//+vmFw/oOR2MTPiIxFt5dfOw9YDFM0OE/HvOLaYwiREyNnSQUKEFqFIf9vows9N05osiB
28V2HB9xoBoX8NbsieXwMOIzSRwW70SxBTxgjO4y7ozCHTWWEebRLAndg/OZiXuA0JFr7C5KrCz3
ZylwLHGZ7EbYcvM+RYlEIU6w9NQzdoixY3aPCbHiekAmnAk2ld5j4u0i4gzJiIytaloo7ZEY8jJ3
OQj5tmJz8MjbZdQ16x4+spHwbiDqcH6EqRXGW2gmUewyOUIxNQO+j2TkcnI45xMT1xcSMh1iyrx+
gIVw6dzjMF8j6XeAZtxpP6Dz2EZySQ5dNvcRYyayxw67EYpTF3ZIksjEfi4OoUSRd59JF/yA2W+I
uoc8oGRtuh8RbKX7bDZ4CAxrurQoEPVkxh25vIWZVb/DOZ0irKkGGoDF6zFJziT5JXpv/nf0DiR6
+sNLx4yuhtLdhq18XJDMdzhxvk17SxS+DrdM3F3GA/Lh83YPzZL7GF6V1eb1kbY/0rb/v6ftde/z
1ZP1gp+ButWyNVuu68V7vHbtPiWUDuWc4n2hl+8CulIwAKHS03tUXO7l0ggu1ZsMA1i4kCOt43Em
vyAyGkYohTV+1VdGQpGbDoWXMgFLfy122lZ4OosPWJBtWatVtT3NyEMguZBXmqUcthsyQ7fai21Y
aV57G+rtcuGA0r2IE8ZgthN1hxPtQqiCpDfnEDSHE3pmV+LFpsOL68p8kaoVL8C1MiuwbPJgsdXx
mw1QASXYVSGKA5WnLNVFdnUyrzLT64JpVQCsIYoKWGR6U/m6dnpqdlmpnSPTlhNGudlO6MjoHiYi
FOC8OpX0PG5cNNebi5Ra7qlQ6PGgtBZutK+/z4vL5hr0lrmBJiZT0MQ77vitehNKZoLSjj+FrT9c
xinUjlDLXURDODSbSJ698JdhlpQL2UMiygKuSSdjg5hIzD1K4o6vpl+mgSaaQ7Rv1RoQwgfr3CbQ
yofmHCTdTjKeTvFEmmk3JCrS2S0wfMYVzqda/fJgpclmkO5hFBx7YzrjDxCUWLNdVQEMiIAToGoW
zYDAkWZJZIv6W2pMOe2aZ4q6hjI5ommE8o5iknkG11ReuqPvyhgYd/mcIaBGSPJGOA5VgzWDanXT
smtkPqztumcrqcgZpLnomRarqK7pZjFrhKINLMXyck3e8KoIMXCa2eEz6l6m3M2C65bWCWWXgICX
8XN03XM0BMO1xWCWa8rjVRpWnJ1L7d5RTPAM187TJAzWbxVml+JW9gjncCC8VOcHveWqBdG0WFfq
SLs+Txyg1BuH1Y4PnwjgbOIpXMFHBh9kNSWrKRlcwZcDaBfZcX/Hzy8KCTzPJCWmXkjqBaZRSBqF
pFlImoWkVUhavqfPxeFbjDoS973i2Bt6WH5Mnq8t7G842/8CAAD//wMAUEsDBBQABgAIAAAAIQCc
ZkZBuwAAACQBAAAqAAAAY2xpcGJvYXJkL2RyYXdpbmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxz
hI/NCsIwEITvgu8Q9m7SehCRJr2I0KvUBwjJNi02PyRR7Nsb6EVB8LIws+w3s037sjN5YkyTdxxq
WgFBp7yenOFw6y+7I5CUpdNy9g45LJigFdtNc8VZ5nKUxikkUigucRhzDifGkhrRykR9QFc2g49W
5iKjYUGquzTI9lV1YPGTAeKLSTrNIXa6BtIvoST/Z/thmBSevXpYdPlHBMulFxagjAYzB0pXZ501
LV2BiYZ9/SbeAAAA//8DAFBLAQItABQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAAAAAAAAAAAAA
AAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAK0wP/HBAAAAMgEAAAsAAAAA
AAAAAAAAAAAANgEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAM2Xi/O1AwAA+wgAAB8AAAAA
AAAAAAAAAAAAIAIAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWxQSwECLQAUAAYACAAA
ACEAkS1qSVgGAAAPGgAAGgAAAAAAAAAAAAAAAAASBgAAY2xpcGJvYXJkL3RoZW1lL3RoZW1lMS54
bWxQSwECLQAUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAAAAAAAAAAAAAACiDAAAY2xpcGJvYXJk
L2RyYXdpbmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzUEsFBgAAAAAFAAUAZwEAAKUNAAAAAA==
" filled="f" fillcolor="#d9f9fb" strokeweight="1pt">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;mso-bidi-font-size:
    9.0pt;line-height:85%;color:black;mso-font-kerning:12.0pt;mso-ansi-language:
    EN-US'>Additional dose of 150&nbsp;mg can be considered</span></b><span
    style='font-size:11.0pt;mso-bidi-font-size:9.0pt;line-height:85%;
    mso-ansi-language:EN-US'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:shape id="_x0000_s1034" type="#_x0000_t32" style='position:absolute;
 margin-left:40.5pt;margin-top:121pt;width:45.45pt;height:54.95pt;flip:x;
 z-index:251695104;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" strokecolor="windowText" strokeweight="1.5pt">
 <v:stroke endarrow="open"/>
 <o:lock v:ext="edit" shapetype="f"/>
</v:shape><v:shape id="_x0000_s1033" type="#_x0000_t32" style='position:absolute;
 margin-left:98.25pt;margin-top:121pt;width:50.9pt;height:54.35pt;z-index:251696128;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAVet9kwACAACCBAAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWysVNtu2zAMfR+wfxD0vtrJHK826hRb
0vSl6wqk+wBWli+oLAmSajt/P8p23DQYNmBrnsiQOjw8JH113TeCtNzYWsmMLi5CSrhkKq9lmdGf
j7tPl5RYBzIHoSTP6IFber3++OEK0tKArmpGEEHaFDJaOafTILCs4g3YC6W5xFihTAMOXVMGuYEO
kRsRLMMwDhqoJV2/Qm3BAXkx9T9ACcWeeb4B2YJFSMHS038mjoL9PzKksr01eq8fjGfO7tsHQ+o8
o6ichAYlosEUmNLQDc5ela8AfWEan6+KgvQZXS6iy2W4ouTg7SSJo3DE470jDBPiKI4+Yy2GCXES
LqPVVK/68RcEVt38EQNJjmTQOCHIernXnqFsN94873sRRl+Ore+dgbqsHPlqjOrIRknJmVOGDElH
XU5hPOIdzs6OKqGcc3QQbfYgtViaPHXfVY4iw4tTw+q8j35z75BqY90tVw3xRkbt1NLcy2IoC+2d
dSPn4wOvkVWizne1EINjyqeNMKQFkdFtskt23/yssNabNCFJh6eXhCs/VtAZLQQ4NBuNa2VlSQmI
Eq+TOTPUfvPaHuxcA28rV90jrgolAqzDAO7l8PtdYU98C7YaCQ6o4y45qMWNzIk7aC+1n+X0Xkjf
GC8KHOssgB/M0BYbVyU4u74hNn0t/Imf+utfAAAA//8DAFBLAwQUAAYACAAAACEAkS1qSVgGAAAP
GgAAGgAAAGNsaXBib2FyZC90aGVtZS90aGVtZTEueG1s7FlLbxs3EL4X6H9Y7L2x3oqNyIGtR9zE
ToJISZEjpaV2GXOXC5Kyo1uRnHopUCAtemiA3nooigZogAa99McYcNCmP6JD7kOkRMUPuEBQxAKM
3dlvhsOZ2W9I7o2bT2PqHWEuCEs6fvVaxfdwMmEBScKO/3A0+Oy67wmJkgBRluCOP8fCv7n96Sc3
0NaEknTMEA9GEY6xB4YSsYU6fiRlurWxISYgRuIaS3ECz6aMx0jCLQ83Ao6OYYCYbtQqldZGjEji
b4NFqQz1KfxLpFCCCeVDZQZ7CYph9HvTKZlgjQ0Oqwoh5qJLuXeEaMcHmwE7HuGn0vcoEhIedPyK
/vM3tm9soK1cico1uobeQP/lerlCcFjTY/JwXA7aaDQbrZ3SvgZQuYrrt/utfqu0pwFoMoGZZr6Y
Npu7m7u9Zo41QNmlw3av3atXLbxhv77i805T/Sy8BmX2Gyv4waALUbTwGpThmyv4RqNd6zYsvAZl
+NYKvl3Z6TXaFl6DIkqSwxV0pdmqd4vZlpApo3tO+GazMWjXcuMLFFRDWV1qiClL5Lpai9ETxgcA
UECKJEk8OU/xFE2gJruIkjEn3j4JIyi8FCVMgLhSqwwqdfivfg19pSOCtjAytJVf4IlYESl/PDHh
JJUd/zZY9Q3I6Zs3J89enzz7/eT585Nnv+Zja1OW3h5KQlPv3U/f/PPyS+/v33589+LbbOhlvDDx
b3/56u0ff77PPMx4EYrT7169ff3q9Puv//r5hcP6DkdjEz4iMRbeXXzsPWAxTNDhPx7zi2mMIkRM
jZ0kFChBahSH/b6MLPTdOaLIgdvFdhwfcaAaF/DW7Inl8DDiM0kcFu9EsQU8YIzuMu6Mwh01lhHm
0SwJ3YPzmYl7gNCRa+wuSqws92cpcCxxmexG2HLzPkWJRCFOsPTUM3aIsWN2jwmx4npAJpwJNpXe
Y+LtIuIMyYiMrWpaKO2RGPIydzkI+bZic/DI22XUNesePrKR8G4g6nB+hKkVxltoJlHsMjlCMTUD
vo9k5HJyOOcTE9cXEjIdYsq8foCFcOnc4zBfI+l3gGbcaT+g89hGckkOXTb3EWMmsscOuxGKUxd2
SJLIxH4uDqFEkXefSRf8gNlviLqHPKBkbbofEWyl+2w2eAgMa7q0KBD1ZMYdubyFmVW/wzmdIqyp
BhqAxesxSc4k+SV6b/539A4kevrDS8eMrobS3YatfFyQzHc4cb5Ne0sUvg63TNxdxgPy4fN2D82S
+xheldXm9ZG2P9K2/7+n7XXv89WT9YKfgbrVsjVbruvFe7x27T4llA7lnOJ9oZfvArpSMACh0tN7
VFzu5dIILtWbDANYuJAjreNxJr8gMhpGKIU1ftVXRkKRmw6FlzIBS38tdtpWeDqLD1iQbVmrVbU9
zchDILmQV5qlHLYbMkO32ottWGleexvq7XLhgNK9iBPGYLYTdYcT7UKogqQ35xA0hxN6ZlfixabD
i+vKfJGqFS/AtTIrsGzyYLHV8ZsNUAEl2FUhigOVpyzVRXZ1Mq8y0+uCaVUArCGKClhkelP5unZ6
anZZqZ0j05YTRrnZTujI6B4mIhTgvDqV9DxuXDTXm4uUWu6pUOjxoLQWbrSvv8+Ly+Ya9Ja5gSYm
U9DEO+74rXoTSmaC0o4/ha0/XMYp1I5Qy11EQzg0m0ievfCXYZaUC9lDIsoCrkknY4OYSMw9SuKO
r6ZfpoEmmkO0b9UaEMIH69wm0MqH5hwk3U4ynk7xRJppNyQq0tktMHzGFc6nWv3yYKXJZpDuYRQc
e2M64w8QlFizXVUBDIiAE6BqFs2AwJFmSWSL+ltqTDntmmeKuoYyOaJphPKOYpJ5BtdUXrqj78oY
GHf5nCGgRkjyRjgOVYM1g2p107JrZD6s7bpnK6nIGaS56JkWq6iu6WYxa4SiDSzF8nJN3vCqCDFw
mtnhM+peptzNguuW1glll4CAl/FzdN1zNATDtcVglmvK41UaVpydS+3eUUzwDNfO0yQM1m8VZpfi
VvYI53AgvFTnB73lqgXRtFhX6ki7Pk8coNQbh9WOD58I4GziKVzBRwYfZDUlqykZXMGXA2gX2XF/
x88vCgk8zyQlpl5I6gWmUUgahaRZSJqFpFVIWr6nz8XhW4w6Eve94tgbelh+TJ6vLexvONv/AgAA
//8DAFBLAwQUAAYACAAAACEAnGZGQbsAAAAkAQAAKgAAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVs
cy9kcmF3aW5nMS54bWwucmVsc4SPzQrCMBCE74LvEPZu0noQkSa9iNCr1AcIyTYtNj8kUezbG+hF
QfCyMLPsN7NN+7IzeWJMk3ccaloBQae8npzhcOsvuyOQlKXTcvYOOSyYoBXbTXPFWeZylMYpJFIo
LnEYcw4nxpIa0cpEfUBXNoOPVuYio2FBqrs0yPZVdWDxkwHii0k6zSF2ugbSL6Ek/2f7YZgUnr16
WHT5RwTLpRcWoIwGMwdKV2edNS1dgYmGff0m3gAAAP//AwBQSwECLQAUAAYACAAAACEAu+VIlAUB
AAAeAgAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAA
IQCtMD/xwQAAADIBAAALAAAAAAAAAAAAAAAAADYBAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAA
IQBV632TAAIAAIIEAAAfAAAAAAAAAAAAAAAAACACAABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2lu
ZzEueG1sUEsBAi0AFAAGAAgAAAAhAJEtaklYBgAADxoAABoAAAAAAAAAAAAAAAAAXQQAAGNsaXBi
b2FyZC90aGVtZS90aGVtZTEueG1sUEsBAi0AFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAAAAAAAA
AAAAAAAA7QoAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc1BLBQYA
AAAABQAFAGcBAADwCwAAAAA=
" filled="t" fillcolor="#d9f9fb" strokecolor="windowText" strokeweight="1.5pt">
 <v:stroke endarrow="open"/>
 <o:lock v:ext="edit" shapetype="f"/>
</v:shape><v:shape id="_x0000_s1028" type="#_x0000_t32" style='position:absolute;
 margin-left:142.55pt;margin-top:239.45pt;width:39.1pt;height:0;rotation:90;
 z-index:251708416;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:3.17497mm;
 mso-wrap-distance-top:0;mso-wrap-distance-right:3.17497mm;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" strokeweight="1.5pt"/><v:shape id="_x0000_s1039" type="#_x0000_t202" style='position:absolute;
 margin-left:121.1pt;margin-top:129.3pt;width:36.65pt;height:20.65pt;z-index:251709440;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:middle' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" strokecolor="white">
 <v:stroke opacity="0"/>
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:95%'><b><span
    lang=DE-CH style='font-size:11.0pt;mso-bidi-font-size:9.0pt;line-height:
    95%;color:black'>No</span></b><span lang=DE-CH style='font-size:11.0pt;
    mso-bidi-font-size:9.0pt;line-height:95%'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><v:shape id="_x0000_s1038" type="#_x0000_t202" style='position:absolute;
 margin-left:25.9pt;margin-top:129.3pt;width:36.6pt;height:20.65pt;z-index:251710464;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:middle' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" strokecolor="white">
 <v:stroke opacity="0"/>
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:95%'><b><span
    lang=DE-CH style='font-size:11.0pt;line-height:95%;color:black'>Yes</span></b><span
    lang=DE-CH style='font-size:11.0pt;line-height:95%'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><v:rect id="_x0000_s1026" style='position:absolute;margin-left:85.95pt;
 margin-top:261.45pt;width:150pt;height:41.65pt;z-index:251714560;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:middle'
 o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEA71u/6tsDAAArDAAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsVttu2zgQfV9g/4Hg8zqSbDmxjSqF
Y8dFgWwbxO0H0NTIIkKRWpK+dbH/0m/pl+2Qkmyn6QXYy0vRXGDSHB3OHJ4z1IuX+0qSLRgrtMpo
chFTAorrXKh1Rt+/W/RGlFjHVM6kVpDRA1j68vrXX16wydqwuhScIIKyE5bR0rl6EkWWl1Axe6Fr
ULhWaFMxh1OzjnLDdohcyagfx5dRxYSi1yeoOXOMbIz4B1BS80fIZ0xtmUVIySfn37Q5Sv7vkdlE
bV+ZelnfG585f7O9N0TkGUXmFKuQIhq1C20YTqPPnlqfAPaFqXy8LgqyxxMYj/FvSMkhowMcjobD
Bg/2jvAQEA/jGDfjGDHsj8ZdAC/ffgeCl7ffBsE0m3RwcJairX2Cavu85mTcFf0AHFWylkCSOB0c
KegesfUdHpAlSs9KDIOpMXpXAsstluyjcUeksgkPbJ2eRH5Xu991jtSi5A5BMP8Ra8eC2aQ21r0C
XRE/yKjBesJObHtnXZNgFxLY0AshZThpqcgOq+hf4an4JaulyP1qmJj1aiYN2TKJEgk/bblPwirh
wBApqoyOjkFs4hm6VXnYxjEhmzFmLZUHR01gcu2oMc6f43h8O7odpb20f3nbS+P5vDddzNLe5SK5
Gs4H89lsnvzl80zSSSnyHJRPtTNxkj5zSCW40VYX7oLrKkKZCg6dkdHGSXyy8ZOS7Hnl8/FivLh5
Xnn0NI2gA6yq+wzVYbm2dZvbL4MW3f5G5wdf+Ao/USBG45mhKbCT4aDU5gMlO+xPGbV/bJgBSuRr
hVobJ2mKYS5M0uFVHyfmfGV1vsIUR6iMcmcoaSYzh3N8aFMbsS5xryScudLTjdOFaJXSZOXzk9Yt
3UFCOMKQO5ZCKmbuAgwOHsKAyTX237BRoZWbhumKWQjwUi1r7uFsze+5a9Q0Cn2gkeZ5wA0UXaiz
rfA65mt+Wp0WQToe8gtxYRWpb5k3HtJg6hLtm1FQvfdLvBk+IAGJ70YrzwR5BONvEWzuIe2v6+Hr
ToCiQOs1nkP6mBOKuEMNBePYAN6JCix5AzvyoCumKKmZ0hYX4j7+XsYDbI4p/vdxlOKqcLxcsEpI
bJYJXmW8ZMZC0Eo4EWD/Gzhyh3x52tz164IUG3SZM8BcBcoRA7bWygIRljBeCthC/hvqQigHCqUG
JMe6Jr4vNm4ISKDye2bYwxfPoWP9R2LwVHBoCY2BPKc/XfTN++RH0sDRRYM4/vSxWhP0ijmQ9NPH
HcCj/WmRrid0FvE943hBbiwsa/921lwUzQ2KEf6lLvrsNTkAtK/1/l38fH79NwAAAP//AwBQSwME
FAAGAAgAAAAhAJEtaklYBgAADxoAABoAAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUxLnhtbOxZS28b
NxC+F+h/WOy9sd6KjciBrUfcxE6CSEmRI6WldhlzlwuSsqNbkZx6KVAgLXpogN56KIoGaIAGvfTH
GHDQpj+iQ+5DpETFD7hAUMQCjN3Zb4bDmdlvSO6Nm09j6h1hLghLOn71WsX3cDJhAUnCjv9wNPjs
uu8JiZIAUZbgjj/Hwr+5/eknN9DWhJJ0zBAPRhGOsQeGErGFOn4kZbq1sSEmIEbiGktxAs+mjMdI
wi0PNwKOjmGAmG7UKpXWRoxI4m+DRakM9Sn8S6RQggnlQ2UGewmKYfR70ymZYI0NDqsKIeaiS7l3
hGjHB5sBOx7hp9L3KBISHnT8iv7zN7ZvbKCtXInKNbqG3kD/5Xq5QnBY02PycFwO2mg0G62d0r4G
ULmK67f7rX6rtKcBaDKBmWa+mDabu5u7vWaONUDZpcN2r92rVy28Yb++4vNOU/0svAZl9hsr+MGg
C1G08BqU4Zsr+EajXes2LLwGZfjWCr5d2ek12hZegyJKksMVdKXZqneL2ZaQKaN7TvhmszFo13Lj
CxRUQ1ldaogpS+S6WovRE8YHAFBAiiRJPDlP8RRNoCa7iJIxJ94+CSMovBQlTIC4UqsMKnX4r34N
faUjgrYwMrSVX+CJWBEpfzwx4SSVHf82WPUNyOmbNyfPXp88+/3k+fOTZ7/mY2tTlt4eSkJT791P
3/zz8kvv799+fPfi22zoZbww8W9/+ertH3++zzzMeBGK0+9evX396vT7r//6+YXD+g5HYxM+IjEW
3l187D1gMUzQ4T8e84tpjCJETI2dJBQoQWoUh/2+jCz03TmiyIHbxXYcH3GgGhfw1uyJ5fAw4jNJ
HBbvRLEFPGCM7jLujMIdNZYR5tEsCd2D85mJe4DQkWvsLkqsLPdnKXAscZnsRthy8z5FiUQhTrD0
1DN2iLFjdo8JseJ6QCacCTaV3mPi7SLiDMmIjK1qWijtkRjyMnc5CPm2YnPwyNtl1DXrHj6ykfBu
IOpwfoSpFcZbaCZR7DI5QjE1A76PZORycjjnExPXFxIyHWLKvH6AhXDp3OMwXyPpd4Bm3Gk/oPPY
RnJJDl029xFjJrLHDrsRilMXdkiSyMR+Lg6hRJF3n0kX/IDZb4i6hzygZG26HxFspftsNngIDGu6
tCgQ9WTGHbm8hZlVv8M5nSKsqQYagMXrMUnOJPklem/+d/QOJHr6w0vHjK6G0t2GrXxckMx3OHG+
TXtLFL4Ot0zcXcYD8uHzdg/NkvsYXpXV5vWRtj/Stv+/p+117/PVk/WCn4G61bI1W67rxXu8du0+
JZQO5ZzifaGX7wK6UjAAodLTe1Rc7uXSCC7VmwwDWLiQI63jcSa/IDIaRiiFNX7VV0ZCkZsOhZcy
AUt/LXbaVng6iw9YkG1Zq1W1Pc3IQyC5kFeapRy2GzJDt9qLbVhpXnsb6u1y4YDSvYgTxmC2E3WH
E+1CqIKkN+cQNIcTemZX4sWmw4vrynyRqhUvwLUyK7Bs8mCx1fGbDVABJdhVIYoDlacs1UV2dTKv
MtPrgmlVAKwhigpYZHpT+bp2emp2WamdI9OWE0a52U7oyOgeJiIU4Lw6lfQ8blw015uLlFruqVDo
8aC0Fm60r7/Pi8vmGvSWuYEmJlPQxDvu+K16E0pmgtKOP4WtP1zGKdSOUMtdREM4NJtInr3wl2GW
lAvZQyLKAq5JJ2ODmEjMPUrijq+mX6aBJppDtG/VGhDCB+vcJtDKh+YcJN1OMp5O8USaaTckKtLZ
LTB8xhXOp1r98mClyWaQ7mEUHHtjOuMPEJRYs11VAQyIgBOgahbNgMCRZklki/pbakw57ZpnirqG
MjmiaYTyjmKSeQbXVF66o+/KGBh3+ZwhoEZI8kY4DlWDNYNqddOya2Q+rO26ZyupyBmkueiZFquo
rulmMWuEog0sxfJyTd7wqggxcJrZ4TPqXqbczYLrltYJZZeAgJfxc3TdczQEw7XFYJZryuNVGlac
nUvt3lFM8AzXztMkDNZvFWaX4lb2COdwILxU5we95aoF0bRYV+pIuz5PHKDUG4fVjg+fCOBs4ilc
wUcGH2Q1JaspGVzBlwNoF9lxf8fPLwoJPM8kJaZeSOoFplFIGoWkWUiahaRVSFq+p8/F4VuMOhL3
veLYG3pYfkyery3sbzjb/wIAAP//AwBQSwMEFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAABjbGlw
Ym9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHOEj80KwjAQhO+C7xD2btJ6EJEm
vYjQq9QHCMk2LTY/JFHs2xvoRUHwsjCz7DezTfuyM3liTJN3HGpaAUGnvJ6c4XDrL7sjkJSl03L2
DjksmKAV201zxVnmcpTGKSRSKC5xGHMOJ8aSGtHKRH1AVzaDj1bmIqNhQaq7NMj2VXVg8ZMB4otJ
Os0hdroG0i+hJP9n+2GYFJ69elh0+UcEy6UXFqCMBjMHSldnnTUtXYGJhn39Jt4AAAD//wMAUEsB
Ai0AFAAGAAgAAAAhALvlSJQFAQAAHgIAABMAAAAAAAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVz
XS54bWxQSwECLQAUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAAAAAAAAAAAAAAA2AQAAX3JlbHMv
LnJlbHNQSwECLQAUAAYACAAAACEA71u/6tsDAAArDAAAHwAAAAAAAAAAAAAAAAAgAgAAY2xpcGJv
YXJkL2RyYXdpbmdzL2RyYXdpbmcxLnhtbFBLAQItABQABgAIAAAAIQCRLWpJWAYAAA8aAAAaAAAA
AAAAAAAAAAAAADgGAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUxLnhtbFBLAQItABQABgAIAAAAIQCc
ZkZBuwAAACQBAAAqAAAAAAAAAAAAAAAAAMgMAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJh
d2luZzEueG1sLnJlbHNQSwUGAAAAAAUABQBnAQAAyw0AAAAA
" filled="f" fillcolor="#d9f9fb" strokeweight="1pt">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;mso-bidi-font-size:
    9.0pt;line-height:85%;color:black;mso-font-kerning:12.0pt;mso-ansi-language:
    EN-US'>If full treatment response is achieved, maintenance dose:<o:p></o:p></span></b></p>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;mso-bidi-font-size:
    9.0pt;line-height:85%;color:black;mso-font-kerning:12.0pt;mso-ansi-language:
    EN-US'>300&nbsp;mg every 4&nbsp;weeks</span></b><span style='font-size:
    11.0pt;mso-bidi-font-size:9.0pt;line-height:85%;mso-ansi-language:EN-US'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:rect id="_x0000_s1036" style='position:absolute;margin-left:242.2pt;
 margin-top:175.5pt;width:88.95pt;height:39pt;z-index:251697152;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:middle'
 o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
" filled="f" fillcolor="#d9f9fb" strokeweight="1pt">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;mso-bidi-font-size:
    9.0pt;line-height:85%;color:black;mso-font-kerning:12.0pt;mso-ansi-language:
    EN-US'>Maintenance dose 2&nbsp;mg/kg every 4&nbsp;weeks</span></b><span
    style='font-size:11.0pt;mso-bidi-font-size:9.0pt;line-height:85%;
    mso-ansi-language:EN-US'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:shape id="_x0000_s1035" type="#_x0000_t32" style='position:absolute;
 margin-left:289.8pt;margin-top:120.2pt;width:63.15pt;height:54.7pt;flip:x;
 z-index:251712512;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" strokecolor="windowText" strokeweight="1.5pt">
 <v:stroke endarrow="open"/>
 <o:lock v:ext="edit" shapetype="f"/>
</v:shape><v:shape id="_x0000_s1040" type="#_x0000_t202" style='position:absolute;
 margin-left:283.1pt;margin-top:129.3pt;width:36.6pt;height:19.45pt;z-index:251713536;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:middle' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" strokecolor="white">
 <v:stroke opacity="0"/>
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center'><b><span lang=DE-CH
    style='font-size:11.0pt;mso-bidi-font-size:9.0pt;color:black'>Yes</span></b><span
    lang=DE-CH style='font-size:11.0pt;mso-bidi-font-size:9.0pt'><o:p></o:p></span></p>
    <p align=center style='margin:0in;text-align:center'><span lang=DE-CH
    style='font-size:9.0pt'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><v:rect id="_x0000_s1037" style='position:absolute;margin-left:364.2pt;
 margin-top:174.8pt;width:94pt;height:39.65pt;z-index:251698176;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:middle'
 o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAcJOcmrYDAAD8CAAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzcVtuO2zYQfS/QfyD47tVlJd8QbeD1
JSiwSRbr5ANokpKIpUiVpG8J8i/9ln5ZhpS89mbTFmjSl9owTHpGh2dmzgz96vWhkWjHjRVaFTi5
ijHiimomVFXgjx9WgzFG1hHFiNSKF/jILX598+svr8i0MqStBUWAoOyUFLh2rp1GkaU1b4i90i1X
YCu1aYiDrakiZsgekBsZpXE8jBoiFL45Qy2II2hrxL+Akpo+cjYnakcsQEo6vfyl5yjpjyOTqdq9
Me26vTeeOX23uzdIsAJD5hRpIEU46g29G2yjb56qzgCH0jTeX5clOhQ4z9N8NAKsY4HT8TidxHGH
xw8OUXBIksn1GH5EFDzy+DrP8/7A+v0/QNB6+fcgQLOjA4sLirb1BNXuZczp8BT0A6egkkpylMaT
njLk5vSIbe+gQBYpPa/Bjc+M0fuaE2YhIs8fTnxyD9k6Pwn53ezfagapBckdg2B+UtaeAibT1lj3
husG+UWBDcQTTiK7O+s6gieXkA29ElKGSkuF9hBFOoKqeJPVUjBvDRtTbebSoB2RIJHw6sN95tYI
xw2SoikwFBdeXU19hpaKhWMcEbJbA2upPDhoAsj1q65xPk/iyXK8HGeDLB0uB1m8WAxmq3k2GK6S
Ub64Xszni+SL55lk01owxpWnemriJHvRIY2gRltduiuqmwhkKig/NTK0cRKf2/hZSPYy8sVkNVnd
vow8ek4j6ACiOn2H6CBc23ebO6yDFt3hVrOjD3wD3yAQo6Fm0BQwyWBRa/MJoz3MpwLb37fEcIzk
bwq0NkmyDNxc2GT5KIWNubRsLi1EUYAqMHUGo24zd7CHh7atEVUNZyWh5krPtk6XoldKx8rzk9at
3VHyUMLAHUJBDTF3AQYWD2FBZAXzNxxUauVmYbshlgd4qdYt9XC2pffUdWoa571Ogh7ODre8PLk6
2wvvlPmWnq2zMkjHQ37HL1gBuc+88ZAGqEto3wJzNfi4hpvhkx9IfhptfCbQIzf+FoHhHmj/tR6C
xoPIfXUvG4aXJbRe13OQPuKEQu7Y8pJQGAAfRMMtesf36EE3RGHUEqUtGOIU3sP4Os7jDD4prDKw
CkfrFWmEhGGZwFVGa2IsD1oJFeHkPwOHwCBfPm3uZsaYcHDDEokY0EW6ROmffzRV9FghShTacES1
soJxw5mfhV0HhKe5YvfEkIfv5v6U6f9T1s4BhzEATeMT8tTxW8vXrb9uoIDB4EcCLPwtFX1z7wdD
/z/F/7m43N98BQAA//8DAFBLAwQUAAYACAAAACEAkS1qSVgGAAAPGgAAGgAAAGNsaXBib2FyZC90
aGVtZS90aGVtZTEueG1s7FlLbxs3EL4X6H9Y7L2x3oqNyIGtR9zEToJISZEjpaV2GXOXC5Kyo1uR
nHopUCAtemiA3nooigZogAa99McYcNCmP6JD7kOkRMUPuEBQxAKM3dlvhsOZ2W9I7o2bT2PqHWEu
CEs6fvVaxfdwMmEBScKO/3A0+Oy67wmJkgBRluCOP8fCv7n96Sc30NaEknTMEA9GEY6xB4YSsYU6
fiRlurWxISYgRuIaS3ECz6aMx0jCLQ83Ao6OYYCYbtQqldZGjEjib4NFqQz1KfxLpFCCCeVDZQZ7
CYph9HvTKZlgjQ0Oqwoh5qJLuXeEaMcHmwE7HuGn0vcoEhIedPyK/vM3tm9soK1cico1uobeQP/l
erlCcFjTY/JwXA7aaDQbrZ3SvgZQuYrrt/utfqu0pwFoMoGZZr6YNpu7m7u9Zo41QNmlw3av3atX
Lbxhv77i805T/Sy8BmX2Gyv4waALUbTwGpThmyv4RqNd6zYsvAZl+NYKvl3Z6TXaFl6DIkqSwxV0
pdmqd4vZlpApo3tO+GazMWjXcuMLFFRDWV1qiClL5Lpai9ETxgcAUECKJEk8OU/xFE2gJruIkjEn
3j4JIyi8FCVMgLhSqwwqdfivfg19pSOCtjAytJVf4IlYESl/PDHhJJUd/zZY9Q3I6Zs3J89enzz7
/eT585Nnv+Zja1OW3h5KQlPv3U/f/PPyS+/v33589+LbbOhlvDDxb3/56u0ff77PPMx4EYrT7169
ff3q9Puv//r5hcP6DkdjEz4iMRbeXXzsPWAxTNDhPx7zi2mMIkRMjZ0kFChBahSH/b6MLPTdOaLI
gdvFdhwfcaAaF/DW7Inl8DDiM0kcFu9EsQU8YIzuMu6Mwh01lhHm0SwJ3YPzmYl7gNCRa+wuSqws
92cpcCxxmexG2HLzPkWJRCFOsPTUM3aIsWN2jwmx4npAJpwJNpXeY+LtIuIMyYiMrWpaKO2RGPIy
dzkI+bZic/DI22XUNesePrKR8G4g6nB+hKkVxltoJlHsMjlCMTUDvo9k5HJyOOcTE9cXEjIdYsq8
foCFcOnc4zBfI+l3gGbcaT+g89hGckkOXTb3EWMmsscOuxGKUxd2SJLIxH4uDqFEkXefSRf8gNlv
iLqHPKBkbbofEWyl+2w2eAgMa7q0KBD1ZMYdubyFmVW/wzmdIqypBhqAxesxSc4k+SV6b/539A4k
evrDS8eMrobS3YatfFyQzHc4cb5Ne0sUvg63TNxdxgPy4fN2D82S+xheldXm9ZG2P9K2/7+n7XXv
89WT9YKfgbrVsjVbruvFe7x27T4llA7lnOJ9oZfvArpSMACh0tN7VFzu5dIILtWbDANYuJAjreNx
Jr8gMhpGKIU1ftVXRkKRmw6FlzIBS38tdtpWeDqLD1iQbVmrVbU9zchDILmQV5qlHLYbMkO32ott
WGleexvq7XLhgNK9iBPGYLYTdYcT7UKogqQ35xA0hxN6ZlfixabDi+vKfJGqFS/AtTIrsGzyYLHV
8ZsNUAEl2FUhigOVpyzVRXZ1Mq8y0+uCaVUArCGKClhkelP5unZ6anZZqZ0j05YTRrnZTujI6B4m
IhTgvDqV9DxuXDTXm4uUWu6pUOjxoLQWbrSvv8+Ly+Ya9Ja5gSYmU9DEO+74rXoTSmaC0o4/ha0/
XMYp1I5Qy11EQzg0m0ievfCXYZaUC9lDIsoCrkknY4OYSMw9SuKOr6ZfpoEmmkO0b9UaEMIH69wm
0MqH5hwk3U4ynk7xRJppNyQq0tktMHzGFc6nWv3yYKXJZpDuYRQce2M64w8QlFizXVUBDIiAE6Bq
Fs2AwJFmSWSL+ltqTDntmmeKuoYyOaJphPKOYpJ5BtdUXrqj78oYGHf5nCGgRkjyRjgOVYM1g2p1
07JrZD6s7bpnK6nIGaS56JkWq6iu6WYxa4SiDSzF8nJN3vCqCDFwmtnhM+peptzNguuW1glll4CA
l/FzdN1zNATDtcVglmvK41UaVpydS+3eUUzwDNfO0yQM1m8VZpfiVvYI53AgvFTnB73lqgXRtFhX
6ki7Pk8coNQbh9WOD58I4GziKVzBRwYfZDUlqykZXMGXA2gX2XF/x88vCgk8zyQlpl5I6gWmUUga
haRZSJqFpFVIWr6nz8XhW4w6Eve94tgbelh+TJ6vLexvONv/AgAA//8DAFBLAwQUAAYACAAAACEA
nGZGQbsAAAAkAQAAKgAAAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVs
c4SPzQrCMBCE74LvEPZu0noQkSa9iNCr1AcIyTYtNj8kUezbG+hFQfCyMLPsN7NN+7IzeWJMk3cc
aloBQae8npzhcOsvuyOQlKXTcvYOOSyYoBXbTXPFWeZylMYpJFIoLnEYcw4nxpIa0cpEfUBXNoOP
VuYio2FBqrs0yPZVdWDxkwHii0k6zSF2ugbSL6Ek/2f7YZgUnr16WHT5RwTLpRcWoIwGMwdKV2ed
NS1dgYmGff0m3gAAAP//AwBQSwECLQAUAAYACAAAACEAu+VIlAUBAAAeAgAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQCtMD/xwQAAADIBAAALAAAA
AAAAAAAAAAAAADYBAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQBwk5yatgMAAPwIAAAfAAAA
AAAAAAAAAAAAACACAABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2luZzEueG1sUEsBAi0AFAAGAAgA
AAAhAJEtaklYBgAADxoAABoAAAAAAAAAAAAAAAAAEwYAAGNsaXBib2FyZC90aGVtZS90aGVtZTEu
eG1sUEsBAi0AFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAAAAAAAAAAAAAAAAowwAAGNsaXBib2Fy
ZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc1BLBQYAAAAABQAFAGcBAACmDQAAAAA=
" filled="f" fillcolor="#d9f9fb" strokeweight="1pt">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;mso-bidi-font-size:
    9.0pt;line-height:85%;color:black;mso-font-kerning:12.0pt;mso-ansi-language:
    EN-US'>Additional dose of 2&nbsp;mg/kg can be considered</span></b><b><span
    lang=EN-GB style='font-size:11.0pt;mso-bidi-font-size:9.0pt;line-height:
    85%;color:black;mso-font-kerning:12.0pt;mso-ansi-language:EN-GB'><o:p></o:p></span></b></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:shape id="_x0000_s1041" type="#_x0000_t32" style='position:absolute;
 margin-left:364.5pt;margin-top:121pt;width:53.55pt;height:55.45pt;z-index:251706368;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="t" fillcolor="#d9f9fb" strokecolor="windowText" strokeweight="1.5pt">
 <v:stroke endarrow="open"/>
 <o:lock v:ext="edit" shapetype="f"/>
</v:shape><v:shape id="_x0000_s1032" type="#_x0000_t202" style='position:absolute;
 margin-left:387.15pt;margin-top:131pt;width:36.65pt;height:19.45pt;z-index:251707392;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:middle' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" strokecolor="white">
 <v:stroke opacity="0"/>
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:95%'><b><span
    lang=DE-CH style='font-size:11.0pt;mso-bidi-font-size:9.0pt;line-height:
    95%;color:black'>No</span></b><span lang=DE-CH style='font-size:11.0pt;
    mso-bidi-font-size:9.0pt;line-height:95%'><o:p></o:p></span></p>
    <p align=center style='margin:0in;text-align:center;line-height:95%'><span
    lang=DE-CH style='font-size:9.0pt;line-height:95%'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><v:rect id="_x0000_s1027" style='position:absolute;margin-left:313.5pt;
 margin-top:260.5pt;width:152pt;height:42.6pt;z-index:251703296;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:middle'
 o:bwmode="grayScale" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" fillcolor="#d9f9fb" strokeweight="1pt">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;mso-bidi-font-size:
    9.0pt;line-height:85%;color:black;mso-font-kerning:12.0pt;mso-ansi-language:
    EN-US'>If full treatment response is achieved, maintenance dose:<o:p></o:p></span></b></p>
    <p align=center style='margin:0in;text-align:center;line-height:85%;
    vertical-align:baseline'><b><span style='font-size:11.0pt;mso-bidi-font-size:
    9.0pt;line-height:85%;color:black;mso-font-kerning:12.0pt;mso-ansi-language:
    EN-US'>4&nbsp;mg/kg every 4&nbsp;weeks</span></b><span style='font-size:
    11.0pt;mso-bidi-font-size:9.0pt;line-height:85%;mso-ansi-language:EN-US'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:rect><v:shape id="_x0000_s1029" type="#_x0000_t32" style='position:absolute;
 margin-left:396.5pt;margin-top:239.45pt;width:39.1pt;height:0;rotation:90;
 z-index:251704320;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:3.17497mm;
 mso-wrap-distance-top:0;mso-wrap-distance-right:3.17497mm;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" strokeweight="1.5pt">
 <o:lock v:ext="edit" shapetype="f"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td colspan="3" rowspan="2" style="vertical-align:top"><img width="309" height="110" src="file:///C:/Users/alsheab1/AppData/Local/Temp/8/msohtmlclip1/01/clip_image003.gif" /></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td colspan="7" rowspan="3" style="vertical-align:top"><img width="310" height="156" src="file:///C:/Users/alsheab1/AppData/Local/Temp/8/msohtmlclip1/01/clip_image004.gif" /></td></tr><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td colspan="2">&nbsp;</td><td rowspan="2"><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Satisfactory clinical response after 7&nbsp;days?</strong></p></td></tr></tbody></table></td></tr><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td colspan="7">&nbsp;</td><td colspan="2" rowspan="2" style="vertical-align:top"><img width="152" height="131" src="file:///C:/Users/alsheab1/AppData/Local/Temp/8/msohtmlclip1/01/clip_image005.gif" /></td></tr><tr><td>&nbsp;</td><td colspan="6" rowspan="3" style="vertical-align:top"><img width="327" height="247" src="file:///C:/Users/alsheab1/AppData/Local/Temp/8/msohtmlclip1/01/clip_image006.gif" /></td><td>&nbsp;</td><td>&nbsp;</td><td style="vertical-align:top"><img width="132" height="129" src="file:///C:/Users/alsheab1/AppData/Local/Temp/8/msohtmlclip1/01/clip_image007.gif" /></td></tr><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td colspan="2">&nbsp;</td><td colspan="5" style="vertical-align:top"><img width="209" height="116" src="file:///C:/Users/alsheab1/AppData/Local/Temp/8/msohtmlclip1/01/clip_image008.gif" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Still&rsquo;s disease (SJIA and AOSD)</u></em></p><p>The recommended dose of canakinumab for patients with Still&rsquo;s disease with body weight &ge;&nbsp;7.5&nbsp;kg is 4&nbsp;mg/kg (up to a maximum of 300&nbsp;mg) administered every four weeks via subcutaneous injection. Continued treatment with canakinumab in patients without clinical improvement should be reconsidered by the treating physician.</p><p>&nbsp;</p><p><em><u>Gouty arthritis</u></em></p><p>Management of hyperuricaemia with appropriate urate lowering therapy (ULT) should be instituted or optimised. Canakinumab should be used as an on-demand therapy to treat gouty arthritis attacks.</p><p><u>&nbsp;</u></p><p>The recommended dose of canakinumab for adult patients with gouty arthritis is 150&nbsp;mg administered subcutaneously as a single dose during an attack. For maximum effect, canakinumab should be administered as soon as possible after the onset of a gouty arthritis attack.</p><p>&nbsp;</p><p>Patients who do not respond to initial treatment should not be re-treated with canakinumab. In patients who respond and require re-treatment, there should be an interval of at least 12&nbsp;weeks before a new dose of canakinumab may be administered (see section&nbsp;5.2).</p><p>&nbsp;</p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p><em><u>Paediatric population</u></em></p><p><em>CAPS, TRAPS, HIDS/MKD and FMF</em></p><p>The safety and efficacy of canakinumab in CAPS, <em>TRAPS, HIDS/MKD and FMF</em> patients under 2&nbsp;years of age have not been established. Currently available data are described in sections&nbsp;4.8, 5.1 and 5.2 but no recommendation on a posology can be made.</p><p>&nbsp;</p><p><em>SJIA</em></p><p>The safety and efficacy of canakinumab in SJIA patients under 2&nbsp;years of age have not been established. No data are available.</p><p>&nbsp;</p><p><em>Gouty arthritis</em></p><p>There is no relevant use of canakinumab in the paediatric population in the indication gouty arthritis.</p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p>No dose adjustment is required.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>Canakinumab has not been studied in patients with hepatic impairment. No recommendation on a posology can be made.</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>No dose adjustment is needed in patients with renal impairment. However, clinical experience in such patients is limited.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>For subcutaneous use.</p><p>The following are suitable injection sites: upper thigh, abdomen, upper arm or buttocks. It is recommended to select a different injection site each time the product is injected to avoid soreness. Broken skin and areas which are bruised or covered by a rash should be avoided. Injection into scar tissue should be avoided as this may result in insufficient exposure to canakinumab.</p><p>&nbsp;</p><p>Each vial is for single use in a single patient, for a single dose.</p><p>&nbsp;</p><p>After proper training in the correct injection technique, patients or their caregivers may inject canakinumab if the physician determines that it is appropriate and with medical follow-up as necessary (see section&nbsp;6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Active, severe infections (see section 4.4).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Infections</u></p><p><u>&nbsp;</u></p><p>Canakinumab is associated with an increased incidence of serious infections. Therefore patients should be monitored carefully for signs and symptoms of infections during and after treatment with canakinumab. Physicians should exercise caution when administering canakinumab to patients with infections, a history of recurring infections, or underlying conditions which may predispose them to infections.</p><p>&nbsp;</p><p><em>Treatment of CAPS,</em><em> TRAPS, HIDS/MKD, FMF and Still&rsquo;s disease (SJIA and AOSD)</em></p><p>Canakinumab should not be initiated or continued in patients during an active infection requiring medical intervention.</p><p>&nbsp;</p><p><em>Treatment of gouty arthritis</em></p><p>Canakinumab should not be administered during an active infection.</p><p>Concomitant use of canakinumab with tumour necrosis factor (TNF) inhibitors is not recommended because this may increase the risk of serious infections (see section&nbsp;4.5).</p><p>&nbsp;</p><p>Isolated cases of unusual or opportunistic infections (including aspergillosis, atypical mycobacterial infections, herpes zoster) have been reported during canakinumab treatment. The causal relationship of canakinumab to these events cannot be excluded.</p><p>&nbsp;</p><p><u>Tuberculosis screening</u></p><p>&nbsp;</p><p>In approximately 12% of CAPS patients tested with a PPD (purified protein derivative) skin test in clinical trials, follow-up testing yielded a positive test result while treated with canakinumab without clinical evidence of a latent or active tuberculosis infection.</p><p>&nbsp;</p><p>It is unknown whether the use of interleukin-1 (IL-1) inhibitors such as canakinumab increases the risk of reactivation of tuberculosis. Before initiation of therapy, all patients must be evaluated for both active and latent tuberculosis infection. Particularly in adult patients, this evaluation should include a detailed medical history. Appropriate screening tests (e.g. tuberculin skin test, interferon gamma release assay or chest X-ray) should be performed in all patients (local recommendations may apply). Patients must be monitored closely for signs and symptoms of tuberculosis during and after treatment with canakinumab. All patients should be instructed to seek medical advice if signs or symptoms suggestive of tuberculosis (e.g. persistent cough, weight loss, subfebrile temperature) appear during canakinumab therapy. In the event of conversion from a negative to a positive PPD test, especially in high-risk patients, alternative means of screening for a tuberculosis infection should be considered.</p><p>&nbsp;</p><p><u>Neutropenia and leukopenia</u></p><p><u>&nbsp;</u></p><p>Neutropenia (absolute neutrophil count [ANC] &lt;&nbsp;1.5 x 10<sup>9</sup>/l) and leukopenia have been observed with medicinal products that inhibit IL-1, including canakinumab. Treatment with canakinumab should not be initiated in patients with neutropenia or leukopenia. It is recommended that white blood cell (WBC) counts including neutrophil counts be assessed prior to initiating treatment and again after 1 to 2&nbsp;months. For chronic or repeated therapies, it is also recommended to assess WBC counts periodically during treatment. If a patient becomes neutropenic or leukopenic, the WBC counts should be monitored closely and treatment discontinuation should be considered.</p><p>&nbsp;</p><p><u>Malignancies</u></p><p><u>&nbsp;</u></p><p>Malignancy events have been reported in patients treated with canakinumab. The risk for the development of malignancies with anti-interleukin (IL)-1 therapy is unknown.</p><p>&nbsp;</p><p><u>Hypersensitivity reactions</u></p><p><u>&nbsp;</u></p><p>Hypersensitivity reactions with canakinumab therapy have been reported. The majority of these events were mild in severity. During clinical development of canakinumab in over 2,600&nbsp;patients, no anaphylactoid or anaphylactic reactions attributable to treatment with canakinumab were reported. However, the risk of severe hypersensitivity reactions, which is not uncommon for injectable proteins, cannot be excluded (see section&nbsp;4.3).</p><p>&nbsp;</p><p><u>Hepatic function</u></p><p><u>&nbsp;</u></p><p>Transient and asymptomatic cases of elevations of serum transaminases or bilirubin have been reported in clinical trials (see section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Vaccinations</u></p><p><u>&nbsp;</u></p><p>No data are available on the risk of secondary transmission of infection by live (attenuated) vaccines in patients receiving canakinumab. Therefore, live vaccines should not be given concurrently with canakinumab unless the benefits clearly outweigh the risks (see section&nbsp;4.5).</p><p>&nbsp;</p><p>Prior to initiation of canakinumab therapy it is recommended that adult and paediatric patients receive all vaccinations, as appropriate, including pneumococcal vaccine and inactivated influenza vaccine (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Mutation in NLRP3 gene in CAPS patients</u></p><p>&nbsp;</p><p>Clinical experience in CAPS patients without a confirmed mutation in the NLRP3 gene is limited.</p><p>&nbsp;</p><p><u>Macrophage activation syndrome in patients with Still&rsquo;s disease </u><u>(SJIA and AOSD)</u></p><p>&nbsp;</p><p>Macrophage activation syndrome (MAS) is a known, life-threatening disorder that may develop in patients with rheumatic conditions, in particular Still&rsquo;s disease. If MAS occurs, or is suspected, evaluation and treatment should be started as early as possible. Physicians should be attentive to symptoms of infection or worsening of Still&rsquo;s disease, as these are known triggers for MAS. Based on clinical trial experience, canakinumab does not appear to increase the incidence of MAS in Still&rsquo;s disease patients, but no definitive conclusion can be made.</p><p>&nbsp;</p><p><u>Drug reaction with eosinophilia and systemic symptoms (DRESS)</u></p><p>&nbsp;</p><p>Drug reaction with eosinophilia and systemic symptoms (DRESS) has rarely been reported in patients treated with Ilaris, predominantly in patients with systemic juvenile idiopathic arthritis (sJIA). Patients with DRESS may require hospitalization, as this condition may be fatal. If signs and symptoms of DRESS are present and an alternative aetiology cannot be established, Ilaris should not be re-administered and a different treatment considered.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Interactions between canakinumab and other medicinal products have not been investigated in formal studies.</p><p>&nbsp;</p><p>An increased incidence of serious infections has been associated with administration of another IL-1 blocker in combination with TNF inhibitors. Use of canakinumab with TNF inhibitors is not recommended because this may increase the risk of serious infections.</p><p>&nbsp;</p><p>The expression of hepatic CYP450 enzymes may be suppressed by the cytokines that stimulate chronic inflammation, such as interleukin-1 beta (IL-1 beta). Thus, CYP450 expression may be reversed when potent cytokine inhibitory therapy, such as canakinumab, is introduced. This is clinically relevant for CYP450 substrates with a narrow therapeutic index where the dose is individually adjusted. On initiation of canakinumab in patients being treated with this type of medicinal product, therapeutic monitoring of the effect or of the active substance concentration should be performed and the individual dose of the medicinal product adjusted as necessary.</p><p>&nbsp;</p><p>No data are available on either the effects of live vaccination or the secondary transmission of infection by live vaccines in patients receiving canakinumab. Therefore, live vaccines should not be given concurrently with canakinumab unless the benefits clearly outweigh the risks. Should vaccination with live vaccines be indicated after initiation of canakinumab treatment, the recommendation is to wait for at least 3&nbsp;months after the last canakinumab injection and before the next one (see section&nbsp;4.4).</p><p>&nbsp;</p><p>The results of a study in healthy adult subjects demonstrated that a single dose of canakinumab 300&nbsp;mg did not affect the induction and persistence of antibody responses after vaccination with influenza or glycosylated protein based meningococcus vaccines.</p><p>&nbsp;</p><p>The results of a 56-week, open label study in CAPS patients aged 4&nbsp;years and younger demonstrated that all patients who received non-live, standard of care childhood vaccinations developed protective antibody levels.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential / Contraception in males and females</u></p><p>&nbsp;</p><p>Women should use effective contraceptives during treatment with canakinumab and for up to 3&nbsp;months after the last dose.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There is a limited amount of data from the use of canakinumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section&nbsp;5.3). The risk for the foetus/mother is unknown. Women who are pregnant or who desire to become pregnant should therefore only be treated after a thorough benefit-risk evaluation.</p><p>&nbsp;</p><p>Animal studies indicate that canakinumab crosses the placenta and is detectable in the foetus. No human data are available, but as canakinumab is an immunoglobulin of the G class (IgG1), human transplacental transfer is expected. The clinical impact of this is unknown. However, administration of live vaccines to newborn infants exposed to canakinumab <em>in utero</em> is not recommended for 16&nbsp;weeks following the mother&rsquo;s last dose of canakinumab before childbirth. Women who received canakinumab during pregnancy should be instructed to inform the baby&rsquo;s healthcare professional before any vaccinations are given to their newborn infant.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether canakinumab is excreted in human milk. The decision whether to breast-feed during canakinumab therapy should therefore only be taken after a thorough benefit-risk evaluation.</p><p>&nbsp;</p><p>Animal studies have shown that a murine anti-murine IL-1 beta antibody had no undesirable effects on development in nursing mouse pups and that the antibody was transferred to them (see section&nbsp;5.3).</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>Formal studies of the potential effect of canakinumab on human fertility have not been conducted. Canakinumab had no effect on male fertility parameters in marmosets (<em>C. jacchus</em>). A murine anti-murine IL-1 beta antibody had no undesirable effects on fertility in male or female mice (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ilaris has minor influence on the ability to drive and use machines. Treatment with Ilaris may result in dizziness/vertigo or asthenia (see section&nbsp;4.8). Patients who experience such symptoms during Ilaris treatment should wait for this to resolve completely before driving or operating machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most frequent adverse drug reactions were infections predominantly of the upper respiratory tract. No impact on the type or frequency of adverse drug reactions was seen with longer-term treatment.</p><p>&nbsp;</p><p>Hypersensitivity reactions have been reported in patients treated with canakinumab (see sections&nbsp;4.3 and 4.4).</p><p>&nbsp;</p><p>Opportunistic infections have been reported in patients treated with canakinumab (see section&nbsp;4.4).</p><p>&nbsp;</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Adverse reactions are listed according to MedDRA system organ class. Within each system organ class, the adverse reactions are ranked by frequency category with the most common first. Frequency categories are defined using the following convention: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tabulated list of adverse reactions</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Indications:</strong></p><p><strong>CAPS, TRAPS, HIDS/MKD, FMF, SJIA, gouty arthritis</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Respiratory tract infections (including pneumonia, bronchitis, influenza, viral infection, sinusitis, rhinitis, pharyngitis, tonsillitis, nasopharyngitis, upper respiratory tract infection)</p><p>Ear infection</p><p>Cellulitis</p><p>Gastroenteritis</p><p>Urinary tract infection</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vulvovaginal candidiasis</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness/vertigo</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Upper abdominal pain <sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Gastro-oesophageal reflux disease <sup>2</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Injection site reaction</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Arthralgia <sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Musculoskeletal pain <sup>1</sup></p><p>Back pain <sup>2</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Fatigue/asthenia <sup>2</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Creatinine renal clearance decreased <sup>1,3</sup></p><p>Proteinuria <sup>1,4</sup></p><p>Leukopenia <sup>1,5</sup></p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Neutropenia <sup>5</sup></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Platelet count decreased <sup>5</sup></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><sup>1</sup> In SJIA</p><p><sup>2</sup> In gouty arthritis</p><p><sup>3</sup> Based on estimated creatinine clearance, most were transient</p><p><sup>4</sup> Most represented transient trace to 1+ positive urinary protein by dipstick</p><p><sup>5</sup> See further information below</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Still&rsquo;s Disease (SJIA and AOSD)</u></p><p><u>&nbsp;</u></p><p><em><u>SJIA pooled analysis and AOSD</u></em></p><p>A total of 445 SJIA patients aged 2 to &lt;&nbsp;20&nbsp;years received canakinumab in clinical trials, including 321&nbsp;patients aged 2 to &lt;&nbsp;12&nbsp;years, 88&nbsp;patients aged 12 to &lt;&nbsp;16&nbsp;years, and 36&nbsp;patients aged 16 to &lt;&nbsp;20&nbsp;years. A pooled safety analysis of all SJIA patients showed that in the subset of young adult SJIA patients aged 16 to &lt;&nbsp;20&nbsp;years, the safety profile of canakinumab was consistent with what was observed in SJIA patients less than 16&nbsp;years of age. The safety profile of canakinumab in AOSD patients in a randomised, double blind placebo-controlled study (GDE01T) in 36 adult patients (aged 22 to 70&nbsp;years) was similar to what was observed in SJIA patients.</p><p><u>&nbsp;</u></p><p>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em><u>Long-term data and laboratory abnormalities in CAPS patients</u></em></p><p>During clinical trials with canakinumab in CAPS patients mean values for haemoglobin increased and those for white blood cell, neutrophils and platelets decreased.</p><p>&nbsp;</p><p>Elevations of transaminases have been observed rarely in CAPS patients.</p><p>&nbsp;</p><p>Asymptomatic and mild elevations of serum bilirubin have been observed in CAPS patients treated with canakinumab without concomitant elevations of transaminases.</p><p>&nbsp;</p><p>In the long-term, open-label studies with dose escalation, events of infections (gastroenteritis, respiratory tract infection, upper respiratory tract infection), vomiting and dizziness were more frequently reported in the 600&nbsp;mg or 8&nbsp;mg/kg dose group than in other dose groups.</p><p>&nbsp;</p><p><em><u>Laboratory abnormalities in TRAPS, HIDS/MKD and FMF patients</u></em></p><p><em>Neutrophils</em></p><p>Although &ge;&nbsp;Grade&nbsp;2 reductions in neutrophil count occurred in 6.5% of patients (common) and Grade&nbsp;1 reductions occurred in 9.5% of patients, the reductions are generally transient and neutropenia-associated infection has not been identified as an adverse reaction.</p><p>&nbsp;</p><p><em>Platelets</em></p><p>Although reductions in platelet count (&ge;&nbsp;Grade&nbsp;2) occurred in 0.6% of patients, bleeding has not been identified as an adverse reaction. Mild and transient Grade&nbsp;1 reduction in platelets occurred in 15.9% of patients without any associated bleeding adverse events.</p><p>&nbsp;</p><p><em><u>Laboratory abnormalities in SJIA patients</u></em></p><p><em>Haematology</em></p><p>In the overall SJIA programme, transient decreased white blood cell (WBC) counts &le;&nbsp;0.8 x LLN were reported in 33&nbsp;patients (16.5%).</p><p>&nbsp;</p><p>In the overall SJIA programme, transient decreases in absolute neutrophil count (ANC) to less than 1 x 10<sup>9</sup>/l were reported in 12&nbsp;patients (6.0%).</p><p>&nbsp;</p><p>In the overall SJIA programme, transient decreases in platelet counts (&lt;&nbsp;LLN) were observed in 19&nbsp;patients (9.5%).</p><p>&nbsp;</p><p><em>ALT/AST</em></p><p>In the overall SJIA programme, high ALT and/or AST &gt;&nbsp;3 x upper limit of normal (ULN) were reported in 19&nbsp;patients (9.5%).</p><p><em><u>Laboratory abnormalities in gouty arthritis patients</u></em></p><p><em>Haematology</em></p><p>Decreased white blood cell counts (WBC) &le;&nbsp;0.8 x lower limit of normal (LLN) were reported in 6.7% of patients treated with canakinumab compared to 1.4% treated with triamcinolone acetonide. Decreases in absolute neutrophil counts (ANC) to less than 1 x 10<sup>9</sup>/l were reported in 2% of patients in the comparative trials. Isolated cases of ANC counts &lt;&nbsp;0.5 x 10<sup>9</sup>/l were also observed (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Mild (&lt;&nbsp;LLN and &gt;&nbsp;75 x 10<sup>9</sup>/l) and transient decreases in platelet counts were observed at a higher incidence (12.7%) with canakinumab in the active-controlled clinical studies versus the comparator (7.7%) in gouty arthritis patients.</p><p>&nbsp;</p><p><em>Uric acid</em></p><p>Increases in uric acid level (0.7&nbsp;mg/dl at 12&nbsp;weeks and 0.5&nbsp;mg/dl at 24&nbsp;weeks) were observed after canakinumab treatment in comparative trials in gouty arthritis. In another study, among patients who were starting on ULT, increases in uric acid were not observed. Uric acid increases were not observed in clinical trials in non-gouty arthritis populations (see section&nbsp;5.1).</p><p>&nbsp;</p><p><em>ALT/AST</em></p><p>Mean and median increases in alanine transaminase (ALT) of 3.0&nbsp;U/l and 2.0&nbsp;U/l, respectively, and in aspartate transaminase (AST) of 2.7&nbsp;U/l and 2.0&nbsp;U/l, respectively, from baseline to end of study were seen in the canakinumab-treated groups versus the triamcinolone acetonide-treated group(s), however the incidence of clinically significant changes (&ge;&nbsp;3 x the upper limit of normal) was greater for patients treated with triamcinolone acetonide (2.5% for both AST and ALT) compared with canakinumab-treated patients (1.6% for ALT and 0.8% for AST).</p><p>&nbsp;</p><p><em>Triglycerides</em></p><p>In active-controlled gouty arthritis trials, there was a mean increase in triglycerides of 33.5&nbsp;mg/dl in canakinumab-treated patients compared with a modest decrease of ‑3.1&nbsp;mg/dl with triamcinolone acetonide. The incidence of patients with triglyceride elevations &gt;&nbsp;5 x upper limit of normal (ULN) was 2.4% with canakinumab and 0.7% with triamcinolone acetonide. The clinical significance of this observation is unknown.</p><p>&nbsp;</p><p><u>Long term data from observational study</u></p><p><u>&nbsp;</u></p><p>A total of 243&nbsp;CAPS patients (85&nbsp;paediatric patients aged &ge;&nbsp;2 to &le;&nbsp;17&nbsp;years and 158&nbsp;adult patients aged &ge;&nbsp;18&nbsp;years) were treated with canakinumab in routine clinical practice in a long-term registry study (mean of 3.8&nbsp;years of canakinumab exposure). The safety profile of canakinumab observed following long-term treatment in this setting was consistent with what has been observed in interventional studies in CAPS patients.</p><p>&nbsp;</p><p>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>There were 80&nbsp;paediatric CAPS patients (2‑17&nbsp;years of age) who received canakinumab in the interventional studies. Overall, there were no clinically meaningful differences in the safety and tolerability profile of canakinumab in paediatric patients compared to the overall CAPS population (comprised of adult and paediatric patients, N=211), including the overall frequency and severity of infectious episodes. Infections of the upper respiratory tract were the most frequently reported infection events.</p><p>&nbsp;</p><p>Additionally, 6&nbsp;paediatric patients under the age of 2&nbsp;years were evaluated in a small open-label clinical study. The safety profile of canakinumab appeared similar to that in patients aged 2&nbsp;years and above.</p><p>&nbsp;</p><p>There were 102&nbsp;TRAPS, HIDS/MKD and FMF patients (2‑17&nbsp;years of age) who received canakinumab in a 16-week study.<strong> </strong>Overall, there were no clinically meaningful differences in the safety and tolerability profile of canakinumab in paediatric patients compared to the overall population.</p><p>&nbsp;</p><p>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Elderly population</u></p><p><u>&nbsp;</u></p><p>There is no significant difference in safety profile observed in patients &ge;&nbsp;65&nbsp;years of age.</p><p><u>&nbsp;</u></p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>&nbsp;</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Reported experience with overdose is limited. In early clinical trials, patients and healthy volunteers received doses as high as 10&nbsp;mg/kg, administered intravenously or subcutaneously, without evidence of acute toxicity.</p><p>&nbsp;</p><p>In case of overdose, it is recommended for the patient to be monitored for any signs or symptoms of adverse reactions, and appropriate symptomatic treatment instituted immediately.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Immunosuppressants, interleukin inhibitors, ATC code: L04AC08</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p><u>&nbsp;</u></p><p>Canakinumab is a human monoclonal anti-human interleukin-1 beta (IL-1 beta) antibody of the IgG1/&kappa; isotype. Canakinumab binds with high affinity specifically to human IL-1 beta and neutralises the biological activity of human IL-1 beta by blocking its interaction with IL-1 receptors, thereby preventing IL-1 beta-induced gene activation and the production of inflammatory mediators.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><u>&nbsp;</u></p><p><em><u>CAPS, TRAPS, HIDS/MKD and FMF</u></em></p><p>In clinical studies, CAPS, TRAPS, HIDS/MKD and FMF patients who have uncontrolled over-production of IL-1 beta show a rapid and sustained response to therapy with canakinumab, i.e. laboratory parameters such as high C-reactive protein (CRP) and serum amyloid&nbsp;A (SAA), high neutrophil and platelet counts, and leukocytosis rapidly returned to normal.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Still&rsquo;s disease (SJIA and AOSD)</u></em></p><p>Adult-onset Still&rsquo;s disease and systemic juvenile idiopathic arthritis are severe autoinflammatory diseases, driven by innate immunity by means of pro-inflammatory cytokines, a key one being IL-1-beta.</p><p>&nbsp;</p><p>Common features of SJIA and AOSD include fever, rash, hepatosplenomegaly, lymphadenopathy, polyserositis and arthritis. Treatment with canakinumab resulted in a rapid and sustained improvement of both the articular and the systemic features of SJIA with significant reduction of the number of inflamed joints, prompt resolution of fever and reduction of acute phase reactants in the majority of patients (see Clinical efficacy and safety).</p><p>&nbsp;</p><p><em><u>Gouty arthritis</u></em></p><p>A gouty arthritis attack is caused by urate (monosodium urate monohydrate) crystals in the joint and surrounding tissue, which trigger resident macrophages to produce IL-1 beta via the &ldquo;NALP3 inflammasome&rdquo; complex. Activation of macrophages and concomitant over-production of IL-1 beta results in an acute painful inflammatory response. Other activators of the innate immune system, such as endogenous agonists of toll-like receptors, may contribute to the transcriptional activation of the IL-1 beta gene, initiating a gouty arthritis attack. Following canakinumab treatment, the inflammatory markers CRP or SAA and signs of acute inflammation (e.g. pain, swelling, redness) in the affected joint subside rapidly.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><u>&nbsp;</u></p><p><em><u>CAPS</u></em></p><p>The efficacy and safety of canakinumab have been demonstrated in a total of 211 adult and paediatric patients with varying degrees of disease severity and different CAPS phenotypes (including FCAS/FCU, MWS, and NOMID/CINCA).<strong><em> </em></strong>Only patients with confirmed NLRP3 mutation were included in the pivotal study.</p><p>&nbsp;</p><p>In the Phase I/II study, treatment with canakinumab had a rapid onset of action, with disappearance or clinically significant improvement of symptoms within one day after dosing. Laboratory parameters such as high CRP and SAA, high neutrophils and platelet counts normalised rapidly within days of canakinumab injection.</p><p>&nbsp;</p><p>The pivotal study consisted of a 48-week three-part multicentre study, i.e. an 8-week open-label period (Part&nbsp;I), a 24-week randomised, double-blind, placebo-controlled withdrawal period (Part&nbsp;II), followed by a 16-week open-label period (Part&nbsp;III). The aim of the study was to assess efficacy, safety, and tolerability of canakinumab (150&nbsp;mg or 2&nbsp;mg/kg every 8&nbsp;weeks) in patients with CAPS.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Part&nbsp;I: A complete clinical and biomarker response to canakinumab (defined as composite of physician&rsquo;s global assessment on autoinflammatory and on skin disease &le; minimal and CRP or SAA values &lt;&nbsp;10&nbsp;mg/litre) was observed in 97% of patients and appeared within 7&nbsp;days of initiation of treatment. Significant improvements were seen in physician&rsquo;s clinical assessment of autoinflammatory disease activity: global assessment of autoinflammatory disease activity, assessment of skin disease (urticarial skin rash), arthralgia, myalgia, headache/migraine, conjunctivitis, fatigue/malaise, assessment of other related symptoms, and patient&rsquo;s assessment of symptoms.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Part&nbsp;II: In the withdrawal period of the pivotal study, the primary endpoint was defined as the proportion of patients with a disease relapse/flare: none (0%) of the patients randomised to canakinumab flared, compared with 81% of the patients randomised to placebo.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Part&nbsp;III: Patients treated with placebo in Part&nbsp;II who flared regained and maintained clinical and serological response following entry into the open-label canakinumab extension.</p><p>&nbsp;</p><p><strong>Table&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tabulated summary of efficacy in Phase&nbsp;III trial, pivotal placebo-controlled withdrawal period (Part&nbsp;II)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:642px"><thead><tr><td colspan="4" style="vertical-align:top"><p><strong>Phase III trial,</strong><strong> pivotal </strong><strong>placebo-controlled withdrawal period (Part&nbsp;II)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Canakinumab</p><p>N=15</p><p>n(%)</p></td><td style="vertical-align:top"><p>Placebo</p><p>N=16</p><p>n(%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>p-value</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>&nbsp;</p><p><strong>Primary endpoint (flare)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proportion of patients with disease flare in Part&nbsp;II</p></td><td style="vertical-align:top"><p>0 (0%)</p></td><td style="vertical-align:top"><p>13 (81%)</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>&nbsp;</p><p><strong>Inflammatory markers*</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; C-reactive protein, mg/l</p></td><td style="vertical-align:top"><p>1.10 (0.40)</p></td><td style="vertical-align:top"><p>19.93 (10.50)</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.001</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serum amyloid A, mg/l</p></td><td style="vertical-align:top"><p>2.27 (‑0.20)</p></td><td style="vertical-align:top"><p>71.09 (14.35)</p></td><td style="vertical-align:top"><p>0.002</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>* mean (median) change from beginning of Part&nbsp;II</p></td></tr></tbody></table><p>&nbsp;</p><p>Two open-label, uncontrolled, long-term phase III studies were performed. One was a safety, tolerability, and efficacy study of canakinumab in patients with CAPS. The total treatment duration ranged from 6&nbsp;months to 2&nbsp;years. The other was an open-label study with canakinumab to evaluate the efficacy and safety in Japanese CAPS patients for 24&nbsp;weeks, with an extension phase up to 48&nbsp;weeks. The primary objective was to assess the proportion of patients who were free of relapse at week&nbsp;24, including those patients whose dose was increased.</p><p>&nbsp;</p><p>In the pooled efficacy analysis for these two studies, 65.6% of patients who had not previously been treated with canakinumab achieved complete response at 150&nbsp;mg or 2&nbsp;mg/kg, while 85.2% of patients achieved complete response at any dose. Of the patients treated with 600&nbsp;mg or 8&nbsp;mg/kg (or even higher), 43.8% achieved complete response. Fewer patients aged 2 to &lt;&nbsp;4&nbsp;years achieved complete response (57.1%) than older paediatric and adult patients. Of the patients who had achieved a complete response, 89.3% maintained response without relapsing.</p><p>&nbsp;</p><p>Experience from individual patients who achieved a complete response following dose escalation to 600&nbsp;mg (8&nbsp;mg/kg) every 8&nbsp;weeks suggests that a higher dose may be beneficial in patients not achieving complete response or not maintaining complete response with the recommended doses (150&nbsp;mg or 2&nbsp;mg/kg for patients &ge;&nbsp;15&nbsp;kg and &le;&nbsp;40&nbsp;kg). An increased dose was administered more frequently to patients aged 2 to &lt;&nbsp;4&nbsp;years and to patients with NOMID/CINCA symptoms compared with FCAS or MWS.</p><p>&nbsp;</p><p>A 6-year observational registry study was conducted to provide data on the long-term safety and effectiveness of canakinumab treatment in paediatric and adult CAPS patients in routine clinical practice. The study included 243&nbsp;CAPS patients (including 85&nbsp;patients less than 18&nbsp;years of age). Disease activity was rated as absent or mild/moderate in more than 90% of patients at all post-baseline time points in the study, and median serological markers of inflammation (CRP and SAA) were normal (&lt;&nbsp;10&nbsp;mg/litre) at all post-baseline time points. Although approximately 22% of patients receiving canakinumab required dose adjustment, only a small percentage of patients (1.2%) discontinued canakinumab due to lack of therapeutic effect.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The CAPS interventional trials with canakinumab included a total of 80&nbsp;paediatric patients with an age range from 2 to 17&nbsp;years (approximately half of them treated on an mg/kg basis). Overall, there were no clinically meaningful differences in the efficacy, safety and tolerability profile of canakinumab in paediatric patients compared to the overall CAPS population. The majority of paediatric patients achieved improvement in clinical symptoms and objective markers of inflammation (e.g. SAA and CRP).</p><p>&nbsp;</p><p>A 56-week, open-label study was conducted to assess the efficacy, safety and tolerability of canakinumab in paediatric CAPS patients &le;&nbsp;4&nbsp;years of age. Seventeen patients (including 6&nbsp;patients under the age of 2&nbsp;years) were evaluated, using weight-based starting doses of 2‑8&nbsp;mg/kg. The study also evaluated the effect of canakinumab on the development of antibodies to standard childhood vaccines. No differences in safety or efficacy were observed in patients under the age of 2&nbsp;years compared with patients aged 2&nbsp;years and above. All patients who received non-live, standard of care childhood vaccinations (N=7) developed protective antibody levels.</p><p>&nbsp;</p><p><em><u>TRAPS, HIDS/MKD and FMF</u></em></p><p>The efficacy and safety of canakinumab for the treatment of TRAPS, HIDS/MKD and FMF were demonstrated in a single, pivotal, phase&nbsp;III, 4-part study (N2301) consisting of three separate disease cohorts.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Part&nbsp;I: Patients in each disease cohort aged 2&nbsp;years and older entered a 12-week screening period during which they were evaluated for the onset of disease flare.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Part&nbsp;II: Patients at flare onset were randomised into a 16-week double-blind, placebo-controlled treatment period during which they received either 150&nbsp;mg canakinumab (2&nbsp;mg/kg for patients with body weight &le;&nbsp;40&nbsp;kg) subcutaneous (s.c.) or placebo every 4&nbsp;weeks. Patients &gt;&nbsp;28&nbsp;days but &lt;&nbsp;2&nbsp;years of age were allowed to enter the study directly into an open-arm of Part&nbsp;II as non-randomised patients (and were excluded from the primary efficacy analysis).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Part&nbsp;III: Patients who completed 16&nbsp;weeks of treatment and were classified as responders were re-randomised into a 24-week, double-blind withdrawal period during which they received canakinumab 150&nbsp;mg (2&nbsp;mg/kg for patients &le;&nbsp;40&nbsp;kg) s.c. or placebo every 8&nbsp;weeks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Part&nbsp;IV: All Part&nbsp;III patients treated with canakinumab were eligible to enter into a 72-week open-label treatment extension period.</p><p>&nbsp;</p><p>A total of 185&nbsp;patients aged 28&nbsp;days and above were enrolled and a total of 181&nbsp;patients aged 2&nbsp;years and above were randomised in part&nbsp;II of the study.</p><p>&nbsp;</p><p>The primary efficacy endpoint of the randomised treatment period (Part&nbsp;II) was the proportion of responders within each cohort who had resolution of their index disease flare at Day&nbsp;15 and did not experience a new flare during the remainder of the 16-week treatment period (defined as complete response). Resolution of the index disease flare was defined as having a Physician&rsquo;s Global Assessment (PGA) of Disease Activity score &lt;&nbsp;2 (&ldquo;minimal or no disease&rdquo;) and CRP within normal range (&le;&nbsp;10&nbsp;mg/l) or reduction &ge;&nbsp;70% from baseline. A new flare was defined as a PGA score &ge;&nbsp;2 (&ldquo;mild, moderate, or severe disease&rdquo;) and CRP &ge;&nbsp;30&nbsp;mg/l. Secondary endpoints, all based on week&nbsp;16 results (end of Part&nbsp;II), included the proportion of patients who achieved a PGA score of &lt;&nbsp;2, the proportion of patients with serological remission (defined as CRP &le;&nbsp;10&nbsp;mg/l), and the proportion of patients with a normalised SAA level (defined as SAA &le;&nbsp;10&nbsp;mg/l).</p><p>&nbsp;</p><p>For the primary efficacy endpoint, canakinumab was superior to placebo for all three disease cohorts. Canakinumab also demonstrated superior efficacy compared to placebo on the secondary endpoints of PGA &lt;&nbsp;2 and CRP &le;&nbsp;10&nbsp;mg/l in all three cohorts. Higher proportions of patients had normalised SAA (&le;&nbsp;10&nbsp;mg/l) at week&nbsp;16 with canakinumab treatment compared to placebo in all three cohorts, with a statistically significant difference observed in TRAPS patients (see Table&nbsp;3 with study results below).</p><p>&nbsp;</p><p><strong>Table&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tabulated summary of efficacy in Phase&nbsp;III trial, pivotal</strong><strong>, randomised,</strong><strong> placebo-controlled </strong><strong>treatment</strong><strong> period (Part&nbsp;II)</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:623px"><thead><tr><td colspan="4" style="vertical-align:top"><p><strong>Phase&nbsp;III trial,</strong><strong> pivotal, randomised </strong><strong>placebo-controlled </strong><strong>treatment</strong><strong> period (Part&nbsp;II)</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Canakinumab</p><p>n/N (%)</p></td><td style="vertical-align:top"><p>Placebo</p><p>n/N (%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>p-value</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Primary endpoint (disease flare) - </strong>Proportion of patients who had index disease flare resolution at day&nbsp;15 and did not experience a new flare during the remainder of the 16-week treatment period</p></td></tr><tr><td style="vertical-align:top"><p>FMF</p></td><td style="vertical-align:top"><p>19/31 (61.29)</p></td><td style="vertical-align:top"><p>2/32 (6.25)</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.0001*</p></td></tr><tr><td style="vertical-align:top"><p>HIDS/MKD</p></td><td style="vertical-align:top"><p>13/37 (35.14)</p></td><td style="vertical-align:top"><p>2/35 (5.71)</p></td><td style="vertical-align:top"><p>0.0020*</p></td></tr><tr><td style="vertical-align:top"><p>TRAPS</p></td><td style="vertical-align:top"><p>10/22 (45.45)</p></td><td style="vertical-align:top"><p>2/24 (8.33)</p></td><td style="vertical-align:top"><p>0.0050*</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Secondary endpoints (disease and inflammatory markers)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Physician Global Assessment &lt;&nbsp;2</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>FMF</p></td><td style="vertical-align:top"><p>20/31 (64.52)</p></td><td style="vertical-align:top"><p>3/32 (9.38)</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.0001**</p></td></tr><tr><td style="vertical-align:top"><p>HIDS/MKD</p></td><td style="vertical-align:top"><p>17/37 (45.95)</p></td><td style="vertical-align:top"><p>2/35 (5.71)</p></td><td style="vertical-align:top"><p>0.0006**</p></td></tr><tr><td style="vertical-align:top"><p>TRAPS</p></td><td style="vertical-align:top"><p>10/22 (45.45)</p></td><td style="vertical-align:top"><p>1/24 (4.17)</p></td><td style="vertical-align:top"><p>0.0028**</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; C-reactive protein &le;&nbsp;10&nbsp;mg/l</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>FMF</p></td><td style="vertical-align:top"><p>21/31 (67.74)</p></td><td style="vertical-align:top"><p>2/32 (6.25)</p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.0001**</p></td></tr><tr><td style="vertical-align:top"><p>HIDS/MKD</p></td><td style="vertical-align:top"><p>15/37 (40.54)</p></td><td style="vertical-align:top"><p>2/35 (5.71)</p></td><td style="vertical-align:top"><p>0.0010**</p></td></tr><tr><td style="vertical-align:top"><p>TRAPS</p></td><td style="vertical-align:top"><p>8/22 (36.36)</p></td><td style="vertical-align:top"><p>2/24 (8.33)</p></td><td style="vertical-align:top"><p>0.0149**</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp; Serum amyloid A &le;&nbsp;10&nbsp;mg/l</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>FMF</p></td><td style="vertical-align:top"><p>8/31 (25.81)</p></td><td style="vertical-align:top"><p>0/32 (0.00)</p></td><td style="vertical-align:top"><p>0.0286</p></td></tr><tr><td style="vertical-align:top"><p>HIDS/MKD</p></td><td style="vertical-align:top"><p>5/37 (13.51)</p></td><td style="vertical-align:top"><p>1/35 (2.86)</p></td><td style="vertical-align:top"><p>0.0778</p></td></tr><tr><td style="vertical-align:top"><p>TRAPS</p></td><td style="vertical-align:top"><p>6/22 (27.27)</p></td><td style="vertical-align:top"><p>0/24 (0.00)</p></td><td style="vertical-align:top"><p>0.0235**</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p>n=number&nbsp;of&nbsp;responders; N=number&nbsp;of&nbsp;evaluable patients</p><p>* indicates statistical significance (one-sided) at the 0.025&nbsp;level based on Fisher exact test</p><p>**Indicates statistical significance (one-sided) at the 0.025&nbsp;level based on the logistic regression model with treatment group and baseline PGA, CRP or SAA respectively, as explanatory variables for each cohort</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Up-titration</em></p><p>In Part&nbsp;II of the study, patients treated with canakinumab who had persistent disease activity received an additional dose of 150&nbsp;mg (or 2&nbsp;mg/kg for patients &le;&nbsp;40&nbsp;kg) within the first month. This additional dose could be provided as early as 7&nbsp;days after the first treatment dose. All up-titrated patients remained at the increased dose of 300&nbsp;mg (or 4&nbsp;mg/kg for patients &le;&nbsp;40&nbsp;kg) every 4&nbsp;weeks.</p><p>&nbsp;</p><p>In an exploratory analysis of the primary endpoint, it was observed that in patients with an inadequate response after the first dose, an up-titration within the first month to a dose of 300&nbsp;mg (or 4&nbsp;mg/kg) every 4&nbsp;weeks further improved flare control, reduced disease activity and normalised CRP and SAA levels.</p><p>&nbsp;</p><p>Paediatric patients:</p><p>Two non-randomised HIDS/MKD patients aged &gt;&nbsp;28&nbsp;days but &lt;&nbsp;2&nbsp;years were included in the study and received canakinumab. One patient had resolution of index flare by day&nbsp;15 after receiving one single dose of canakinumab 2&nbsp;mg/kg, but discontinued treatment after this first dose due to serious adverse events (pancytopenia and hepatic failure). This patient presented at study entry with a history of immune thrombocytopenic purpura and an active medical condition of abnormal hepatic function. The second patient received a starting dose of canakinumab 2&nbsp;mg/kg and an add-on dose of 2&nbsp;mg/kg at week&nbsp;3, and was up-titrated at week&nbsp;5 to receive a dose of 4&nbsp;mg/kg administered every 4&nbsp;weeks until the end of Part II of the study. Resolution of disease flare was achieved by week&nbsp;5 and the patient had not experienced any new flare at the end of Part&nbsp;II of the study (week&nbsp;16).</p><p>&nbsp;</p><p><em><u>Still&rsquo;s disease </u></em><u>(SJIA and AOSD)</u></p><p><em>SJIA</em></p><p>The efficacy of canakinumab for the treatment of active SJIA was assessed in two pivotal phase&nbsp;III studies (G2305 and G2301). Patients enrolled were aged 2 to &lt;&nbsp;20&nbsp;years (mean age of 8.5&nbsp;years and mean disease duration of 3.5&nbsp;years at baseline) and had active disease defined as &ge;&nbsp;2&nbsp;joints with active arthritis, fever and elevated CRP.</p><p>&nbsp;</p><p><em>Study G2305</em></p><p>Study G2305 was a randomised, double-blind, placebo-controlled, 4-week study assessing the short-term efficacy of canakinumab in 84&nbsp;patients randomised to receive a single dose of 4&nbsp;mg/kg (up to 300&nbsp;mg) canakinumab or placebo. The primary objective was the proportion of patients at day&nbsp;15 who achieved a minimum 30% improvement in the paediatric American College of Rheumatology (ACR) response criterion adapted to include absence of fever. Canakinumab treatment improved all paediatric ACR response scores as compared to placebo at days&nbsp;15 and 29 (Table&nbsp;4).</p><p>&nbsp;</p><p><strong>Table&nbsp;4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paediatric ACR response and disease status at days&nbsp;15 and 29</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:625px"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Day&nbsp;15</p></td><td colspan="2" style="vertical-align:top"><p>Day&nbsp;29</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Canakinumab</p><p>N=43</p></td><td style="vertical-align:top"><p>Placebo</p><p>N=41</p></td><td style="vertical-align:top"><p>Canakinumab</p><p>N=43</p></td><td style="vertical-align:top"><p>Placebo</p><p>N=41</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>ACR30</p></td><td style="vertical-align:top"><p>84%</p></td><td style="vertical-align:top"><p>10%</p></td><td style="vertical-align:top"><p>81%</p></td><td style="vertical-align:top"><p>10%</p></td></tr><tr><td style="vertical-align:top"><p>ACR50</p></td><td style="vertical-align:top"><p>67%</p></td><td style="vertical-align:top"><p>5%</p></td><td style="vertical-align:top"><p>79%</p></td><td style="vertical-align:top"><p>5%</p></td></tr><tr><td style="vertical-align:top"><p>ACR70</p></td><td style="vertical-align:top"><p>61%</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>67%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>ACR90</p></td><td style="vertical-align:top"><p>42%</p></td><td style="vertical-align:top"><p>0%</p></td><td style="vertical-align:top"><p>47%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>ACR100</p></td><td style="vertical-align:top"><p>33%</p></td><td style="vertical-align:top"><p>0%</p></td><td style="vertical-align:top"><p>33%</p></td><td style="vertical-align:top"><p>2%</p></td></tr><tr><td style="vertical-align:top"><p>Inactive disease</p></td><td style="vertical-align:top"><p>33%</p></td><td style="vertical-align:top"><p>0%</p></td><td style="vertical-align:top"><p>30%</p></td><td style="vertical-align:top"><p>0%</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p>Treatment difference for all ACR scores was significant (p&nbsp;&le;&nbsp;0.0001)</p></td></tr></tbody></table><p>&nbsp;</p><p>Results for the components of the adapted paediatric ACR which included systemic and arthritic components, were consistent with the overall ACR response results. At day&nbsp;15, the median change from baseline in the number of joints with active arthritis and limited range of motion were ‑67% and ‑73% for canakinumab (N=43), respectively, compared to a median change of 0% and 0% for placebo (N=41). The mean change in patient pain score (0‑100&nbsp;mm visual analogue scale) at day&nbsp;15 was ‑50.0&nbsp;mm for canakinumab (N=43), as compared to +4.5&nbsp;mm for placebo (N=25). The mean change in pain score among canakinumab treated patients was consistent at day&nbsp;29.</p><p>&nbsp;</p><p><em>Study G2301</em></p><p>Study G2301 was a randomised, double-blind, placebo-controlled withdrawal study of flare prevention by canakinumab. The study consisted of two parts with two independent primary endpoints (successful steroid taper and time to flare). In Part&nbsp;I (open label) 177&nbsp;patients were enrolled and received 4&nbsp;mg/kg (up to 300&nbsp;mg) canakinumab administered every 4&nbsp;weeks for up to 32&nbsp;weeks. Patients in Part&nbsp;II (double-blind) received either canakinumab 4&nbsp;mg/kg or placebo every 4&nbsp;weeks until 37&nbsp;flare events occurred.</p><p>&nbsp;</p><p><em>Corticosteroid dose tapering</em>:</p><p>Of the total 128&nbsp;patients who entered Part&nbsp;I taking corticosteroids, 92 attempted corticosteroid tapering. Fifty-seven (62%) of the 92&nbsp;patients who attempted to taper were able to successfully taper their corticosteroid dose and 42 (46%) discontinued corticosteroids.</p><p>&nbsp;</p><p><em>Time to flare</em>:</p><p>Patients taking canakinumab in Part&nbsp;II had a 64% reduced risk of a flare event as compared to the placebo group (hazard ratio of 0.36; 95% CI: 0.17 to 0.75; p=0.0032). Sixty-three of the 100&nbsp;patients entering Part&nbsp;II, whether assigned to placebo or canakinumab, did not experience a flare over the observation period (up to a maximum of 80&nbsp;weeks).</p><p>&nbsp;</p><p><em>Health-related and quality of life outcomes in studies G2305 and G2301</em></p><p>Treatment with canakinumab resulted in clinically relevant improvements in patients&rsquo; physical function and quality of life. In study G2305, the Childhood Health Assessment Questionnaire Least Squares means improvement was 0.69 for canakinumab vs placebo representing 3.6&nbsp;times the minimal clinically important difference of 0.19 (p=0.0002). The median improvement from baseline to end of Part&nbsp;I of study G2301 was 0.88 (79%). Statistically significant improvements in the Child Health Questionnaire-PF50 scores were reported for canakinumab vs placebo in study G2305 (physical p=0.0012; psychosocial well-being p=0.0017).</p><p>&nbsp;</p><p><em>Pooled efficacy analysis</em></p><p>Data from the first 12&nbsp;weeks of canakinumab treatment from studies G2305, G2301 and the extension study were pooled to assess maintenance of efficacy. These data showed similar improvements from baseline to week&nbsp;12 in the adapted paediatric ACR responses and its components to those observed in the placebo controlled study (G2305). At week&nbsp;12, the adapted paediatric ACR30, 50, 70, 90 and 100 responses were: 70%, 69%, 61%, 49% and 30%, respectively and 28% of patients had inactive disease (N=178).</p><p>&nbsp;</p><p>Although limited, evidence from the clinical trials suggests that patients not responding to tocilizumab or anakinra may respond to canakinumab.</p><p>&nbsp;</p><p><em>Study G2301E1</em></p><p>The efficacy observed in the studies G2305 and G2301 was maintained in the open-label long-term extension study G2301E1. Of the 270 SJIA patients in the study, 147&nbsp;patients had received treatment with canakinumab in studies G2305 or G2301 (Cohort&nbsp;I), and 123&nbsp;patients were canakinumab-naive patients (Cohort&nbsp;II). Patients in Cohort&nbsp;I were treated for a median duration of 3.2&nbsp;years (up to 5.2&nbsp;years), and patients in Cohort&nbsp;II were treated for a median duration of 1.8&nbsp;years (up to 2.8&nbsp;years). In the extension study, all patients received canakinumab 4&nbsp;mg/kg (up to maximum 300&nbsp;mg) every 4&nbsp;weeks. In both cohorts, patients who were well-controlled responders (retrospectively defined as adapted paediatric ACR&nbsp;&ge;&nbsp;90) and who did not require a concomitant corticosteroid were permitted to reduce their canakinumab dose to 2&nbsp;mg/kg every 4&nbsp;weeks (62/270; 23%).</p><p>&nbsp;</p><p><em>Study G2306</em></p><p>Study G2306 was an open-label study to assess maintenance of treatment response with canakinumab dose reduction (2&nbsp;mg/kg every 4&nbsp;weeks) or dose interval prolongation (4&nbsp;mg/kg every 8&nbsp;weeks) in SJIA patients who were receiving canakinumab 4&nbsp;mg/kg every 4&nbsp;weeks. Seventy five patients aged 2 to 22&nbsp;years who maintained inactive disease status for at least 6&nbsp;consecutive months (clinical remission) with canakinumab monotherapy, including patients who were able to maintain inactive disease status with discontinuation of concomitant corticosteroid and/or methotrexate use for at least 4&nbsp;weeks, were randomised to receive canakinumab 2&nbsp;mg/kg every 4&nbsp;weeks (N=38) or canakinumab 4&nbsp;mg/kg every 8&nbsp;weeks (N=37). After 24&nbsp;weeks, 71% (27/38) of patients who received the reduced dose (2&nbsp;mg/kg every 4&nbsp;weeks) and 84% (31/37) of patients who received the prolonged dosing interval (4&nbsp;mg/kg every 8&nbsp;weeks) were able to maintain inactive disease status for 6&nbsp;months. Of the patients in clinical remission who continued with further dose reduction (1&nbsp;mg/kg every 4&nbsp;weeks) or dose interval prolongation (4&nbsp;mg/kg every 12&nbsp;weeks), 93% (26/28) and 91% (30/33) of patients, respectively, were able to maintain inactive disease status for 6&nbsp;months. Patients who maintained inactive disease status for 6&nbsp;additional months at this lowest dose regimen were allowed to discontinue canakinumab. Overall, 33% (25/75) of patients randomised to dose reduction or dose interval prolongation arms were able to discontinue treatment with canakinumab and maintain inactive disease status for 6&nbsp;months. The rate of adverse events in both treatment arms was similar to the rate seen in patients treated with canakinumab 4&nbsp;mg/kg every 4&nbsp;weeks.</p><p>&nbsp;</p><p><em>AOSD</em></p><p>The efficacy of canakinumab 4&nbsp;mg/kg (up to maximum 300&nbsp;mg) administered every 4&nbsp;weeks in AOSD patients in a randomised, double-blind placebo-controlled study in 36&nbsp;patients (22 to 70&nbsp;years old) was comparable to that observed in SJIA patients. In study GDE01T, a higher proportion of patients (12/18, 66.7%) in the canakinumab group than in the placebo group (7/17, 41.2%) demonstrated an improvement from baseline in Disease Activity Score&nbsp;28 Erythrocyte Sedimentation Rate (DAS28-ESR) of &gt;&nbsp;1.2 at week&nbsp;12, which failed to reach statistical significance (odds ratio 2.86, treatment difference [%] 25.49 [95% CI: 9.43, 55.80]). By week&nbsp;4, 7 of 18&nbsp;patients (38.9%) treated with canakinumab had already achieved DAS28-ESR remission versus 2 of 17&nbsp;patients (11.8%) on placebo. These data are consistent with the results of a pooled efficacy analysis of 418 SJIA patients which showed that the efficacy of canakinumab in a subset of SJIA patients aged 16 to &lt;&nbsp;20&nbsp;years (n=34) was consistent with the efficacy observed in patients less than 16&nbsp;years of age (n=384).</p><p>&nbsp;</p><p><em><u>Gouty arthritis</u></em></p><p>The efficacy of canakinumab for the treatment of acute gouty arthritis attacks was demonstrated in two multicentre, randomised, double-blind, active-controlled studies in patients with frequent gouty arthritis (&ge;&nbsp;3&nbsp;attacks in the previous 12&nbsp;months) unable to use NSAIDs or colchicine (due to contraindication, intolerance or lack of efficacy). The studies were 12&nbsp;weeks followed by 12-week double-blind extension. A total of 225&nbsp;patients were treated with subcutaneous canakinumab 150&nbsp;mg and 229&nbsp;patients were treated with intramuscular triamcinolone acetonide (TA) 40&nbsp;mg at study entry, and when experiencing a new attack thereafter. The mean number of gouty arthritis attacks in the previous 12&nbsp;months was 6.5. Over 85% of patients had comorbidity, including hypertension (60%), diabetes (15%), ischaemic heart disease (12%), and stage &ge;&nbsp;3 chronic kidney disease (25%). Approximately one-third of the patients enrolled (76 [33.8%] in the canakinumab group and 84 [36.7%] in the triamcinolone acetonide group) had documented inability (intolerance, contraindication or lack of response) to use both NSAIDs and colchicine. Concomitant treatment with ULTs was reported by 42% of patients at entry.</p><p>&nbsp;</p><p>The co-primary endpoints were: (i) gouty arthritis pain intensity (visual analogue scale, VAS) at 72&nbsp;hours post-dose, and (ii) time to first new gouty arthritis attack.</p><p>&nbsp;</p><p>For the overall study population, pain intensity was statistically significantly lower for canakinumab 150&nbsp;mg compared with triamcinolone acetonide at 72&nbsp;hours. Canakinumab also reduced the risk of subsequent attacks (see Table&nbsp;5).</p><p>&nbsp;</p><p>Efficacy results in a subgroup of patients unable to use both NSAIDs and colchicine and who were on ULT, failed ULT or had a contraindication to ULT (N=101) were consistent with the overall study population with a statistically significant difference compared to triamcinolone acetonide in pain intensity at 72&nbsp;hours (‑10.2&nbsp;mm, p=0.0208) and in reduction of risk of subsequent attacks (Hazard ratio 0.39, p=0.0047 at 24&nbsp;weeks).</p><p>&nbsp;</p><p>Efficacy results for a more stringent subgroup limited to current users of ULT (N=62) are presented in Table&nbsp;5. Treatment with canakinumab induced a reduction of pain and reduced the risk of subsequent attacks in patients using ULT and unable to use both NSAIDs and colchicine, although the observed treatment difference compared to triamcinolone acetonide was less pronounced than with the overall study population.</p><p>&nbsp;</p><p><strong>Table&nbsp;5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy for the overall study population and in a subgroup of patients currently using ULT and unable to use both NSAIDs and colchicine</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:621px"><tbody><tr><td style="vertical-align:top"><p><strong>Efficacy endpoint</strong></p></td><td style="vertical-align:top"><p><strong>Overall study population; </strong></p><p><strong>N=454</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Unable to use both NSAIDs and colchicine; on ULT</strong></p><p><strong>N=62</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Treatment of gouty arthritis attacks as measured by pain intensity (VAS) at 72&nbsp;h</strong></p></td></tr><tr><td style="vertical-align:top"><p>Least Squares mean estimated difference to triamcinolone acetonide</p><p>CI</p><p>p-value, 1-sided</p></td><td style="vertical-align:top"><p>‑10.7</p><p>&nbsp;</p><p>(‑15.4, ‑6.0)</p><p>p&nbsp;&lt;&nbsp;0.0001*</p></td><td colspan="2" style="vertical-align:top"><p>‑3.8</p><p>&nbsp;</p><p>(‑16.7, 9.1)</p><p>p=0.2798</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><strong>Risk reduction of subsequent gouty arthritis attacks as measured by time to first new flare (24&nbsp;weeks)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio to triamcinolone acetonide</p><p>CI</p><p>p-value, 1-sided</p></td><td style="vertical-align:top"><p>0.44</p><p>&nbsp;</p><p>(0.32, 0.60)</p><p>p&nbsp;&lt;&nbsp;0.0001*</p></td><td colspan="2" style="vertical-align:top"><p>0.71</p><p>&nbsp;</p><p>(0.29, 1.77)</p><p>p=0.2337</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>* Denotes significant p-value <u>&le;</u>&nbsp;0.025</p></td><td><p>&nbsp;</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>Safety results showed an increased incidence of adverse events for canakinumab compared to triamcinolone acetonide, with 66% vs 53% of patients reporting any adverse event and 20% vs 10% of patients reporting an infection adverse event over 24&nbsp;weeks.</p><p>&nbsp;</p><p><em>Elderly population</em></p><p>Overall, the efficacy, safety and tolerability profile of canakinumab in elderly patients &ge;&nbsp;65&nbsp;years of age was comparable to patients &lt;&nbsp;65&nbsp;years of age.</p><p>&nbsp;</p><p><em>Patients on urate lowering therapy (ULT)</em></p><p>In clinical studies, canakinumab has been safely administered with ULT. In the overall study population, patients on ULT had a less pronounced treatment difference in both pain reduction and reduction in the risk of subsequent gouty arthritis attacks compared to patients not on ULT.</p><p><u>&nbsp;</u></p><p><u>Immunogenicity</u></p><p><u>&nbsp;</u></p><p>Antibodies against canakinumab were observed in approximately 1.5%, 3% and 2% of the patients treated with canakinumab for CAPS, SJIA and gouty arthritis, respectively. No neutralising antibodies were detected. No apparent correlation of antibody development to clinical response or adverse events was observed.</p><p>&nbsp;</p><p>There were no antibodies against canakinumab observed in TRAPS, HIDS/MKD and FMF patients treated with doses of 150&nbsp;mg and 300&nbsp;mg over 16&nbsp;weeks of treatment.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The Marketing Authorisation Holder has completed four Paediatric Investigation Plans for canakinumab (for CAPS, SJIA, FMF &ndash; HIDS/MKD and TRAPS respectively). This product information has been updated to include the results of studies with canakinumab in the paediatric population.</p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with canakinumab in all subsets of the paediatric population in gouty arthritis (see section&nbsp;4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>CAPS</u></p><p><u>&nbsp;</u></p><p><em><u>Absorption</u></em></p><p>The peak serum canakinumab concentration (C<sub>max</sub>) occurred approximately 7&nbsp;days following single subcutaneous administration of 150&nbsp;mg in adult CAPS patients. The mean terminal half-life was 26&nbsp;days. Mean values for C<sub>max</sub> and AUC<sub>inf</sub> after a single subcutaneous dose of 150&nbsp;mg in a typical adult CAPS patient (70&nbsp;kg) were 15.9&nbsp;&micro;g/ml and 708&nbsp;&micro;g*d/ml. The absolute bioavailability of subcutaneously administered canakinumab was estimated to be 66%. Exposure parameters (such as AUC and C<sub>max</sub>) increased in proportion to dose over the dose range of 0.30 to 10.0&nbsp;mg/kg given as intravenous infusion or from 150 to 600&nbsp;mg as subcutaneous injection. Predicted steady-state exposure values (C<sub>min,ss</sub>, C<sub>max,ss</sub>, AUC<sub>,ss,8w</sub>) after 150&nbsp;mg subcutaneous administration (or 2&nbsp;mg/kg, respectively) every 8&nbsp;weeks were slightly higher in the weight category 40‑70&nbsp;kg (6.6&nbsp;&micro;g/ml, 24.3&nbsp;&micro;g/ml, 767&nbsp;&micro;g*d/ml) compared to the weight categories &lt;&nbsp;40&nbsp;kg (4.0&nbsp;&micro;g/ml, 19.9&nbsp;&micro;g/ml, 566&nbsp;&micro;g*d/ml) and &gt;&nbsp;70&nbsp;kg (4.6&nbsp;&micro;g/ml, 17.8&nbsp;&micro;g/ml, 545&nbsp;&micro;g*d/ml). The expected accumulation ratio was 1.3-fold following 6&nbsp;months of subcutaneous administration of 150&nbsp;mg canakinumab every 8&nbsp;weeks.</p><p>&nbsp;</p><p><em><u>Distribution</u></em></p><p>Canakinumab binds to serum IL-1 beta. The distribution volume (V<sub>ss</sub>) of canakinumab varied according to body weight. It was estimated to be 6.2&nbsp;litres in a CAPS patient of body weight 70&nbsp;kg.</p><p>&nbsp;</p><p><em><u>Elimination</u></em></p><p>The apparent clearance (CL/F) of canakinumab increases with body weight. It was estimated to be 0.17&nbsp;l/d in a CAPS patient of body weight 70&nbsp;kg and 0.11&nbsp;l/d in a SJIA patient of body weight 33&nbsp;kg. After accounting for body weight differences, no clinically significant differences in the pharmacokinetic properties of canakinumab were observed between CAPS and SJIA patients.</p><p>&nbsp;</p><p>There was no indication of accelerated clearance or time-dependent change in the pharmacokinetic properties of canakinumab following repeated administration. No gender or age-related pharmacokinetic differences were observed after correction for body weight.</p><p>&nbsp;</p><p><u>TRAPS, HIDS/MKD and FMF</u></p><p><u>&nbsp;</u></p><p>Bioavailability in TRAPS, HIDS/MKD and FMF patients has not been determined independently. Apparent clearance (CL/F) in the TRAPS, HIDS/MKD and FMF population at body weight of 55&nbsp;kg (0.14&nbsp;l/d) was comparable to CAPS population at body weight of 70&nbsp;kg (0.17&nbsp;l/d). The apparent volume of distribution (V/F) was 4.96&nbsp;l at body weight of 55&nbsp;kg.</p><p>&nbsp;</p><p>After repeated subcutaneous administration of 150&nbsp;mg every 4&nbsp;weeks, canakinumab minimal concentration at week&nbsp;16 (C<sub>min</sub>) was estimated to be 15.4&nbsp;&plusmn;&nbsp;6.6&nbsp;mg/ml. The estimated steady state AUC<sub>tau</sub> was 636.7&nbsp;&plusmn;&nbsp;260.2&nbsp;&mu;g*d/ml.</p><p>&nbsp;</p><p><u>Still&rsquo;s disease (SJIA and AOSD)</u></p><p><u>&nbsp;</u></p><p>Bioavailability in SJIA patients has not been determined independently. Apparent clearance per kg body weight (CL/F per kg) was comparable between the SJIA and CAPS population (0.004&nbsp;l/d per kg). The apparent volume of distribution per kg (V/F per kg) was 0.14&nbsp;l/kg. Sparse pharmacokinetics (PK) data in AOSD patients suggest similar PK of canakinumab as compared to SJIA and other patient populations.</p><p>&nbsp;</p><p>After repeated administration of 4&nbsp;mg/kg every 4&nbsp;weeks the accumulation ratio of canakinumab was 1.6&nbsp;fold in SJIA patients. Steady state was reached after 110&nbsp;days. The overall predicted mean (&plusmn;SD) for C<sub>min,ss</sub>, C<sub>max,ss </sub>and AUC<sub>,ss4w</sub> were 14.7&plusmn;8.8&nbsp;&mu;g/ml, 36.5 &plusmn; 14.9&nbsp;&mu;g/ml and 696.1 &plusmn; 326.5&nbsp;&mu;g*d/ml, respectively.</p><p>&nbsp;</p><p>The AUC<sub>ss4w</sub> in each age group was 692, 615, 707 and 742&nbsp;&micro;g*d/ml for 2‑3, 4‑5, 6‑11, and 12‑19&nbsp;years old, respectively. When stratified by weight, a lower (30‑40%) median of exposure for C<sub>min,ss </sub>(11.4 vs 19&nbsp;&micro;g/ml) and AUC<sub>ss</sub> (594 vs 880&nbsp;&micro;g*d/ml) for the lower bodyweight category (&le;&nbsp;40&nbsp;kg) vs the higher bodyweight category (&gt;&nbsp;40&nbsp;kg) was observed.</p><p>&nbsp;</p><p>Based on the population pharmacokinetic modelling analysis, the pharmacokinetics of canakinumab in young adult SJIA patients aged 16 to 20&nbsp;years were similar to those in patients less than 16&nbsp;years of age. Predicted canakinumab steady state exposures at a dose level of 4&nbsp;mg/kg (maximum 300&nbsp;mg) in patients over the age of 20&nbsp;years were comparable to those in SJIA patients younger than 20&nbsp;years of age.</p><p>&nbsp;</p><p><u>Gouty arthritis population</u></p><p>&nbsp;</p><p>Bioavailability in gouty arthritis patients has not been determined independently. Apparent clearance per kg body weight (CL/F per kg) was comparable between the gouty arthritis and CAPS population (0.004&nbsp;l/d/kg). Mean exposure in a typical gouty arthritis patient (93&nbsp;kg) after a single subcutaneous 150&nbsp;mg dose (C<sub>max</sub>: 10.8&nbsp;&micro;g/ml and AUC<sub>inf</sub>: 495&nbsp;&micro;g*d/ml) was lower than in a typical 70&nbsp;kg CAPS patient (15.9&nbsp;&micro;g/ml and 708&nbsp;&micro;g*d/ml). This is consistent with the observed increase in CL/F with body weight.</p><p>&nbsp;</p><p>The expected accumulation ratio was 1.1-fold following subcutaneous administration of 150&nbsp;mg canakinumab every 12&nbsp;weeks.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>Peak concentrations of canakinumab occurred between 2 to 7&nbsp;days (T<sub>max</sub>) following single subcutaneous administration of canakinumab 150&nbsp;mg or 2&nbsp;mg/kg in paediatric patients 4&nbsp;years of age and older. The terminal half-life ranged from 22.9 to 25.7&nbsp;days, similar to the pharmacokinetic properties observed in adults. Based on the population pharmacokinetic modelling analysis, the pharmacokinetics of canakinumab in children aged 2 to &lt;&nbsp;4&nbsp;years were similar to those in patients 4&nbsp;years of age and older. Subcutaneous absorption rate was estimated to decrease with age and appeared to be fastest in the youngest patients. Accordingly, T<sub>max</sub> was shorter (3.6&nbsp;days) in younger SJIA patients (2‑3&nbsp;years) compared to older SJIA patients (12‑19&nbsp;years; T<sub>max </sub>6&nbsp;days). Bioavailability (AUC<sub>ss</sub>) was not affected.</p><p>&nbsp;</p><p>An additional pharmacokinetics analysis showed that the pharmacokinetics of canakinumab in 6&nbsp;paediatric CAPS patients under the age of 2&nbsp;years were similar to the pharmacokinetics in paediatric patients 2‑4&nbsp;years of age. Based on the population pharmacokinetic modelling analysis, the expected exposures after a dose of 2&nbsp;mg/kg were comparable across the CAPS paediatric age groups, but were approximately 40% lower in paediatric patients of very low body weight (e.g. 10&nbsp;kg) than in adult patients (150&nbsp;mg dose). This is consistent with the observations of higher exposure in higher body weight groups in CAPS patients.</p><p>&nbsp;</p><p>In TRAPS, HIDS/MKD and FMF, exposure parameters (trough concentrations) were comparable across age groups from 2 to &lt;&nbsp;20&nbsp;years old following subcutaneous administration of canakinumab 2&nbsp;mg/kg every 4&nbsp;weeks.</p><p>&nbsp;</p><p>Pharmacokinetic properties are similar in CAPS, TRAPS, HIDS/MKD, FMF and SJIA paediatric populations.</p><p>&nbsp;</p><p><u>Elderly population</u></p><p><u>&nbsp;</u></p><p>No change in pharmacokinetic parameters based on clearance or volume of distribution were observed between elderly patients and adult patients &lt;&nbsp;65&nbsp;years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of cross-reactivity, repeated dose toxicity, immunotoxicity, toxicity to reproduce and development.</p><p>&nbsp;</p><p>Formal carcinogenicity studies have not been conducted with canakinumab.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mannitol</p><p>Histidine</p><p>Histidine hydrochloride monohydrate</p><p>Polysorbate 80</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.

From a microbiological point of view, the product should be used immediately after first opening.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C&nbsp;‑&nbsp;8&deg;C).</p><p>Do not freeze.</p><p>Store in the original package in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Solution for injection in a vial (type&nbsp;I glass) with a stopper (laminated chlorobutyl rubber) and flip-off cap (aluminium).</p><p>&nbsp;</p><p>Packs containing 1&nbsp;vial.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ilaris 150&nbsp;mg/ml solution for injection is supplied in a single-use vial for individual use.</p><p><u>&nbsp;</u></p><p><u>Instructions for administration</u></p><p><u>&nbsp;</u></p><p>Allow the vial to warm to room temperature before injection. The solution should be practically free of visible particles and clear to opalescent. The solution should be colourless or may have a slight brownish-yellow tint. Using an 18&nbsp;G or 21&nbsp;G&nbsp;x&nbsp;2&nbsp;inch needle (or similar as available on the market) and a 1&nbsp;ml syringe, carefully withdraw the required volume depending on the dose to be administered. Once the required volume is withdrawn, recap and remove the withdrawal needle from the syringe and attach a 27&nbsp;G&nbsp;x&nbsp;0.5&nbsp;inch needle (or similar as available on the market) to immediately inject the solution subcutaneously.</p><p>&nbsp;</p><p><u>Disposal</u></p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma AG. 
www.Novartis.com


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05/2021 (EMA)
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>